Method for discharging a patient from an intensive care unit

ABSTRACT

The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

The invention relates to a method for determining, diagnosis, prognosis,treatment guidance, treatment monitoring, risk assessment and/or riskstratification of patients with abnormal platelet levels, comprisingproviding a sample of said patient, determining a level ofproadrenomedullin (proADM) or fragment(s) thereof in said sample,wherein said level of proADM or fragment(s) thereof correlates with theabnormal platelet levels in said patient. In embodiments of theinvention, a high severity level of proADM or fragment(s) thereofindicates low platelet levels in the subject, and subsequent initiatingor modifying a treatment of the patient to improve said condition. Insome embodiments the method comprises determining a level of one or moreadditional markers in a sample isolated from the patient, such as thelevel of platelets, the level of PCT or fragment(s) thereof, one or moremarkers of thrombocytopenia and/or one or more markers of aninflammatory response.

BACKGROUND OF THE INVENTION

Despite significant improvements in diagnostic and preventativemeasures, the incidence of sepsis has continued to escalate rapidly inhospitalized patients (1), with mortality rates ranging between 10% and54%, depending on the level of disease severity, definition of organdysfunction used, and country specific incidence (2, 3). An early andaccurate assessment of both the infectious load and disease severity, interms of the overall pathophysiological host response, is therefore ofcrucial importance in the early stages of sepsis in order to make promptand reliable decisions concerning diagnostic testing and treatmentstrategies, as well as in the later phase to reliably guide patientmanagement, treatment monitoring, discharge decisions in the presence ofclinical recovery.

It is therefore surprising that no gold standard diagnostic test forsepsis currently exists (4). The use of Procalcitonin (PCT) haspartially filled this unmet need with regards to infectious loadassessment, with observational and interventional data in the field ofantibiotic guidance (5-7). However an accurate measure of diseaseseverity has not yet been shown.

As such, numerous biomarkers and clinical scores have consequently beenproposed, including the use of severity scores such as the SequentialOrgan Failure Assessment (SOFA), Acute Physiological and Chronic HealthEvaluation (APACHE) II and Simplified Acute Physiological (SAPS) IIscore, however these are rarely calculated on a daily basis in a routinemanner due to the relatively high complexity and time resourcerequirements associated with each score. The use of novel biomarkers cansatisfy this unmet clinical need, however few, if any, have successfullymade it into widespread clinical routine (8).

Of these biomarkers, mid-regional pro-adrenomedullin (MR-proADM)—apeptide generated by multiple tissues in order to stabilise themicrocirculation and protect against endothelial permeability andconsequent organ failure (9-16)—has shown considerable promise,especially in the fields of sepsis (17), lower respiratory tractinfections (18-21), lung transplantation (22), thoracic surgery (23) andhypervolemia (WO2017/89474). Indeed, the endothelium andmicrocirculation is widely acknowledged to play a significant role inthe pathophysiological host response to sepsis (24, 25), with theregulation and distribution of blood flow within each organ of majorimportance (25), and may therefore provide an alternative indication asto the severity of the general host response, compared to scores ofindividual organ dysfunction.

Understanding the host response to sepsis is crucial in order toinitiate appropriate treatment strategies. One fundamental factor isunderstanding the processes behind developing organ dysfunction. Eachorgan system is made up of a complex and vast network of capillaries,arterioles and venules, which is termed the microvascular system.Particularly during inflammatory responses platelets can have harmfuleffects on vascular integrity which can for example lead to an increasedvascular barrier permeability (59). However specific organs have varyingdegrees microvascular density and complexity, with the microcirculationplaying different roles depending on specific organ.

The contribution of blood platelets to sepsis pathophysiology and organfailure has been the subject of renewed attention. Using common plateletcount thresholds, thrombocytopenia (an abnormally low level of plateletsin the blood) accounts for 20-50% of patients in the ICU, and isassociated with poor outcomes (38-47). Platelets are well known playersin coagulation and likely contribute to disseminated intravascularcoagulation (DIC), as well as being essential factors of the immuneresponse, reacting to infection and disturbed tissue integrity andcontributing to inflammation, pathogen killing and tissue repair(48-53). Furthermore, the role of platelets and thrombocytopenia in thecontext of existing and developing critical illness, such as sepsis andorgan failure, is a topic of intense research (54-57).

Under healthy vascular conditions, platelets encounter inhibitorysignals generated from endothelial cells that prevent their activation.They circulate in close proximity to vessel walls and disruption in theendothelial cell lining overcomes these inhibitory signals and drivesplatelet adherence, activation and aggregation, which temporarily plugthe damaged vessel.

Activated platelets secrete a profusion of pro-inflammatory material andcytokines, which target endothelial cells and leucocytes. In normalconditions, the endothelium is a non-adhesive surface, however whenactivated by platelets it undergoes profound changes which include theexpression of cell adhesion molecules and tissue factors. Plateletsadhere to the activated endothelial cells following a multi-step processin which glycans play a critical role. Platelet activation can furtheralter vascular tone and lead to structural changes, thereby increasingvascular permeability. The formation of platelet aggregates in blood isan early phenomenon in sepsis progression.

Understanding developing organ dysfunction, as indicated by thesequential organ failure assessment score, is therefore crucial tohelping develop personalised sepsis treatments. An early warning ofincreasing or decreasing SOFA scores at the earliest moments followingsepsis diagnosis, is critical. However, so far there are no reliablediagnostic and/or prognostic markers available that indicate a to beexpected increasing or decreasing SOFA score and/or the presence ordevelopment of abnormal platelet levels, disseminated intravascularcoagulation (DIC) and/or associated organ failure, in particularspecific organ failure.

Especially for critically ill patients, the management ofthrombocytopenia can be challenging since different mechanisms can leadto a significant low platelet number: hemodilution (infusion of fluids),increased platelet consumption (e.g. due to DIC, hemophagocytosis,thrombosis), increased platelet destruction (e.g. due to plateletautoantibodies, heparin, drugs), decreased platelet production (e.g. dueto bacterial toxins, drugs, chronic liver disease) or increased plateletsequestration (e.g. due to hypersplenism, hypothermia). Furthermore alow platelet count could be insignificant and non-pathological due toseasonal and individual variations (58). In addition different scenarioscause a thrombocytopenic phenotype without being pathologically relevant(pseudothrombocytopenia). Clotting in a blood sample or EDTA-induced exvivo platelet clumping can be reasons for pseudothrombocytopenia andcould mislead therapeutic measures such as platelet transfusion.

Therefore, there is an urgent need for the development of diagnostic andprognostic tools and methods that indicate an abnormal development ofthe platelet level, and the associated severity of an abnormal plateletlevel.

SUMMARY OF THE INVENTION

In light of the difficulties in the prior art, the technical problemunderlying the present invention is the provision of means fordetermining abnormal platelet levels in a subject. One object of theinvention may be considered providing means for the diagnosis,prognosis, treatment guidance, treatment monitoring, risk assessmentand/or risk stratification of a present or subsequent adverse eventassociated with abnormal platelet levels, such as organ failure,specific organ failure and/or death in in a patient. One object of theinvention is therefore providing one or more biomarkers or combinationsof biomarkers to identify patients who have a high risk of such anadverse event.

The solution to the technical problem of the invention is provided inthe independent claims.

Preferred embodiments of the invention are provided in the dependentclaims.

The method therefore relates to a method for determining, diagnosis,prognosis, treatment guidance, treatment monitoring, risk assessmentand/or risk stratification of abnormal platelet levels in a patient,comprising

-   -   a. providing a sample of said patient,    -   b. determining a level of proadrenomedullin (proADM) or        fragment(s) thereof in said sample,    -   c. wherein said level of proADM or fragment(s) thereof        correlates with the abnormal platelet levels in said patient.

The invention also relates to a method for the diagnosis, prognosis,treatment guidance, treatment monitoring, risk assessment and/or riskstratification of thrombocytopenia and/or associated medical conditions,such as for example disseminated intravascular coagulation (DIC) ororgan dysregulation or organ failure based on a level ofproadrenomedullin (proADM) or fragment(s) thereof in said sample. Theinvention therefore relates to a method for the diagnosis, prognosis,risk assessment and/or risk stratification of thrombocytopenia and/ordisseminated intravascular coagulation (DIC) based on a level ofproadrenomedullin (proADM) or fragment(s) thereof in said sample.

The present invention is based on the surprising finding that the levelof proADM and in particular MR-proADM in a sample of a patientcorrelates with the platelet count of said patient at the moment ofsample isolation. Even more surprising, it was found that an increasinglevel of proADM correlates with decreasing thrombocyte numbers. Thesecorrelations persist with time, such that increasing proADM values atday 1 and day 4 after baseline measurement, correlate with loweringplatelet levels, and eventual mortality.

In some embodiments, the likelihood of the occurrence of a subsequentadverse event, such as failure of the coagulation system, abnormalplatelet levels, DIC and/or thrombocytopenia, can be assessed on thecomparison of the level of proADM or fragments thereof in the sample incomparison to a reference level (such as a threshold or cut-off valueand/or a population average), wherein the reference level may correspondto proADM or fragments thereof in healthy patients, or in patients whohave been diagnosed as critically ill, if applicable.

However, there is a need in the art to develop personalised treatmentstrategies that are formulated on an organ by organ basis. Accordingly,it is a great advantage of the method of the present invention that itis possible to predict with a high likelihood a specific organ failurethat may develop in the near future, in particular for the kidney, liverand the coagulation system on the basis of a level of proADM determinedat time point 0 (day 0). The examples provided herein demonstrate thatMR-proADM can significantly better predict improvements ordeteriorations with respect to an adverse event, such as preferablyimprovements or deteriorations in the coagulation, nephrotic and hepaticorgan systems.

Accordingly, the method of the present invention can help to predict thelikelihood of a subsequent adverse event in the health of the patient,such as failure of the coagulation system, abnormal platelet levels, DICand/or thrombocytopenia. This means, that the method of the inventioncan discriminate high risk patients, who are more likely to suffer fromcomplications, or whose state will become more critical in the future,from low risk patients, whose health state is stable or even improving,so that it is not expected that they will suffer from an adverse event,such as failure of the coagulation system, abnormal platelet levels,death, DIC and/or thrombocytopenia, which might require certaintherapeutic measures and/or more intense monitoring of the patient.

The method also relates to a method for assessing the severity of lowplatelet levels or associated consitions, such as thrombocytopeniaand/or disseminated intravascular coagulation (DIC). ProADM can be usedin a quantitative or semi-quantitative manner to assess the likelihoodof severity or severity of an existing condition.

The invention therefore relates to a method for determining, diagnosis,prognosis, treatment guidance, treatment monitoring, risk assessmentand/or risk stratification of a present, or subsequent, adverse event inthe health of a patient, comprising providing a sample of said patient,determining a level of adrenomedullin (ADM) or fragment(s) thereof insaid sample, wherein said level of proADM or fragment(s) thereofcorrelates with the likelihood of a subsequent adverse event in thehealth of said patient.

In embodiments of the invention, the subsequent adverse event is organfailure, specific organ failure, death, death within 28-90 days from thetime point of isolating the sample, abnormal platelet levels,thrombocytopenia, disseminated intravascular coagulation (DIC) and/orliver failure or an infection.

In preferred embodiments, the invention relates to a method fordetermining, diagnosis, prognosis, treatment guidance, treatmentmonitoring, risk assessment and/or risk stratification of specific organfailure in a patient, comprising providing a sample of said patient,determining a level of pro-adrenomedullin (proADM) or fragment(s)thereof in said sample, wherein said level of proADM or fragment(s)thereof correlates with the failure of a specific organ in said patient.

In preferred embodiments, the invention relates to a method fordetermining, diagnosis, prognosis, treatment guidance, treatmentmonitoring, risk assessment and/or risk stratification of liver failurein a patient, comprising providing a sample of said patient, determininga level of pro-adrenomedullin (proADM) or fragment(s) thereof in saidsample, wherein said level of proADM or fragment(s) thereof correlateswith the failure of the liver in said patient.

In some embodiments, the method for determining, diagnosis, prognosis,treatment guidance, treatment monitoring, risk assessment and/or riskstratification of specific organ failure in a patient is carried out ina patient with or suspected of having low platelet levels, or a relatedcondition.

The term “specific organ failure” refers to the failure of a specificorgan. For example, in case of a method of prognosis, the method of theinvention can be used for prognosing failure not only of failure of anyorgan, but of a specific organ. For example, the method can be used tospecifically prognose the failure of the kidney, liver and/or the bloodcoagulation system.

Herein, failure of an organ or a system, such as the liver or thecoagulation system, can relate to both, total breakdown of the system,in the sense of the absence or almost absence of any physiologicalfunction of the organ or system, and dysregulation, which refers to animbalance of the homeostasis of an organ or a system. A milddysregulation may occur without initial clinical symptoms, whereas aprogressive dysregulation may lead to a partial loss of function of thesystem leading to clinical symptoms and a strong dysregulation may beequivalent to a breakdown.

The invention therefore relates to a method for the prognosis, riskassessment and/or risk stratification of low platelet levels and/orthrombocytopenia and/or disseminated intravascular coagulation (DIC) ina patient, wherein a level of proADM or fragment(s) thereof equal to orabove a high severity level (or cut-off value) is indicative of thelikelihood of developing low platelet levels and/or thrombocytopeniaand/or DIC within 12 hours to 120 hours, preferably within 24 hours to72 hours, after obtaining a sample.

A particular advantage of the method of the present invention is that apatient who has been identified as a low risk patient by means of themethod of the present invention could be more rapidly discharged, forexample form an ICU, an emergency department, a private practice or ahospital. Also, for low risk patients, the intensity and/or frequency ofthe observation of the health status of the patient could be decreased.Accordingly, the hospital or other medical institution in charge of thepatient could more efficiently decide which patients require intensivemedical care and observation. Consequently, the respective hospital orinstitution could, for example, more efficiently occupy ICU beds withhigh-risk patients. This would lead to an improved medical care for thehigh-risk patients, since the medical personnel could focus on suchpatients, while low risk patients could be discharged. This would alsolead to significant benefits from avoided costs for unnecessary measuresthat would otherwise be applied to low risk patients.

It was entirely surprising that the level of proADM or fragments thereofin a sample from the patient can provide critical information about thelikelihood of the occurrence or presence and severity of, for example,abnormal platelet levels associated with DIC and/or thrombocytopenia orthrombocytopenia secondary to sepsis.

The use of proADM or fragments thereof as a single parameter inembodiments of the present invention is advantageous over the use ofother single parameters, such as biomarkers or clinical scores, sinceproADM is more precise in the prediction of failure of the coagulationsystem, abnormal platelet levels, DIC and/or thrombocytopenia ascompared to other markers and clinical parameters such as plateletcount, lactate or clinical scores such as SOFA, qSOFA, SAPS II or APACHEII.

In embodiments of the invention the patient showing symptoms or nosymptoms of any physiological disorder can be examined at any medicalsetting. According to a preferred embodiment, the sample is isolatedfrom a patient during a medical examination.

In embodiments of the invention, the patient is being or has beendiagnosed as being critically ill. According to a further embodiment,the sample is isolated from the patient at or after the time point ofdiagnosis. Furthermore, in embodiments of the method of the inventionmedical treatment has been initiated at or before the time point ofdiagnosis. In embodiments, the patient has been diagnosed as beingcritically ill and medical treatment has been initiated. The sample maybe isolated from the patient before, at or after diagnosis and treatmentinitiation.

In one embodiment, the patient is, or has been diagnosed as, criticallyill.

In one embodiment, the sample is isolated from the patient at or afterthe time point of diagnosis as being critically ill.

In one embodiment, the patient is diagnosed with an infectious disease.

In one embodiment, the patient is diagnosed with sepsis, severe sepsisor septic shock.

In one embodiment, the patient is diagnosed with one or more existingorgan failure(s), and/or is a posttraumatic or postsurgical patient

In one embodiment, the patient is diagnosed with a dysregulation of thecoagulation system, such as disseminated intravascular coagulation (DIC)or thrombocytopenia, and/or with a dysfunction of an organ associatedwith the coagulation system, such as blood vessels, spleen, bone marrowand/or the immune system.

According to a further embodiment, the patient is being or has beendiagnosed as suffering from disseminated intravascular coagulation(DIC).

DIC can be regarded as a syndrome that can occur in the context ofdifferent types of diseases, such as for example solid tumors, bloodcancer, lymphoma, leukemia, obstetric complications (such as(pre)eclampsia, abruptio placentae, amniotic fluid embolism, abortion),massive injuries (such as severe trauma, burns, hyperthermia, extensivesurgery), sepsis, severe sepsis, septic shock, severe infections (forexample bacterial, viral, fungal, protozoan,superinfection/co-infection(s)), transfusion reactions (such as AOBincompatibility hemolytic reactions), adverse drug reactions (e.g.induced by antiinfectives, antineoplastic agents, antithromboticagents), severe allergic or toxic reactions or giant hemangiomas.

The skilled person is aware of further conditions and diseases that canbe associated DIC. DIC can lead to (multi) organ dysfunction/damage(independently if the problem came from bleeding or clotting (dependingon the “DIC stage”). A combination of widespread loss of tissue bloodflow and simultaneous bleeding leads to an increased risk of death.Therefore DIC is a medical emergency that can be associated with severecomplications. The earlier the prediction or diagnosis of DIC the betteris the prognosis of the patient.

Several treatments have been suggested for DIC, such as Factor V, FactorXIII-AP, shingosine-1-phosphate (S1P), thombomodulin, antibodies againsttissue factor or tissue factor pre-mRNA splicing, reactive nitrogeninhibiting peptide (RNIP) fragment, TAFIa(i), procoagulant phospholipid,as well as thrombin inhibitor.

In embodiments of the invention, the DIC can lead to (multi) organdysfunction/damage (independently if the problem came from bleeding orclotting (depending on the “DIC stage”). A combination of widespreadloss of tissue blood flow and simultaneous bleeding leads to anincreased risk of death.

In embodiments of the invention, the patient receives a treatment ofDIC, such as, for example, Factor V, Factor XIII-AP,shingosine-1-phosphate (S1P), thombomodulin, antibodies against tissuefactor or tissue factor pre-mRNA splicing, reactive nitrogen inhibitingpeptide (RNIP) fragment, TAFIa(i), Procoagulant Phospholipid, and/orthrombin inhibitor.

In further embodiments, the treatment received by the patient comprisesone or more of antibiotic treatment, invasive mechanical ventilation,non-invasive mechanical ventilation, renal replacement therapy,vasopressor use, fluid therapy, corticosteroids, blood or platelettransfusion, splenectomy, direct thrombin inhibitors (such as lepirudinor argatroban), blood thinners (such as bivalirudin and fondaparinux),discontinuation of heparin in case of heparin-induced thrombocytopenia,lithium carbonate, folate, extracorporal blood purification and/or organprotection.

In preferred embodiments of the invention, said level of proADMinversely correlates with the platelet level.

Preferably the sample can be a bodily fluid. More preferably, the sampleis selected from the group consisting of a blood sample, a serum sample,a plasma sample and/or a urine sample.

Preferably, the method is carried out in some embodiments by determininga level of proADM or fragment(s) thereof, wherein said determining ofproADM comprises determining a level of MR-proADM in the sample. Theemployment of determining MR-proADM is preferred for any givenembodiment described herein and may be considered in the context of eachembodiment, accordingly. In preferred embodiments the “ADM fragment” maybe considered to be MR-proADM.

In some embodiments, any fragment or precursor of ADM, such pre-pro-ADM,pro-ADM, the peptide known as ADM itself, or fragments thereof, such asMR-proADM, may be employed.

According to another embodiment of the invention, determining a level ofproADM or fragment(s) thereof comprises determining a level of MR-proADMin the sample.

In a preferred embodiment of the method of the invention,

-   -   a level of proADM or fragment(s) thereof below a high severity        level (cut-off value) is indicative of normal or high platelet        levels, or    -   a level of proADM or fragment(s) thereof equal or above a high        severity level (or cut-off value) is indicative of the presence        of, or likelihood of developing, low platelet levels and/or        thrombocytopenia and/or disseminated intravascular coagulation        (DIC),    -   wherein a high severity level (or cut-off value) of proADM or        fragments thereof is a level above 6.5 nmol/l, 6.95 nmol/l, or        preferably 10.9 nmol/l.

According to the present invention, the term “indicate” in the contextof “indicative of a subsequent adverse event” and “indicative of theabsence of a subsequent adverse event” is intended as a measure of riskand/or likelihood. Preferably, the “indication” of the presence orabsence of an adverse event is intended as a risk assessment, and istypically not to be construed in a limiting fashion as to pointdefinitively to the absolute presence or absence of said event.

Therefore, the term “indicative of the absence of a subsequent adverseevent” or “indicative of a subsequent adverse event” can be understoodas indicating a low or high risk of the occurrence of an adverse event,respectively. In some embodiments a low risk relates to a lower riskcompared to proADM levels detected above the indicated values. In someembodiments a high risk relates to a higher risk compared to proADMlevels detected below the indicated values.

Keeping the above in mind, the determination of high and/or low severitylevels of proADM is however very reliable with respect to determiningthe presence or absence of a subsequent adverse event when using thecut-off values disclosed herein, such that the estimation of riskenables an appropriate action by a medical professional.

In some embodiments, the low or intermediate or high severity level ofproADM indicates the severity of a physical condition of a patient withregard to an adverse event.

In some embodiments, the low or intermediate or high severity level ofproADM indicates the severity of a physical condition of a patient withthrombocytopenia or symptoms of thrombocytopenia.

In some embodiments, the low or intermediate or high severity level ofproADM indicates the severity of a physical condition of a patient withthrombocytopenia or symptoms of thrombocytopenia secondary to sepsis.

It was entirely surprising that a level of proADM or fragments thereofcould be correlated with the likelihood of the presence or absence of asubsequent adverse event, such as failure of the coagulation system,abnormal platelet levels, DIC and/or thrombocytopenia, also in thecontext of critically ill patients who were receiving treatments atthese time points.

ProADM levels in samples can preferably be assigned to 3 differentseverity levels of proADM. High levels of proADM indicate a highseverity level, intermediate levels indicate an intermediate severitylevel and low levels indicate a low severity levels. The respectiveconcentrations that determine the cut-off values for the respectiveseverity levels depend on multiple parameters such as the time point ofsample isolation, for example after prognosis, diagnosis and treatmentinitiation of the patient, and the method used for determining the levelof proADM or fragments thereof in said sample.

The cut-off values disclosed herein refer preferably to measurements ofthe protein level of proADM or fragments thereof in a plasma sampleobtained from a patient by means of the BRAHMS MR proADM KRYPTOR assay.Accordingly, the values disclosed herein may vary to some extentdepending on the detection/measurement method employed, and the specificvalues disclosed herein are intended to also read on the correspondingvalues determined by other methods.

In one embodiment of the invention, a low and/or intermediate severitylevel of proADM or fragment(s) thereof is indicative of the absence of a(subsequent) adverse event, such as failure of the coagulation system,abnormal platelet levels, DIC and/or thrombocytopenia, wherein the lowseverity level is below a cut-off value in the range of 1.5 nmol/l and 4nmol/l. Any value within these ranges may be considered as anappropriate cut-off value for a low severity levels of proADM orfragments thereof. For example, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8,1.85, 1.9, 1.95, 2.0, 2.05, 2.1, 2.15, 2.2, 2.25, 2.3, 2.35, 2.4, 2.45,2.5, 2.55, 2.6, 2.65, 2.7, 2.75, 2.8, 2.85, 2.9, 2.95, 3.0, 3.05, 3.1,3.15, 3.2, 3.25, 3.3, 3.35, 3.4, 3.45, 3.5, 3.55, 3.6, 3.65, 3.7, 3.75,3.8, 3.85, 3.9, 3.95, 4.0 nmol/l.

In one embodiment of the invention, a high severity level of proADM orfragment(s) thereof is indicative of a (subsequent) adverse event, suchas failure of the coagulation system, abnormal platelet levels, DICand/or thrombocytopenia, wherein the high severity level is above acut-off value in the range of 6.5 nmol/l to 12 nmol/l. Any value withinthese ranges may be considered as an appropriate cut-off value for ahigh severity levels of proADM or fragments thereof. For example, 6.5,6.55, 6.6, 6.65, 6.7, 6.75, 6.8, 6.85, 6.9, 6.95, 7.0, 7.05, 7.1, 7.15,7.2, 7.25, 7.3, 7.35, 7.4, 7.45, 7.5, 7.55, 7.6, 7.65, 7.7, 7.75, 7.8,7.85, 7.9, 7.95, 8.0, 8.05, 8.1, 8.15, 8.2, 8.25, 8.3, 8.35, 8.4, 8.45,8.5, 8.55, 8.6, 8.65, 8.7, 8.75, 8.8, 8.85, 8.9, 8.95, 9.0, 9.05, 9.1,9.15, 9.2, 9.25, 9.3, 9.35, 9.4, 9.45, 9.5, 9.55, 9.6, 9.65, 9.7, 9.75,9.8, 9.85, 9.9, 9.95, 10.0, 10.05, 10.1, 10.15, 10.2, 10.25, 10.3,10.35, 10.4, 10.45, 10.5, 10.55, 10.6, 10.65, 10.7, 10.75, 10.8, 10.85,10.9, 10.95, 11.0, 11.05, 11.1, 11.15, 11.2, 11.25, 11.3, 11.35, 11.4,11.45, 11.5, 11.55, 11.6, 11.65, 11.7, 11.75, 11.8, 11.85, 11.9, 11.95,12.0 nmol/l.

All cut-off values disclosed herein relating to the level of a marker orbiomarker, such as proADM or PCT, are to be understood as “equal orabove” a certain cut-off or “equal or below” a certain cut-off. Forexample, an embodiment relating to a level of proADM or fragment(s)thereof below 4 nmol/l, preferably below 3 nmol/l, more preferably below2.7 nmol/l is to be understood as relating to a level of proADM orfragment(s) thereof equal or below 4 nmol/l, preferably equal or below 3nmol/l, more preferably equal or below 2.7 nmol/l. Conversely, anembodiment relating to a level of proADM or fragment(s) thereof above6.5 nmol/l, preferably above 6.95 nmol/l, more preferably above 10.9nmol/l is to be understood as relating to a level of proADM orfragment(s) thereof equal or above 6.5 nmol/l, preferably equal or above6.95 nmol/l, more preferably equal or above 10.9 nmol/l.

In other embodiments described herein, the severity levels are definedpreferably by cut-off values, that represent boundaries between low,intermediate or high severity levels. Any embodiments that presentcut-offs therefore may use the format of a single cut-off value as aboundary between two severity levels, or a single cutoff level for eachseverity level.

In some embodiments, the proADM cut-off value between low andintermediate severity levels is:

2.75 nmol/l±20%, or 2.75 nmol/l±15%, or ±12%, ±10%, ±8%, or ±5%,

and between intermediate and high severity levels:

10.9 nmol/l±20%, or 10.9 nmol/l±15%, or ±12%, ±10%, ±8%, or ±5%.

These cut-off values are preferably relevant for an assessment of proADMseverity level at baseline, in other words upon diagnosis and/or therapybegin and/or hospitalization. The baseline levels themselves, throughe.g. a single measurement or measurements taken at an initial singletime point, are able to indicate fluid therapy prescription.

In some embodiments, the proADM cut-off value between low andintermediate severity levels is:

2.80 nmol/l±20%, or 2.80 nmol/l±15%, or ±12%, ±10%, ±8%, or ±5%,

and between intermediate and high severity levels:

9.5 nmol/l±20%, or 9.5 nmol/l±15%, or ±12%, ±10%, ±8%, or ±5%.

These cut-off values are preferably relevant for an assessment of proADMseverity level after 1 day, in other words approx. 24 hours afterbaseline, in other words, approx. 1 day after diagnosis and/or therapybegin and/or hospitalization. For example, in embodiments where theproADM is measured one day after therapy begin, the cut-off values forday 1 may be employed. As is evident from the above, the cutoff betweenintermediate and high is somewhat lower than at baseline, i.e. as timeprogresses, even somewhat lower (but still relatively high) levels areassociated with high risk and are classed in the high severity level.

In some embodiments, the proADM cut-off value between low andintermediate severity levels is:

2.80 nmol/l±20% or 2.80 nmol/l±15%, or ±12%, ±10%, ±8%, or ±5%,

and between intermediate and high severity levels:

7.7 nmol/l±20% or 7.7 nmol/l±15%, or ±12%, ±10%, ±8%, or ±5%.

These cut-off values are preferably relevant for an assessment of proADMseverity level after 4 days, in other words approx. 4 days afterbaseline, in other words, approx. 4 days after diagnosis and/or therapybegin and/or hospitalization. For example, in embodiments where theproADM is measured 4 days after therapy begin, the cut-off values forday 4 may be employed. As is evident from the above, the cutoff betweenintermediate and high is somewhat lower than at baseline or at day 1,i.e. as time progresses, even somewhat lower (but still relatively high)levels are associated with high risk and are classed in the highseverity level.

In some embodiments, the cutoff levels to be employed in the embodimentsdescribed above may be adjusted according to an appropriate leveldepending on the day the measurement is made. Each of the cut-off valuesis subject to some variation due to common variance as may be expectedby the skilled person. The relevant cut-off levels are determined basedon extensive data, as presented below, but are not intended in allpossible embodiments to be final or exact values. By using a similarcut-off to those recited, i.e. within the ±20%, ±15%, ±12%, ±10%, ±8%,or ±5%, as can be determined by a skilled person, similar results may beexpected.

Any embodiment reciting ±20% of a given cut-off value, may be consideredto also disclose ±15%, ±12%, ±10%, ±8%, or ±5%.

Any embodiment reciting a particular cut-off value for baseline, day 1or day 4, may be considered to also disclose the corresponding cut-offvalues for the other days, e.g. an embodiment reciting a baselinecut-off value may be considered to also relate to the same embodimentreciting the day 1 or day 4 cut-off value.

Cut-off values apply in preferred embodiments to blood samples, orsample derived from blood, but are not limited thereto.

In embodiments of the invention, the level of proADM or fragment(s)thereof equal or above the high severity level (cut-off value) indicatesinitiating or modifying a treatment of the patient, such as provision ofcorticosteroids, blood or platelet transfusion, transfusion of bloodcomponents, such as serum, plasma or specific cells or combinationsthereof, drugs promoting the formation of thrombocytes, causativetreatment or preforming a splenectomy. Preferably, the cause of thedysregulation of the coagulation system may be identified and treated(causative treatment).

According to another embodiment, the patients are intensive care unit(ICU)-patients, wherein

-   -   the level of proADM or fragment(s) thereof below the low        severity level (cut-off value) indicates discharging of said        patient from ICU, or    -   the level of proADM or fragment(s) thereof equal or above the        high severity level (cut-off value) indicates modifying the        treatment of the patient in the ICU.

It is a particular advantage of the present invention that based on theclassification of the determined levels of proADM or fragments thereofit is possible to assess the probability of the occurrence of a futureadverse event in the health of the patient. Based on this assessment itis possible to adjust the next treatment options and decisions.

A treatment modification in the sense of the present invention wouldinclude, without limitation, an adjustment of the dose or administrationregime of the ongoing medication, change of the ongoing treatment to adifferent treatment, addition of a further treatment option to theongoing treatment or stop of an ongoing treatment or the identificationand treatment of the cause of the dysfunction. Different treatments thatcan be applied to patients in the context of the present invention havebeen disclosed in the detailed description of this patent application.

In preferred embodiments of the invention, the method additionallycomprises determining a level of one or more additional markers in asample isolated from the patient.

The one or more additional marker may be determined in the same or adifferent sample from said patient. In case of a different sample, thesample may be isolated at the same time, before or after isolation ofthe sample for determining proADM or fragment(s) thereof. Irrespectiveof whether the one or more additional marker is determined in the sameor a different sample, the measurement may occur in parallel,simultaneously, before and/or after the measurement of proADM.

In a preferred embodiment, the one or more additional markers comprisethe level of platelets in a blood sample.

In one embodiment, the one or more additional markers comprises PCT orfragment(s) thereof.

It is particularly advantageous to combine the determination of proADMor fragments thereof with the determination of platelet levels in asample, wherein the sample used for determining proADM may be the sameor a different sample used for conducting the platelet count.

According to a further preferred embodiment of the present invention,the method described herein comprises additionally

-   -   determining a level of platelets in a sample isolated from the        patient, or    -   determining a level of platelets in a first sample isolated from        the patient, wherein said first sample is isolated before, at or        after the time point of diagnosis and treatment initiation,    -   determining a level of platelets in a second sample isolated        from said patient, wherein the second sample has been isolated        after the first sample, preferably within 30 minutes after        isolation of the first sample or 30 minutes, 1 hour, 2 hours, 6        hours, 12 hours, 24 hours, 4 days, 7 or 10 days after isolation        of the first sample, and    -   determining a difference in the level of platelets in the second        sample in comparison to the level of platelets in the first        sample.

In further embodiments, the one or more additional markers comprise oneor more markers for a dysregulation of the coagulation system, such asdisseminated intravascular coagulation (DIC) or thrombocytopenia,comprising membrane microparticle, platelet count, mean platelet volume(MPV) sCD14-ST, prothrombinase, antithrombin and/antithrombin activity,cationic protein 18 (CAP18), von Willebrand factor (vWF)-cleavingproteases, lipoproteins in combination with CRP, fibrinogen, fibrin,B2GP1, GPIIb-IIIa, non-denatured D-dimer of fibrin, platelet factor 4,histones and a PT-Assay. In embodiments, the additional one or moremarkers comprise one or more histones.

In embodiments of the invention, proADM is determined in the context ofa method for therapeutic guidance in patients with heparinadministration to predict thrombocytopenia, e.g. adaption/change of themedication until the patient shows normal platelet counts and/or proADMlevels are below a cut-off disclosed herein.

In embodiments of the invention, proADM is determined in the context ofa method for therapeutic guidance in patients with antimicrobialtreatment to predict leukocytopenia, e.g. adaption/change of themedication until the patient shows normal platelet counts and/or proADMlevels are below a cut-off value disclosed herein.

In further embodiments, PCT is included in the monitoring, e.g. for thepurpose of antibiotic stewardship and/or prevention of misuse ofantibiotics and/or prevention of side effects, for example to lower therisk of getting thrombocytopenia or DIC. In this context, plateletcounts may be determined as an additional marker.

In embodiments of the invention, proADM is determined in the context ofplatelet transfusion. In further embodiments, PCT is included in themonitoring, e.g. for the detection of a bacterial infection, for thepurpose of antibiotic stewardship and/or prevention of misuse ofantibiotics and/or prevention of side effects, for example to lower therisk of getting thrombocytopenia or DIC. In this context, plateletcounts may be determined as an additional marker.

In embodiments of the invention, proADM is determined in the context ofa method for the prediction and/or diagnosis of dysregulation of thecoagulation system, DIC and/or thrombocytopenia in a patient, forexample a shock patient or a septic shock patient, wherein preferablyPCT is determined as an additional marker.

In embodiments of the invention, the absolute immature platelet count(AIPC) may be determined as an additional marker.

In embodiments of the invention, proADM is a better marker than plateletcounts for the prediction of getting DIC or thrombocytopenia. Inembodiments, a treatment may be fluid management.

In embodiments, patients with acute kidney injury (AKT)+/−continuousrenal replacement therapy (CRRT), community acquired pneumonia (CAP),sepsis and ICU-patients in general with a higher proADM have a higherrisk of mortality.

In one embodiment the invention additionally comprises informing thepatient of the results of the method described herein.

In one embodiment, the method enables prognosis, risk assessment or riskstratification of an adverse event in a patient with an abnormalplatelet level, comprising:

-   -   a. providing a sample of said patient,    -   b. determining a level of proadrenomedullin (proADM) or        fragment(s) thereof in said sample,    -   c. wherein said level of proADM or fragment(s) thereof        correlates with the abnormal platelet levels and with the        likelihood of an adverse event occurring in said patient.

In one embodiment, the adverse event is one or more of mortality,sepsis-related mortality, organ failure and/or organ dysfunction.

In one embodiment, the organ failure or organ dysfunction is associatedwith thrombocytopenia.

In one embodiment, the at least one additional marker or clinicalparameter is measured, preferably selected from the group consisting ofprocalcitonin, Histone 3, Histone 2A, Histone 2B, Histone 4 orfragment(s) thereof, platelet count, mean platelet volume and/or one ormore markers for a dysregulation of the coagulation system.

In one embodiment, the patient shows symptoms of an infectious diseaseor sepsis, or is diagnosed with an infectious disease and/or one or moreexisting organ failure(s), or has been diagnosed as suffering fromsepsis, severe sepsis or septic shock.

In a further embodiment, the method enables determining, diagnosis,prognosis, treatment guidance, treatment monitoring, risk assessmentand/or risk stratification of septic thrombocytopenia in a patient,comprising

-   -   a. providing a sample of said patient,    -   b. determining a level of proadrenomedullin (proADM) or        fragment(s) thereof in said sample, and    -   c. determining a level of procalcitonin (PCT) or fragment(s)        thereof in said sample,    -   d. wherein when a level of procalcitonin (PCT) or fragment(s)        thereof of is ≥0.5 ng/ml it indicates the presence of, or        increased risk of acquiring, sepsis, and wherein when a proADM        level or fragment(s) thereof of is 2.75 nmol/L it indicates the        presence of, or increased risk of acquiring, thrombocytopenia.

This embodiment enables a combination of beneficial functions notpreviously derivable from the art that enables practitioners to identifynot only the presence of septic disease, but also to initiate directedtreatment towards improving platelet levels. Elevated levels of PCT orfragments thereof indicate the presence of infectious disease, inparticular sepsis, using known values established in the art. Thecombination with measuring ADM, indicating platelet levels, followedpreferably by appropriate platelet or thrombocyte improving measures,provides practitioners with an leap on underlying pathological processin sepsis, allowing improved, faster treatment.

The invention further relates to a kit for carrying out the methoddescribed herein, comprising:

-   -   a. detection reagents for determining the level proADM or        fragment(s) thereof, and optionally additionally for determining        the level of PCT or fragment(s) thereof and/or one or more        additional markers as described herein, in a sample from a        subject, and    -   b. reference data, such as a reference level, corresponding to        high severity levels of proADM, wherein the high severity level        is above 6.5 nmol/l, preferably above 6.95 nmol/l, more        preferably above 10.9 nmol/l, and optionally PCT levels and/or        levels of one or more additional markers as described herein,        wherein said reference data is stored on a computer readable        medium and/or employed in the form of computer executable code        configured for comparing the determined levels of proADM or        fragment(s) thereof, and optionally additionally the determined        levels of PCT or fragment(s) thereof and/or additional markers        as described herein, to said reference data.

In some embodiments the kit comprises additionally therapeutic agentsfor improving platelet levels, as described in more detail herein.

The detection reagents for determining the level of proADM orfragment(s) thereof, and optionally for determining the level of PCT orfragment(s) thereof and/or additional markers of the invention, arepreferably selected from those necessary to perform the method, forexample antibodies directed to proADM, suitable labels, such asfluorescent labels, preferably two separate fluorescent labels suitablefor application in the BRAHMS KRYPTOR assay, sample collection tubes.

In one embodiment of the method described herein the level of proADM orfragment(s) thereof and optionally additionally other biomarkers such asfor example PCT or fragment(s) thereof is determined using a methodselected from the group consisting of mass spectrometry (MS),luminescence immunoassay (LIA), radioimmunoassay (RIA),chemiluminescence- and fluorescence-immunoassays, enzyme immunoassay(EIA), Enzyme-linked immunoassays (ELISA), luminescence-based beadarrays, magnetic beads based arrays, protein microarray assays, rapidtest formats such as for instance immunochromatographic strip tests,rare cryptate assay, and automated systems/analyzers.

The method according to the present invention can furthermore beembodied as a homogeneous method, wherein the sandwich complexes formedby the antibody/antibodies and the marker, e.g., the proADM or afragment thereof, which is to be detected remains suspended in theliquid phase. In this case it is preferred, that when two antibodies areused, both antibodies are labelled with parts of a detection system,which leads to generation of a signal or triggering of a signal if bothantibodies are integrated into a single sandwich.

Such techniques are to be embodied in particular as fluorescenceenhancing or fluorescence quenching detection methods. A particularlypreferred aspect relates to the use of detection reagents which are tobe used pair-wise, such as for example the ones which are described inU.S. Pat. No. 4,882,733 A, EP-B1 0 180 492 or EP-B1 0 539 477 and theprior art cited therein. In this way, measurements in which onlyreaction products comprising both labelling components in a singleimmune-complex directly in the reaction mixture are detected, becomepossible.

For example, such technologies are offered under the brand names TRACE®(Time Resolved Amplified Cryptate Emission) or KRYPTOR®, implementingthe teachings of the above-cited applications. Therefore, in particularpreferred aspects, a diagnostic device is used to carry out the hereinprovided method. For example, the level of the proADM protein or afragment thereof, and/or the level of any further marker of the hereinprovided method are determined. In particular preferred aspects, thediagnostic device is KRYPTOR®.

In one embodiment of the method described herein the method is animmunoassay and wherein the assay is performed in homogeneous phase orin heterogeneous phase.

In further embodiments of the method described herein, the methodadditionally comprises a molecular analysis of a sample from saidpatient for detecting an infection. The sample used for the molecularanalysis for detecting an infection preferably is a blood sample orfragment thereof, such as serum, plasma or whole blood. In a preferredembodiment the molecular analysis is a method aiming to detect one ormore biomolecules derived from a pathogen. Said one or more biomoleculemay be a nucleic acid, protein, sugar, carbohydrades, lipid and or acombination thereof such as glycosylated protein, preferably a nucleicacid. Said biomolecule preferably is specific for one or morepathogen(s). According to preferred embodiments, such biomolecules aredetected by one or more methods for analysis of biomolecules selectedfrom the group comprising nucleic acid amplification methods such asPCR, qPCR, RT-PCR, qRT-PCR, high-throughput sequencing (such as NGS) orisothermal amplification, mass spectrometry, detection of enzymaticactivity and immunoassay based detection methods. Further methods ofmolecular analysis are known to the person skilled in the art and arecomprised by the method of the present invention.

In one embodiment of the method described herein a first antibody and asecond antibody are present dispersed in a liquid reaction mixture, andwherein a first labelling component which is part of a labelling systembased on fluorescence or chemiluminescence extinction or amplificationis bound to the first antibody, and a second labelling component of saidlabelling system is bound to the second antibody so that, after bindingof both antibodies to said proADM or fragments thereof to be detected, ameasurable signal which permits detection of the resulting sandwichcomplexes in the measuring solution is generated.

In one embodiment of the method described herein the labelling systemcomprises a rare earth cryptate or chelate in combination with afluorescent or chemiluminescent dye, in particular of the cyanine type.

In one embodiment of the method described herein, the methodadditionally comprises comparing the determined level of proADM orfragment(s) thereof to a reference level, threshold value and/or apopulation average corresponding to proADM or fragments thereof inpatients who have been diagnosed as being critically ill and are undermedical treatment or who are at risk of getting or having a dyregulatedcoagulation system, wherein said comparing is carried out in a computerprocessor using computer executable code.

The methods of the present invention may in part becomputer-implemented. For example, the step of comparing the detectedlevel of a marker, e.g. the proADM or fragments thereof, with areference level can be performed in a computer system. In thecomputer-system, the determined level of the marker(s) can be combinedwith other marker levels and/or parameters of the subject in order tocalculate a score, which is indicative for the diagnosis, prognosis,risk assessment and/or risk stratification, treatment guidance andpatient management. For example, the determined values may be entered(either manually by a health professional or automatically from thedevice(s) in which the respective marker level(s) has/have beendetermined) into the computer-system. The computer-system can bedirectly at the point-of-care (e.g. primary care, ICU or ED) or it canbe at a remote location connected via a computer network (e.g. via theinternet, or specialized medical cloud-systems, optionally combinablewith other IT-systems or platforms such as hospital information systems(HIS)). Typically, the computer-system will store the values (e.g.marker level or parameters such as age, blood pressure, weight, sex,etc. or clinical scoring systems such as SOFA, qSOFA, BMI, PCT, plateletcounts, etc.) on a computer-readable medium and calculate the scorebased-on pre-defined and/or pre-stored reference levels or referencevalues. The resulting score will be displayed and/or printed for theuser (typically a health professional such as a physician).Alternatively or in addition, the associated prognosis, diagnosis,assessment, treatment guidance, patient management guidance orstratification will be displayed and/or printed for the user (typicallya health professional such as a physician or nurse).

In one embodiment of the invention, a software system can be employed,in which a machine learning algorithm is evident, preferably to identifyhospitalized patients at risk for sepsis, severe sepsis and septic shockusing data from electronic health records (EHRs). A machine learningapproach can be trained on a random forest classifier using EHR data(such as labs, biomarker expression, vitals, and demographics) frompatients. Machine learning is a type of artificial intelligence thatprovides computers with the ability to learn complex patterns in datawithout being explicitly programmed, unlike simpler rule-based systems.Earlier studies have used electronic health record data to triggeralerts to detect clinical deterioration in general. In one embodiment ofthe invention the processing of proADM levels may be incorporated intoappropriate software for comparison to existing data sets, for exampleproADM levels may also be processed in machine learning software toassist in diagnosing or prognosing the occurrence of an adverse event,dysregulated coagulation such as thrombocytopenia or DIC.

The combined employment of proADM or fragments thereof in combinationwith another biomarker such as PCT or CRP may be realised either in asingle multiplex assay, or in two separate assays conducted on a sampleform the patient. The sample may relate to the same sample, or todifferent samples. The assay employed for the detection anddetermination of proADM and for example PCT may also be the same ordifferent, for example an immunoassay may be employed for thedetermination of one of the above markers. More detailed descriptions ofsuitable assays are provided below.

Cut-off values and other reference levels of proADM or fragments thereofin patients who have been diagnosed as being critically ill and areunder treatment or who are at risk of getting or having a dyregulatedcoagulation system may be determined by previously described methods.

For example, methods are known to a skilled person for using theCoefficient of variation in assessing variability of quantitative assaysin order to establish reference values and/or cut-offs (George F. Reedet al., Clin Diagn Lab Immunol. 2002; 9(6):1235-1239).

Additionally, functional assay sensitivity can be determined in order toindicate statistically significant values for use as reference levels orcut-offs according to established techniques. Laboratories are capableof independently establishing an assays functional sensitivity by aclinically relevant protocol. “Functional sensitivity” can be consideredas the concentration that results in a coefficient of variation (CV) of20% (or some other predetermined % CV), and is thus a measure of anassays precision at low analyte levels. The CV is therefore astandardization of the standard deviation (SD) that allows comparison ofvariability estimates regardless of the magnitude of analyteconcentration, at least throughout most of the working range of theassay.

Furthermore, methods based on ROC analysis can be used to determinestatistically significant differences between two clinical patientgroups. Receiver Operating Characteristic (ROC) curves measure thesorting efficiency of the model's fitted probabilities to sort theresponse levels. ROC curves can also aid in setting criterion points indiagnostic tests. The higher the curve from the diagonal, the better thefit. If the logistic fit has more than two response levels, it producesa generalized ROC curve. In such a plot, there is a curve for eachresponse level, which is the ROC curve of that level versus all otherlevels. Software capable of enabling this kind of analysis in order toestablish suitable reference levels and cut-offs is available, forexample the statistics software R (version 3.1.2), JMP 12, JMP 13,Statistical Discovery, from SAS.

Cut off values may similarly be determined for PCT. Literature isavailable to a skilled person for determining an appropriate cut-off,for example Philipp Schuetz et al. (BMC Medicine. 2011; 9:107) describethat at a cut-off of 0.1 ng/mL, PCT had a very high sensitivity toexclude infection. Terence Chan et al. (Expert Rev. Mol. Diagn. 2011;11(5), 487.496) described that indicators such as the positive andnegative likelihood ratios, which are calculated based on sensitivityand specificity, are also useful for assessing the strength of adiagnostic test. Values are commonly graphed for multiple cut-off values(CVs) as a receiver operating characteristic curve. The area under thecurve value is used to determine the best diagnostically relevant CV.This literature describes the variation of CVs (cut-off values, that isdependent on the assay and study design), and suitable methods fordetermining cut-off values.

Population averages levels of proADM or fragments thereof may also beused as reference values, for example mean proADM population values,whereby patients that are diagnosed as critically ill, such as patientwith a dysregulation of the coagulation system, may be compared to acontrol population, wherein the control group preferably comprises morethan 10, 20, 30, 40, 50 or more subjects.

In one embodiment of the invention, the cut-off level for PCT may be avalue in the range of 0.01 to 100.00 ng/mL in a serum sample, when usingfor example a Luminex MAC Pix E-Bioscience Assay or the BRAHMS PCTKryptor Assay.

In a preferred embodiment the cut-off level of PCT may be in the rangeof 0.01 to 100, 0.05 to 50, 0.1 to 20, or 0.1 to 2 ng/mL, and mostpreferably >0.05 to 10 ng/mL. Any value within these ranges may beconsidered as an appropriate cut-off value. For example, 0.01, 0.05,0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4,1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30,35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 ng/mL may beemployed. In some embodiments, PCT levels for healthy subjects areapproximately 0.05 ng/mL.

As derived from the one study below, by way of example, the data showthat septic patients with abnormal low levels of platelets have a PCTvalue >7 ng/ml.

The advantages and embodiments of each of the various methods and kitsof the invention disclosed herein also apply and read on the respectiveother methods and kits.

Embodiments of the Invention Relating to Determining a Method forTherapy Monitoring, Comprising the Prognosis, Risk Assessment and/orRisk Stratification of a Subsequent Adverse Event in the Health of aPatient

As described above, a subsequent adverse event in some embodiments isone or more of thrombocytopenia, DIC, infection, organ failure, organdysfunction and/or mortality.

The invention relates to a method for therapy monitoring, comprising theprognosis, risk assessment and/or risk stratification of a subsequentadverse event in the health of a patient, comprising

-   -   providing a sample of said patient, wherein the patient has been        diagnosed as being critically ill and/or medical treatment has        been initiated, wherein the sample is isolated from the patient        after diagnosis and treatment initiation,    -   determining a level of proADM or fragment(s) thereof in said        sample,    -   wherein said level of proADM or fragment(s) thereof correlates        with the likelihood of a subsequent adverse event in the health        of said patient.

In one embodiment, the patients of the method of the present inventionhave already been diagnosed as being critically ill and are alreadyreceiving treatment. The method of the present invention can thereforebe used for monitoring the success of the treatment or therapy that hasbeen initiated, on the basis of determining the likelihood of asubsequent adverse event. The therapy monitoring preferably involves theprognosis of an adverse event and/or the risk stratification or riskassessment of the patient with respect to a future adverse event,wherein this risk assessment and the determination of said risk is to beconsidered as a means of monitoring the initiated therapy.

Physicians or medical personnel who are treating patients that have beendiagnosed as being critically ill can employ the method of the presentinvention in different clinical settings, such as primary care settingor, preferably, in a hospital setting, such as in an emergencydepartment, or in an intensive care unit (ICU). The method is veryuseful to monitor the effect of a therapy that has been initiated on acritically ill patient and can be used to judge whether a patient undertreatment is a high risk patient that should be under intense medicalobservation and should potentially receive additional therapeuticmeasures, or whether the patient is a low risk patient with an improvinghealth state that might not require as intense observation and furthertreatment measures, possibly because the initiated treatment issuccessfully improving the state of the patient. Initial treatments ofcritically ill patients may have a direct effect on the likelihood ofadverse events in the health of the patient. As such, the assessment ofrisk/prognosis of a future adverse event provides feedback on ormonitoring of the therapy instigated.

The likelihood of the occurrence of a subsequent adverse event can beassessed on the comparison of the level of proADM or fragments thereofin the sample in comparison to a reference level (such as a threshold orcut-off value and/or a population average), wherein the reference levelmay correspond to proADM or fragments thereof in healthy patients, or inpatients who have been diagnosed as critically ill.

Accordingly, the method of the present invention can help to predict thelikelihood of a subsequent adverse event in the health of the patient.This means, that the method of the invention can discriminate high riskpatients, who are more likely to suffer from complications, or whosestate will become more critical in the future, from low risk patients,whose health state is stable or even improving, so that it is notexpected that they will suffer from an adverse event, such as death ofthe patient or a deterioration of the patient's clinical symptoms orsigns, which might require certain therapeutic measures.

A particular advantage of the method of the present invention is that apatient who has been identified as a low risk patient by means of themethod of the present invention could be more rapidly discharged from anICU, the hospital in general or may require less frequent monitoring.

Also, for low risk patients, the intensity and/or frequency of theobservation of the health status of the patient could be decreased.Accordingly, the hospital or other medical institution in charge of thepatient could more efficiently decide which patients require intensivemedical care and observation. Consequently, the respective hospital orinstitution could, for example, more efficiently occupy ICU beds withhigh-risk patients. This would lead to an improved medical care for thehigh-risk patients, since the medical personnel could focus on suchpatients, while low risk patients could be discharged from the ICU. Thiswould also lead to significant benefits from avoided costs forunnecessary measures that would otherwise be applied to low riskpatients.

The time point when the patients have been diagnosed as being criticallyill and the first treatment measures are initiated is defined as “timepoint 0”, which may be the reference for the time point of isolation ofthe sample used for determining proADM or fragments thereof. Ifdiagnosis of the patient and treatment initiation do not occur at thesame time, time point 0 is the time point when the later of the twoevents of diagnosis and initiation of medical treatment occurs.Typically, diagnosis of critically ill patients is immediately followedby or concomitant to initiation of therapy or medical interventions suchas surgery and/or source control (e.g. elimination of necrotic tissue).In the case of coagulative dysfunction the starting point ofinterventions can vary from time to time depending on the severity ofthe condition or other complications.

It was entirely surprising that the level of proADM or fragments thereofin a sample from the patient can provide critical information about thelikelihood of the occurrence of a subsequent adverse event in the healthof said critically ill patients. There has been no indication that asingle measurement of proADM or fragments thereof after diagnosis andtreatment initiation of a critically ill patient could provide suchimportant information with respect to success of the ongoing treatmentand prognosis of the health status of the patient.

The use of proADM or fragments thereof as a single parameter inembodiments of the present invention is advantageous over the use ofother single parameters, such as biomarkers or clinical scores, sinceproADM is more precise in the prediction of an adverse event as comparedto other markers such as for the platelet count, PCT, CRP, lactate orclinical scores such as SOFA, SAPS II or APACHE II, and markers for adysregulation of the coagulation system, such as membrane microparticle,platelet count, mean platelet volume (MPV), sCD14-ST, prothrombinase,antithrombin and/antithrombin activity, cationic protein 18 (CAP18), vonWillebrand factor (vWF)-cleaving proteases, lipoproteins in combinationwith CRP, fibrinogen, fibrin, B2GP1, GPIIb-IIIa, non-denatured D-dimerof fibrin, platelet factor 4, histones and a PT-Assay.

According to a preferred embodiment, the sample is isolated from apatient during a medical examination.

According to a preferred embodiment, the sample is isolated from saidpatient within 30 minutes after said diagnosis and treatment initiation,or at least 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours, 4days, 7 days or 10 days after said diagnosis and treatment initiation.In other embodiments the sample is isolated from said patient 12-36hours and/or 3-5 days after treatment initiation.

The fact that the level of proADM or fragments thereof at a time pointas short as about 30 minutes after diagnosis and treatment initiationcan provide such information was completely unexpected.

In preferred embodiments of the method of the present invention saidsample is isolated from said patient about 30 minutes, 1 hour, 2 hours,3 hours, 4, hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10hours, 11 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours 22hours, 24 hours, 30 hours, 36 hours, 42 hours, 48 hours, 60 hours, 72hours, 84 hours, 4 days, 5 days, 6 days, 7 days, 8 days 9 days or 10days after said diagnosis and treatment initiation.

In other embodiments, the sample is isolated at time points after saiddiagnosis and initiating antibiotic treatment of 30 minutes to 12 hours,12-36 hours, 3-5 days, 7-14 days, 8-12 days, or 9-11 days.

Ranges between any given of the above values may be employed to definethe time point of obtaining the sample.

In another preferred embodiment of the present invention, the patienthas been diagnosed using at least one additional biomarker or a clinicalscore. It is particularly advantageous in the context of the presentinvention, if the initial diagnosis of the critical illness of thepatient at time point 0 was based at least partially on the level of atleast one biomarker or a determined clinical score.

In certain embodiments the present invention comprises the determinationof additional parameters, such as markers, biomarkers, clinical scoresor the like.

In another preferred embodiment of the present invention, the patienthas been diagnosed using at least one of the biomarkers or clinicalscores procalcitonin (PCT), lactate and C-reactive protein and/or atleast one of the clinical scores SOFA, APACHE II, SAPS II, and markersfor a dysregulation of the coagulation system, such as membranemicroparticle, platelet count, mean platelet volume (MPV), sCD14-ST,prothrombinase, antithrombin and/antithrombin activity, cationic protein18 (CAP18), von Willebrand factor (vWF)-cleaving proteases, lipoproteinsin combination with CRP, fibrinogen, fibrin, B2GP1, GPIIb-IIIa,non-denatured D-dimer of fibrin, platelet factor 4, histones and aPT-Assay. In embodiments, the additional one or more markers compriseone or more histones. Determining proADM or fragments thereof in samplesof patients that have been diagnosed as being critically ill and areunder treatment proved to be particularly useful for therapy monitoringif the diagnosis of the patient has been based on of these markers,since the prognosis of an adverse event in such patient groups may bemore precise as compared to critically ill patients that have beendiagnosed by other means.

In one embodiment of the invention, the critically ill patient is apatient diagnosed with or being at risk of developing a dysregulation ofthe coagulation system, an infectious disease, a patient diagnosed withan infectious disease and one or more existing organ failure(s), apatient diagnosed with sepsis, severe sepsis or septic shock and/or aposttraumatic or postsurgical patient. In light of the data presentedherein, the prognostic value of proADM in samples of these patientgroups is particularly accurate in predicting the likelihood of anadverse event in these patients.

In preferred embodiments of the present invention, the adverse event inthe health of said patient is death, preferably death within 28-90 daysafter diagnosis and treatment initiation, a new infection, organ failureand/or a deterioration of clinical symptoms requiring a focus cleaningprocedure, transfusion of blood products, infusion of colloids,emergency surgery, invasive mechanical ventilation, adverse drugreactions and/or renal or liver replacement.

In preferred embodiments of the invention, said level of proADM orfragment(s) thereof correlates with the likelihood of a subsequentadverse event in the health of said patient within 28 days afterdiagnosis and treatment initiation. In further preferred embodiments ofthe invention, said level of proADM or fragment(s) thereof correlateswith the likelihood of a subsequent adverse event in the health of saidpatient within 90 days after diagnosis and treatment initiation.

In certain embodiments of the invention, the treatment received by thepatient comprises one or more of antibiotic or antiinfective treatment,invasive mechanical ventilation, non-invasive mechanical ventilation,renal replacement therapy, vasopressor use, fluid therapy, platelettransfusion, blood transfusion, extracorporal blood purification, sourcecontrol and/or organ protection.

In preferred embodiments of the invention, the sample is selected fromthe group consisting of a blood sample or fraction thereof, a serumsample, a plasma sample and/or a urine sample.

In further embodiments of the invention the level of proADM orfragment(s) thereof correlates with the likelihood of a subsequentadverse event in the health of said patient. In a preferred embodimentthe level of proADM or fragment(s) thereof positively correlates withthe likelihood of a subsequent adverse event in the health of saidpatient. In other words, the higher the level of proADM determined, thegreater the likelihood of a subsequent adverse event.

According to a preferred embodiment of the present invention,

-   -   a low severity level of proADM or fragment(s) thereof is        indicative of the absence of a subsequent adverse event, or        indicates a low risk of a subsequent adverse event, wherein the        low severity level is below 4 nmol/l, preferably below 3 nmol/l,        more preferably below 2.7 nmol/l, or    -   a high severity level of proADM or fragment(s) thereof is        indicative of a subsequent adverse event, or indicates a high        risk of a subsequent adverse event, wherein the high severity        level is above 6.5 nmol/l, preferably above 6.95 nmol/l, more        preferably above 10.9 nmol/l.

According to a preferred embodiment of the present invention,

-   -   a level of proADM or fragment(s) thereof below 4 nmol/l,        preferably below 3 nmol/l, more preferably below 2.7 nmol/l, is        indicative of the absence of a subsequent adverse event, or        indicates a low risk of a subsequent adverse event, or    -   a level of proADM or fragment(s) thereof above 6.5 nmol/l,        preferably above 6.95 nmol/l, more preferably above 10.9 nmol/l,        is indicative of a subsequent adverse event, or indicates a high        risk of a subsequent adverse event.

According to a preferred embodiment of the present invention,

-   -   a low severity level of proADM or fragment(s) thereof is        indicative of the absence of a subsequent adverse event, wherein        the low severity level is below 2.7 nmol/l, or    -   a high severity level of proADM or fragment(s) thereof is        indicative of a subsequent adverse event, wherein the high        severity level is above 10.9 nmol/l.

This embodiment of the present invention is particularly advantageouswhen levels of proADM or fragments thereof are determined in a samplethat has been isolated on the day of diagnosis and treatment initiationof the patient, particularly about 30 minutes after diagnosis andtreatment initiation.

According to a preferred embodiment of the present invention,

-   -   a low severity level of proADM or fragment(s) thereof is        indicative of the absence of a subsequent adverse event, wherein        the low severity level is below 2.7 nmol/l, or    -   a high severity level of proADM or fragment(s) thereof is        indicative of a subsequent adverse event, wherein the high        severity level is above 10.9 nmol/l,    -   wherein the level of proADM or fragments thereof is determined        in a sample that has been isolated preferably on the day of        diagnosis and treatment initiation.

According to a preferred embodiment of the present invention,

-   -   a low severity level of proADM or fragment(s) thereof is        indicative of the absence of a subsequent adverse event, wherein        the low severity level is below 2.8 nmol/l, or    -   a high severity level of proADM or fragment(s) thereof is        indicative of a subsequent adverse event, wherein the high        severity level is above 9.5 nmol/l.

This embodiment of the present invention is particularly advantageouswhen levels of proADM or fragments thereof are determined in a samplethat has been isolated on 1 day after said diagnosis and treatmentinitiation.

According to a preferred embodiment of the present invention,

-   -   a low severity level of proADM or fragment(s) thereof is        indicative of the absence of a subsequent adverse event, wherein        the low severity level is below 2.8 nmol/l, or    -   a high severity level of proADM or fragment(s) thereof is        indicative of a subsequent adverse event, wherein the high        severity level is above 9.5 nmol/l,    -   wherein the level of proADM or fragments thereof is determined        in a sample that has been isolated preferably 1 day after        diagnosis and treatment initiation.

For example, if the level of proADM or fragments thereof falls into thecategory of a low severity level of proADM, the treating physician candecide with more confidence to discharge said patient from ICU, becauseit is unlikely that an adverse event in the health of said patient wouldoccur, preferably, within the next 28 days, more preferably within thenext 90 days. Accordingly, it might not be necessary to keep thispatient on the ICU. It might also be possible to conclude that theongoing treatment is successfully improving the health state of thepatient, as assessed by a measurement of risk of an adverse event.

In contrast, if the determination of the level of proADM or fragmentsthereof of said ICU patient indicates a high severity level of proADM orfragments thereof, the treating physician should keep the patient on theICU. Additionally, it should be considered to adjust the treatment ofthe patient, because it is likely that the current treatment is notimproving the health state of the patient, which is why the patient ismore likely to suffer form an adverse event in the future.

According to a particularly preferred embodiment of the presentinvention the low severity level is below 2.75 nmol/l, said sample isisolated from the ICU-patient 1 day or more after said diagnosis andtreatment initiation, and the low severity level of proADM orfragment(s) thereof indicates discharging of said patient from ICU.

The present invention further relates to a method for for therapymonitoring, comprising the prognosis, risk assessment and/or riskstratification of a subsequent adverse event in the health of a patient,comprising

-   -   providing a sample of said patient, wherein the patient is an        intensive care unit (ICU)-patient and medical treatment has been        initiated, wherein the sample is isolated from the patient after        admission to ICU and treatment initiation,    -   determining a level of proadrenomedullin (proADM) or fragment(s)        thereof in said sample,    -   wherein said level of proADM or fragment(s) thereof correlates        with the likelihood of a subsequent adverse event in the health        of said patient.

In the context of the method of the present invention relating toICU-patients, the reference for the time point of isolation of thesample used for determining proADM or fragments thereof is the timepoint when the patients are admitted to the ICU and the first treatmentmeasures are initiated (time point 0). This time point corresponds tothe time point of diagnosis and treatment initiation in the method ofthe present invention relating to patients that have been diagnosed asbeing critically ill.

All embodiments of the method of the present invention relating topatients that have been diagnosed as being critically ill are herewithalso considered to correspond to embodiments of the method of thepresent invention relating to ICU-patients.

Embodiments of the Invention Relating to Additionally Determining aLevel of PCT and/or Other Biomarkers or Clinical Scores in a First and aSecond Sample (or at the Time Point of Isolation of a First and a SecondSample)

A preferred embodiment of the present invention comprises additionallydetermining a level of PCT or fragment(s) thereof in a sample isolatedfrom the patient. In a preferred embodiment, the sample for determininga level of PCT or fragment(s) thereof is isolated before, at or afterthe time point of diagnosis and treatment initiation.

It is particularly advantageous to combine the determination of proADMor fragments thereof with the determination of PCT or fragments thereofin a sample, wherein the sample used for determining proADM may be thesame or a different sample used for detecting PCT.

The combined determination of proADM or fragments thereof with thedetermination of PCT or fragments thereof, whether in the same sample orin samples obtained at different time points, provides a synergisticeffect with respect to the accuracy and reliability of determining therisk of a subsequent adverse event. These synergistic effects also existfor the combined assessment of proADM or fragments therefor with othermarkers or clinical scores, such as platelet counts, mean plateletvolume (MPV), lactate, CRP, qSOFA, SOFA, SAPS II, APACHE II, or otherclinical assessments.

According to a further preferred embodiment of the present invention,the method described herein comprises additionally

-   -   determining a level of PCT or fragment(s) thereof in a first        sample isolated from the patient, wherein said first sample is        isolated before, at or after the time point of diagnosis and        treatment initiation,    -   determining a level of PCT or fragment(s) thereof in a second        sample isolated from said patient, wherein the second sample has        been isolated after the first sample, preferably within 30        minutes after isolation of the first sample or 30 minutes, 1        hour, 2 hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days        after isolation of the first sample, and    -   determining a difference in the level of PCT or fragment(s)        thereof in the second sample in comparison to the level of PCT        or fragment(s) thereof in the first sample.

It is particularly advantageous to combine the determination of proADMor fragments thereof in a sample isolated from a patient with thedetermination of PCT or fragments thereof in a first sample anddetermining the level of PCT or fragments thereof in a second sampleisolated after the first sample, wherein the sample used for thedetermination of proADM or fragments thereof may be the same ofdifferent than the first sample or the second sample used fordetermining PCT or fragments thereof.

In a preferred embodiment of the method described herein comprisesadditionally

-   -   determining a level of PCT or fragment(s) thereof in a first        sample isolated from the patient, wherein said first sample is        isolated at or before the time point of diagnosis and treatment        initiation (time point 0),    -   determining a level of PCT or fragment(s) thereof in a second        sample (sample of claim 1) isolated from said patient after        diagnosis and treatment initiation, preferably within 30 minutes        after said diagnosis and treatment initiation or 30 minutes, 1        hour, 2 hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days        after said diagnosis and treatment initiation, and    -   determining a difference in the level of PCT or fragment(s)        thereof in the second sample in comparison to the level of PCT        or fragment(s) thereof in the first sample.

It is particularly advantageous to combine the determination of proADMor fragments thereof (in a second sample) with the determination of PCTor fragments thereof in an earlier sample (first sample) that isisolated from said patient and that may be used for diagnosing saidpatient as being critically ill at time point 0 and determining thelevel of PCT or fragments thereof in a second sample isolated at acertain time point after diagnosis and treatment initiation, which isalso preferably the same time point when proADM or fragments thereof aredetermined. As indicated by the data below, determining a difference inthe level of PCT or fragments thereof in the second sample in comparisonto the first sample adds additional information to the informationgained from the levels of proADM or fragments thereof in the secondsample. Based on this combined information it might be possible topredict with a higher probability whether an adverse event in the healthof said patient will occur as compared to predicting the likelihood ofan adverse event purely on the information about the level of proADM orfragments thereof in the second sample. This represents a surprisingfinding, as biomarkers for sepsis are typically not synergistic orcomplementary, but represent mere alternative diagnostic markers.

In a preferred embodiment of the method described herein comprisesadditionally

-   -   determining a platelet count in a first sample isolated from the        patient, wherein said first sample is isolated at or before the        time point of diagnosis and treatment initiation (time point 0),    -   determining a platelet count in a second sample (sample of claim        1) isolated from said patient within 30 minutes after said        diagnosis and treatment initiation or at least 30 minutes,        preferably 1 hour, 2 hours, 6 hours, 12 hours, 24 hours, 4 days,        7 or 10 days after said diagnosis and treatment initiation, and    -   determining a difference in the platelet count in the second        sample in comparison to the platelet count in the first sample.

It is particularly advantageous to combine the determination of proADMor fragments thereof with the determination of platelet counts in asample, wherein the sample used for determining proADM may be the sameor a different sample used for detecting platelet counts.

A preferred embodiment of the present invention comprises additionallydetermining SOFA or qSOFA. In a preferred embodiment, qSOFA or SOFA isdetermined before, at or after the time point of diagnosis and treatmentinitiation.

It is particularly advantageous to combine the determination of proADMor fragments thereof with the determination SOFA, wherein the time pointof sample isolation for determining proADM may be the same or adifferent from the time point of determining SOFA.

According to a further preferred embodiment of the present invention,the method described herein comprises additionally

-   -   determining a first SOFA before, at or after the time point of        diagnosis and treatment initiation,    -   determining a second SOFA within 30 minutes after determining        the first SOFA or 30 minutes, 1 hour, 2 hours, 6 hours, 12        hours, 24 hours, 4 days, 7 or 10 days after determining the        first SOFA, and    -   determining a difference in the two determined SOFA.

In a preferred embodiment of the method described herein comprisesadditionally

-   -   determining SOFA at or before the time point of diagnosis and        treatment initiation (time point 0),    -   determining SOFA within 30 minutes after said diagnosis and        treatment initiation or at least 30 minutes, preferably 1 hour,        2 hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining a difference in SOFA determined after said diagnosis        and treatment initiation and SOFA determined at time point 0.

A preferred embodiment of the present invention comprises additionallydetermining SAPS II. In a preferred embodiment, SAPS II is determinedbefore, at or after the time point of diagnosis and treatmentinitiation.

It is particularly advantageous to combine the determination of proADMor fragments thereof with the determination SAPS II, wherein the timepoint of sample isolation for determining proADM may be the same or adifferent from the time point of determining SAPS II.

According to a further preferred embodiment of the present invention,the method described herein comprises additionally

-   -   determining a first SAPS II before, at or after the time point        of diagnosis and treatment initiation,    -   determining a second SAPS II within 30 minutes after determining        the first SOFA or 30 minutes, 1 hour, 2 hours, 6 hours, 12        hours, 24 hours, 4 days, 7 or 10 days after determining the        first SAPS II, and    -   determining a difference in the two determined SAPS II.

In a preferred embodiment of the method described herein comprisesadditionally

-   -   determining SAPS II at or before the time point of diagnosis and        treatment initiation (time point 0),    -   determining SAPS II within 30 minutes after said diagnosis and        treatment initiation or at least 30 minutes, preferably 1 hour,        2 hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining a difference in SAPS II determined after said        diagnosis and treatment initiation and SAPS II determined at        time point 0.

A preferred embodiment of the present invention comprises additionallydetermining APACHE II. In a preferred embodiment, APACHE II isdetermined before, at or after the time point of diagnosis and treatmentinitiation.

It is particularly advantageous to combine the determination of proADMor fragments thereof with the determination APACHE II, wherein the timepoint of sample isolation for determining proADM may be the same or adifferent from the time point of determining APACHE II.

According to a further preferred embodiment of the present invention,the method described herein comprises additionally

-   -   determining a first APACHE II before, at or after the time point        of diagnosis and treatment initiation,    -   determining a second APACHE II within 30 minutes after        determining the first APACHE II or 30 minutes, 1 hour, 2 hours,        6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        determining the first APACHE II, and    -   determining a difference in the two determined APACHE II.

In a preferred embodiment of the method described herein comprisesadditionally

-   -   determining APACHE II at or before the time point of diagnosis        and treatment initiation (time point 0),    -   determining APACHE II within 30 minutes after said diagnosis and        treatment initiation or at least 30 minutes, preferably 1 hour,        2 hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining a difference in APACHE II determined after said        diagnosis and treatment initiation and APACHE II determined at        time point 0.

In a preferred embodiment, it is possible to identify high-risk patientswith increasing PCT levels and a high severity level of proADM orfragments thereof, which represent a more accurate identification ofsuch patients that a likely to suffer from an adverse event in thefuture.

Accordingly, the treatment of these patients could be adjusted whileminimizing the risk that this patient might have been a low-riskpatient.

Embodiments of the Present Invention Relating to Determining a Level ofproADM or Fragment(s) Thereof in a First and a Second Sample

A preferred embodiment of the method of the present invention comprisesadditionally

-   -   determining a level of proADM or fragment(s) thereof in a first        sample isolated from the patient, wherein said first sample is        isolated before, at or after the time point of diagnosis and        treatment initiation, and    -   determining a level of proADM or fragment(s) thereof in a second        sample isolated from said patient, wherein said second sample        has been isolated after the first sample and after the time        point of diagnosis and treatment initiation, preferably within        30 minutes after isolation of the first sample or 30 minutes, 1        hour, 2 hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days        after isolation of the first sample, and    -   determining whether a difference in the level of proADM or        fragment(s) thereof in the second sample in comparison to the        level of proADM or fragment(s) thereof in the first sample is        evident.

The first and the second sample used for determining a level of proADMor fragment(s) thereof may be the same of different from the first andthe second sample used for determining a level of PCT or fragment(s)thereof.

A preferred embodiment of the method of the present invention comprisesadditionally

-   -   determining a level of proADM or fragment(s) thereof in a first        sample isolated from the patient, wherein said first sample is        isolated at or before the time point of diagnosis and treatment        initiation (time point 0), and    -   determining a level of proADM or fragment(s) thereof in a second        sample isolated after diagnosis and treatment initiation,        preferably within 30 minutes, or after 30 minutes, 1 hour, 2        hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining whether a difference in the level of proADM or        fragment(s) thereof in the second sample in comparison to the        level of proADM or fragment(s) thereof in the first sample is        evident.

A preferred embodiment of the method of the present invention comprisesadditionally

-   -   determining a level of proADM or fragment(s) thereof in a first        sample isolated from the patient, wherein said first sample is        used for diagnosing said patient as being critically ill (time        point 0), and    -   determining a level of proADM or fragment(s) thereof in a second        sample isolated after diagnosis and treatment initiation,        preferably within 30 minutes, or after 30 minutes, 1 hour, 2        hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining whether a difference in the level of proADM or        fragment(s) thereof in the second sample in comparison to the        level of proADM or fragment(s) thereof in the first sample is        evident.

A further preferred embodiment of the method of the present inventioncomprises additionally

-   -   determining a level of proADM or fragment(s) thereof and        optionally PCT or fragment(s) thereof in a first sample isolated        from the patient, wherein said first sample is isolated at or        before the time point of diagnosis and treatment initiation        (time point 0), and    -   determining a level of proADM or fragment(s) thereof and        optionally PCT or fragment(s) thereof in a second sample        isolated from said patient after said diagnosis and treatment        initiation, preferably within 30 minutes or at least 30 minutes        after diagnosis and treatment initiation, preferably 1 hour, 2        hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining a difference in the level of proADM or fragment(s)        thereof and/or a difference in the level of PCT or fragments        thereof in the second sample in comparison to the level of        proADM or fragment(s) thereof in the first sample.

A further preferred embodiment of the method of the present inventioncomprises additionally

-   -   determining a level of proADM or fragment(s) thereof and        optionally PCT or fragment(s) thereof in a first sample isolated        from the patient, wherein said first sample is used for        diagnosing said patient as being critically ill (time point 0),        and    -   determining a level of proADM or fragment(s) thereof and        optionally PCT or fragment(s) thereof in a second sample        isolated from said patient after said diagnosis and treatment        initiation, preferably within 30 minutes or at least 30 minutes        after diagnosis and treatment initiation, preferably 1 hour, 2        hours, 6 hours, 12 hours, 24 hours, 4 days, 7 or 10 days after        said diagnosis and treatment initiation, and    -   determining a difference in the level of proADM or fragment(s)        thereof and/or a difference in the level of PCT or fragments        thereof in the second sample in comparison to the level of        proADM or fragment(s) thereof in the first sample.

It was surprising that the determination of the change of the levels ofproADM or fragments thereof from the time point of diagnosis andtreatment initiation to a later time point can provide additionalinformation with respect to the occurrence of a future adverse event inthe health of a patient that has been diagnosed as being critically ill,e.g. the patient has been diagnosed with thrombocytopenia. It is a greatadvantage of this embodiment of the present invention that the samesample that is used for the determining of a diagnostic marker at timepoint 0 can also be used for determining the baseline level of proADM orfragments thereof, which can be compared to the level of proADM orfragments thereof at a later time point after diagnosis and treatmentinitiation. By determining the change of the level of proADM orfragments thereof of the course of patient treatment the accuracy ofpredicting the occurrence of an adverse event in the health of thepatient can be further increased.

In one embodiment of the method described herein, an elevated level ofproADM or fragment(s) thereof in the second sample compared to the firstsample is indicative of a subsequent adverse event.

It was surprising that based on the change of the level of proADM orfragments thereof it is possible to confidently predict the likelihoodof the occurrence of an adverse event in the health of the patientwithout determining further markers. An increase of the level orseverity level of proADM or fragments thereof from the time point ofdiagnosis and treatment initiation indicates that it is likely that anadverse event will occur. Accordingly, based on the change of proADM orfragments thereof over the course of the treatment a physician candecide whether to change or modify the treatment of the patient or tostick to the initial treatment.

In a preferred embodiment of the method of the present invention

-   -   an elevated level of proADM or fragment(s) thereof and an        elevated level of PCT or fragment(s) thereof in the second        sample compared to the first sample is indicative of a        subsequent adverse event, and/or

In some embodiments of the present invention, an elevated level ofproADM or fragments thereof in the second sample as compared to thefirst sample relates to an elevated severity level of proADM orfragments thereof. Conversely, in some embodiments of the presentinvention, a lower level of proADM or fragments thereof in the secondsample as compared to the first sample refer to a lower severity levelof proADM or fragments thereof in the second sample as compared to thefirst sample.

It is a great advantage that based on the change in the level of proADMor fragments thereof in combination with the determined change of PCT orfragments thereof over the course of treatment of a critically illpatient the likelihood of an adverse event in the health of the patientcan be assessed. Accordingly, it is possible to confidently identifyhigh-risk patients and low-risk patients based on the changes of thesetwo markers.

It is advantageous that by means of a combined analysis of the change inthe level of PCT or fragments thereof and the severity level of proADMor fragments thereof at the time point of the isolation of the secondsample (the later time point) in an ICU patient it can be decidedwhether a patient is a low-risk patient that can be discharged from ICUwhile maintaining the ongoing treatment, or whether a patient is ahigh-risk patient that requires a modification or adjustment of thecurrent therapy on ICU to prevent the occurrence of an adverse eventthat is indicated by the respective combination of the change in PCTlevels and the current severity level of proADM

In a further embodiment, the present invention relates to a kit forcarrying out the method of the present invention, wherein the kitcomprises

-   -   detection reagents for determining the level proADM or        fragment(s) thereof, and optionally additionally for determining        the level of PCT, and    -   reference data, such as a reference level, corresponding to high        and/or low severity levels of proADM, wherein the low severity        level is below 4 nmol/l, preferably below 3 nmol/l, more        preferably below 2.7 nmol/l, and the high severity level is        above 6.5 nmol/l, preferably above 6.95 nmol/l, more preferably        above 10.9 nmol/l, and optionally PCT, wherein said reference        data is preferably stored on a computer readable medium and/or        employed in the form of computer executable code configured for        comparing the determined levels of proADM or fragment(s)        thereof, and optionally additionally the determined levels of        PCT, lactate and/or C-reactive protein or fragment(s) thereof,        to said reference data.

In a further embodiment, the present invention relates to a kit forcarrying out the method of the present invention, wherein the kitcomprises

-   -   detection reagents for determining the level proADM or        fragment(s) thereof, and optionally additionally for determining        the level of PCT and/or one or more markers for a dysregulation        of the coagulation system, such as membrane microparticle,        platelet count, mean platelet volume (MPV), sCD14-ST,        prothrombinase, antithrombin and/antithrombin activity, cationic        protein 18 (CAP18), von Willebrand factor (vWF)-cleaving        proteases, lipoproteins in combination with CRP, fibrinogen,        fibrin, B2GP1, GPIIb-IIIa, non-denatured D-dimer of fibrin,        platelet factor 4, histones and a PT-Assay, in a sample from a        subject, and    -   reference data, such as a reference level, corresponding to high        and/or low severity levels of proADM, wherein the low severity        level is below 4 nmol/l, preferably below 3 nmol/l, more        preferably below 2.7 nmol/l, and the high severity level is        above 6.5 nmol/l, preferably above 6.95 nmol/l, more preferably        above 10.9 nmol/l, and optionally PCT and/or one or more markers        for a dysregulation of the coagulation system, such as membrane        microparticle, platelet count, mean platelet volume, sCD14-ST,        prothrombinase, antithrombin and/antithrombin activity, cationic        protein 18 (CAP18), von Willebrand factor (vWF)-cleaving        proteases, lipoproteins in combination with CRP, fibrinogen,        fibrin, B2GP1, GPIIb-IIIa, non-denatured D-dimer of fibrin,        platelet factor 4, histones and a PT-Assay, wherein said        reference data is preferably stored on a computer readable        medium and/or employed in the form of computer executable code        configured for comparing the determined levels of proADM or        fragment(s) thereof, and optionally additionally the determined        levels of PCT and/or one or more markers for a dysregulation of        the coagulation system, such as membrane microparticle, platelet        count, mean platelet volume (MPV), sCD14-ST, prothrombinase,        antithrombin and/antithrombin activity, cationic protein 18        (CAP18), von Willebrand factor (vWF)-cleaving proteases,        lipoproteins in combination with CRP, fibrinogen, fibrin, B2GP1,        GPIIb-IIIa, non-denatured D-dimer of fibrin, platelet factor 4,        histones and a PT-Assay, to said reference data.

In a further embodiment, the present invention relates to a kit forcarrying out the method of the present invention, wherein the kitcomprises

-   -   detection reagents for determining the level of proADM or        fragment(s) thereof, and optionally additionally for determining        the level of PCT or fragment(s) thereof, in a sample from a        subject, and    -   reference data, such as a reference level, corresponding to high        and/or low severity levels of proADM, wherein the low severity        level is below 4 nmol/l, preferably below 3 nmol/l, more        preferably below 2.7 nmol/l, and the high severity level is        above 6.5 nmol/l, preferably above 6.95 nmol/l, more preferably        above 10.9 nmol/l, and optionally PCT levels, wherein said        reference data is preferably stored on a computer readable        medium and/or employed in the form of computer executable code        configured for comparing the determined levels of proADM or        fragment(s) thereof, and optionally additionally the determined        levels of PCT or fragment(s) thereof, to said reference data.

In one embodiment the invention relates to a kit for carrying out themethod described herein, comprising:

-   -   detection reagents for determining the level proADM or        fragment(s) thereof, and optionally additionally for determining        the level of PCT or fragment(s) thereof, in a sample from a        subject, and    -   reference data, such as a reference level, corresponding to        proADM severity levels of claims 6 and/or 9, and optionally PCT        levels, wherein said reference data is preferably stored on a        computer readable medium and/or employed in in the form of        computer executable code configured for comparing the determined        levels of proADM or fragment(s) thereof, and optionally        additionally the determined levels of PCT or fragment(s)        thereof, to said reference data.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on a finding that identified acorrelation between proADM levels and platelet counts. The presentmethods enable determining, diagnosis, prognosis, treatment guidance,treatment monitoring, risk assessment and/or risk stratification ofabnormal platelet levels in a patient, wherein said level of proADM orfragment(s) thereof correlates with the abnormal platelet levels in saidpatient.

The present invention has the following advantages over the conventionalmethods: the inventive methods and the kits are fast, objective, easy touse and precise for therapy monitoring of critically ill patients. Themethods and kits of the invention relate to markers and clinical scoresthat are easily measurable in routine methods in hospitals, because thelevels of proADM, PCT, lactate, c-reactive protein, SOFA, APACHE II,SAPS II and/or markers for a dysregulation of the coagulation system,such as membrane microparticle, platelet count, mean platelet volume(MPV) sCD14-ST, prothrombinase, antithrombin and/antithrombin activity,cationic protein 18 (CAP18), von Willebrand factor (vWF)-cleavingproteases, lipoproteins in combination with CRP, fibrinogen, fibrin,B2GP1, GPIIb-IIIa, non-denatured D-dimer of fibrin, platelet factor 4,histones and a PT-Assay, can be determined in routinely obtained bloodsamples or further biological fluids or samples obtained from a subject.

As used herein, the “patient” or “subject” may be a vertebrate. In thecontext of the present invention, the term “subject” includes bothhumans and animals, particularly mammals, and other organisms.

In the context of the present invention, an “adverse event in the healthof a patient” relates to events that indicate complications or worseningof the health state of the patient. Such adverse events include, withoutlimitation, death of the patient, death of a patient within 28-90 daysafter diagnosis and treatment initiation, occurrence of an infection ora new infection, organ failure and deterioration of the patient'sgeneral clinical signs or symptoms, such as hypotension or hypertension,tachycardia or bradycardia, dysregulation of the coagulation system,disseminated intravascular coagulation, abnormal platelet levels,thrombocytopenia and dysregulated organ functions or organ failureassociated with thrombocytopenia. Furthermore, examples of adverseevents include situations where a deterioration of clinical symptomsindicates the requirement for therapeutic measures, such as a focuscleaning procedure, transfusion of blood products, infusion of colloids,invasive mechanical ventilation, platelet transfusion, non-invasivemechanical ventilation, emergency surgery, organ replacement therapy,such as renal or liver replacement, and vasopressor therapy.Furthermore, adverse events may include provision of corticosteroids,blood or platelet transfusion, transfusion of blood components, such asserum, plasma or specific cells or combinations thereof, drugs promotingthe formation of thrombocytes, causative treatment or preforming asplenectomy.

The patient described herein who has been diagnosed as being “criticallyill” can be diagnosed as an intensive care unit (ICU) patient, a patientwho requires constant and/or intense observation of his health state, apatient diagnosed with sepsis, severe sepsis or septic shock, a patientdiagnosed with an infectious disease and one or more existing organfailure(s), a pre- or post-surgical patient, an intraoperative patient,a posttraumatic patient, a trauma patient, such as an accident patient,a burn patient, a patient with one or more open lesions. The subjectdescribed herein can be at the emergency department or intensive careunit, or in other point of care settings, such as in an emergencytransporter, such as an ambulance, or at a general practitioner, who isconfronted with a patient with said symptoms. Furthermore, in thecontext of the present invention critically ill may refer to a patientat risk of getting or having a dysregulated coagulation system.Therefore in the context of the present invention critically illpreferably refers to a patient at risk of getting or having a lowplatelet number (thrombocytopenia). More preferably in the context ofthe present invention critically ill refers to a patient at risk ofgetting or having a low platelet number (thrombocytopenia) secondary toa systemic infection, sepsis, severe sepsis or septic shock. Patientsthat are suspected to suffer from SIRS are not necessarily considered tobe critically ill.

The term “ICU-patient” patient relates, without limitation, a patientwho has been admitted to an intensive care unit. An intensive care unitcan also be termed an intensive therapy unit or intensive treatment unit(ITU) or critical care unit (CCU), is a special department of a hospitalor health care facility that provides intensive treatment medicine.ICU-patients usually suffer from severe and life-threatening illnessesand injuries, which require constant, close monitoring and support fromspecialist equipment and medications in order to ensure normal bodilyfunctions.

Common conditions that are treated within ICUs include, withoutlimitation, acute or adult respiratory distress syndrome (ARDS), trauma,organ failure and sepsis.

As use herein, the term “coagulation system” refers to the componentspresent in blood that enable coagulation. Coagulation (also known asclotting) is the process by which blood changes from a liquid to a gel,forming a blood clot. It potentially results in hemostasis, thecessation of blood loss from a damaged vessel, followed by repair. Themechanism of coagulation involves activation, adhesion, and aggregationof platelets along with deposition and maturation of fibrin.

Disorders of coagulation are disease states which can result in bleeding(hemorrhage or bruising) or obstructive clotting (thrombosis).Coagulation begins almost instantly after an injury to the blood vesselhas damaged the endothelium lining the vessel. Leaking of blood throughthe endothelium initiates two processes: changes in platelets, and theexposure of subendothelial tissue factor to plasma Factor VII, whichultimately leads to fibrin formation. Platelets immediately form a plugat the site of injury; this is called primary hemostasis. Secondaryhemostasis occurs simultaneously: Additional coagulation factors orclotting factors beyond Factor VII respond in a complex cascade to formfibrin strands, which strengthen the platelet plug. Examples ofcoagulation factors comprise, without limitation, platelets, factor I(fibrinogen), factor II (prothrombin), factor III (tissue factor ortissue thromboplastin), factor IV Calcium, factor V (proaccelerin,labile factor), factor VI, factor VII (stable factor, proconvertin),factor VIII (Antihemophilic factor A), factor IX (Antihemophilic factorB or Christmas factor), factor X (Stuart-Prower factor), factor XI(plasma thromboplastin antecedent), factor XII (Hageman factor), factorXIII (fibrin-stabilizing factor), von Willebrand factor, prekallikrein(Fletcher factor), high-molecular-weight kininogen (HMWK) (Fitzgeraldfactor), fibronectin, antithrombin III, heparin cofactor II, protein C,protein S, protein Z, Protein Z-related protease inhibitor (ZPI),plasminogen, alpha 2-antiplasmin, tissue plasminogen activator (tPA),urokinase, plasminogen activator inhibitor-1 (PAI1), plasminogenactivator inhibitor-2 (PAI2), cancer procoagulant.

As used herein, the term “abnormal platelet levels” refers to a numberor concentration of platelets in the blood of a patient that isunexpectedly high or low. The to be expected value depends on the statusof the patient. In healthy individuals or individual without a knownbasic disease, predisposition or diagnosis, normal or to be expectedplatelet counts are in the range of about 150-450 billion platelets perL or 150,000 to 450,000 platelets per μl. This range may vary forexample if it is known that a patient suffers from a condition thataffects platelet numbers.

Thrombocytopenia is a condition characterized by abnormally low levelsof thrombocytes, also known as platelets, in the blood. A normal humanplatelet count ranges from 150,000 to 450,000 platelets per microliterof blood. These limits are determined by the 2.5th lower and upperpercentile, so values outside this range do not necessarily indicatedisease. Thrombocytopenia may require emergency treatment, especially ifa platelet count below 50,000 per microliter is determined.

In the context of the present invention, the term thrombocytopeniacomprises all forms and/or causes leading to abnormally low levels ofthrombocytes, such as abnormally low platelet production may be causedby dehydration, Vitamin B12 or folic acid deficiency, leukemia ormyelodysplastic syndrome or aplastic anemia, decreased production ofthrombopoietin by the liver in liver failure, sepsis, systemic viral orbacterial infection, leptospirosis, hereditary syndromes, such ascongenital amegakaryocytic thrombocytopenia, thrombocytopenia absentradius syndrome, Fanconi anemia, Bernard-Soulier syndrome, (associatedwith large platelets), May-Hegglin anomaly, Grey platelet syndrome,Alport syndrome, Wiskott-Aldrich syndrome; abnormally high rates ofplatelet destruction may be due to immune or non-immune conditions,including immune thrombocytopenic purpura, thrombotic thrombocytopenicpurpura, hemolytic-uremic syndrome, disseminated intravascularcoagulation, paroxysmal nocturnal hemoglobinuria, antiphospholipidsyndrome, systemic lupus erythematosus, post-transfusion purpura,neonatal alloimmune thrombocytopenia, hypersplenism, dengue fever,Gaucher's disease, zika virus; medication-induced thrombocytopenia, forexample induced by valproic acid, methotrexate, carboplatin, interferon,isotretinoin, panobinostat, Heparin, H2 blockers and proton-pumpinhibitors; and other causes such as snakebite, niacin toxicity, Lymedisease and thrombocytapheresis (also called plateletpheresis).

The gold standard for measuring platelets/thrombocytes is thedetermination of (absolute) immature platelet counts ((A)IPC) by e.g.flow cytometry. However, this method is associated with the disadvantagethat the technical validation of the platelet counts are sometimesdifficult.

Confounding factors make the results unreliable, leading to arequirement for an additional validation, which costs valuable time andstaff. Analytical interferences can cause a pseudothrombocytopenia (e.g.by giant thrombocytes, reticulated thrombocytes, aggregation ofthrombocytes or EDTA-incompatibility).

The term “septic thrombocytopenia” relates to the associated presence ofsepsis and low platelet levels.

As used herein, “diagnosis” in the context of the present inventionrelates to the recognition and (early) detection of a clinical conditionof a subject linked to an infectious disease. Also the assessment of theseverity of the infectious disease may be encompassed by the term“diagnosis”.

“Prognosis” relates to the prediction of an outcome or a specific riskfor a subject based on an infectious disease. This may also include anestimation of the chance of recovery or the chance of an adverse outcomefor said subject.

The methods of the invention may also be used for monitoring.“Monitoring” relates to keeping track of an already diagnosed infectiousdisease, disorder, complication or risk, e.g. to analyze the progressionof the disease or the influence of a particular treatment or therapy onthe disease progression of the disease of a critically ill patient or aninfectious disease in a patient.

The term “therapy monitoring” or “therapy control” in the context of thepresent invention refers to the monitoring and/or adjustment of atherapeutic treatment of said subject, for example by obtaining feedbackon the efficacy of the therapy.

In the present invention, the terms “risk assessment” and “riskstratification” relate to the grouping of subjects into different riskgroups according to their further prognosis. Risk assessment alsorelates to stratification for applying preventive and/or therapeuticmeasures. Examples of the risk stratification are the low, intermediateand high risk levels disclosed herein.

As used herein, the term “therapy guidance” refers to application ofcertain therapies or medical interventions based on the value of one ormore biomarkers and/or clinical parameter and/or clinical scores.

It is understood that in the context of the present invention“determining the level of proADM or fragment(s) thereof” or the likerefers to any means of determining proADM or a fragment thereof. Thefragment can have any length, e.g. at least about 5, 10, 20, 30, 40, 50or 100 amino acids, so long as the fragment allows the unambiguousdetermination of the level of proADM or fragment thereof. In particularpreferred aspects of the invention, “determining the level of proADM”refers to determining the level of midregional proadrenomedullin(MR-proADM). MR-proADM is a fragment and/or region of proADM.

The peptide adrenomedullin (ADM) was discovered as a hypotensive peptidecomprising 52 amino acids, which had been isolated from a humanphenochromocytome (Kitamura et al., 1993).

Adrenomedullin (ADM) is encoded as a precursor peptide comprising 185amino acids (“preproadrenomedullin” or “pre proADM”). An exemplary aminoacid sequence of proADM is given in SEQ ID NO: 1.

SEQ ID NO: 1: amino acid sequence of pre-pro-ADM:   1MKLVSVALMY LGSLAFLGAD TARLDVASEF RKKWNKWALS RGKRELRMSS  51SYPTGLADVK AGPAQTLIRP QDMKGASRSP EDSSPDAARI RVKRYRQSMN 101NFQGLRSFGC RFGTCTVQKL AHQIYQFTDK DKDNVAPRSK ISPQGYGRRR 151RRSLPEAGPG RTLVSSKPQA HGAPAPPSGS APHFL

ADM comprises the positions 95-146 of the pre-proADM amino acid sequenceand is a splice product thereof. “Proadrenomedullin” (“proADM”) refersto pre-proADM without the signal sequence (amino acids 1 to 21), i.e. toamino acid residues 22 to 185 of pre-proADM. “Midregionalproadrenomedullin” (“MR-proADM”) refers to the amino acids 42 to 95 ofpre-proADM. An exemplary amino acid sequence of MR-proADM is given inSEQ ID NO: 2.

SEQ ID NO: 2: amino acid sequence of MR-pro-ADM(AS 45-92 of pre-pro-ADM): ELRMSSSYPT GLADVKAGPA QTLIRPQDMK GASRSPEDSSPDAARIRV

It is also envisaged herein that a peptide and fragment thereof ofpre-proADM or MR-proADM can be used for the herein described methods.For example, the peptide or the fragment thereof can comprise the aminoacids 22-41 of pre-proADM (PAMP peptide) or amino acids 95-146 ofpre-proADM (mature adrenomedullin, including the biologically activeform, also known as bio-ADM).

A C-terminal fragment of proADM (amino acids 153 to 185 of pre proADM)is called adrenotensin. Fragments of the proADM peptides or fragments ofthe MR-proADM can comprise, for example, at least about 5, 10, 20, 30 ormore amino acids. Accordingly, the fragment of proADM may, for example,be selected from the group consisting of MR-proADM, PAMP, adrenotensinand mature adrenomedullin, preferably herein the fragment is MR-proADM.

The determination of these various forms of ADM or proADM and fragmentsthereof also encompass measuring and/or detecting specific sub-regionsof these molecules, for example by employing antibodies or otheraffinity reagents directed against a particular portion of themolecules, or by determining the presence and/or quantity of themolecules by measuring a portion of the protein using mass spectrometry.

Any one or more of the “ADM peptides or fragments” described herein maybe employed in the present invention.

The methods and kits of the present invention can also comprisedetermining at least one further biomarker, marker, clinical scoreand/or parameter in addition to proADM.

As used herein, a parameter is a characteristic, feature, or measurablefactor that can help in defining a particular system. A parameter is animportant element for health- and physiology-related assessments, suchas a disease/disorder/clinical condition risk, preferably organdysfunction(s). Furthermore, a parameter is defined as a characteristicthat is objectively measured and evaluated as an indicator of normalbiological processes, pathogenic processes, or pharmacologic responsesto a therapeutic intervention. An exemplary parameter can be selectedfrom the group consisting of Acute Physiology and Chronic HealthEvaluation II (APACHE II), the simplified acute physiology score (SAPSIIscore), sequential organ failure assessment score (SOFA score), quicksequential organ failure assessment score (qSOFA), body mass index,weight, age, sex, IGS II, liquid intake, white blood cell count, sodium,platelet count, mean platelet volume (MPV), potassium, temperature,blood pressure, dopamine, bilirubin, respiratory rate, partial pressureof oxygen, World Federation of Neurosurgical Societies (WFNS) grading,and Glasgow Coma Scale (GCS).

As used herein, terms such as “marker”, “surrogate”, “prognosticmarker”, “factor” or “biomarker” or “biological marker” are usedinterchangeably and relate to measurable and quantifiable biologicalmarkers (e.g., specific protein or enzyme concentration or a fragmentthereof, specific hormone concentration or a fragment thereof, orpresence of biological substances or a fragment thereof) which serve asindices for health- and physiology-related assessments, such as adisease/disorder/clinical condition risk, preferably an adverse event. Amarker or biomarker is defined as a characteristic that can beobjectively measured and evaluated as an indicator of normal biologicalprocesses, pathogenic processes, or pharmacologic responses to atherapeutic intervention. Biomarkers may be measured in a sample (as ablood, serum, plasma, urine, or tissue test).

The at least one further marker and/or parameter of said subject can beselected from the group consisting of a level of lactate in said sample,a level of procalcitonin (PCT) in said sample, the sequential organfailure assessment score (SOFA score) of said subject, the simplifiedacute physiology score (SAPSII) of said subject, the Acute Physiologyand Chronic Health Evaluation II (APACHE II) score of said subject and alevel of the soluble fms-like tyrosine kinase-1 (sFlt-1), Histone H2A,Histone H2B, Histone H3, Histone H4, calcitonin, Endothelin-1 (ET-1),Arginine Vasopressin (AVP), Atrial Natriuretic Peptide (ANP), NeutrophilGelatinase-Associated Lipocalin (NGAL), Troponin, Brain NatriureticPeptide (BNP), C-Reactive Protein (CRP), Pancreatic Stone Protein (PSP),Triggering Receptor Expressed on Myeloid Cells 1 (TREM1), Interleukin-6(IL-6), Interleukin-1, Interleukin-24 (IL-24), Interleukin-22 (IL-22),Interleukin (IL-20) other ILs, Presepsin (sCD14-ST), LipopolysaccharideBinding Protein (LBP), Alpha-1-Antitrypsin, Matrix Metalloproteinase 2(MMP2), Metalloproteinase 2 (MMP8), Matrix Metalloproteinase 9 (MMP9),Matrix Metalloproteinase 7 (MMP7, Placental growth factor (PIGF),Chromogranin A, S100A protein, S100B protein and Tumor Necrosis Factor α(TNFα), Neopterin, Alpha-1-Antitrypsin, pro-arginine vasopressin (AVP,proAVP or Copeptin), procalcitonin, atrial natriuretic peptide (ANP,pro-ANP), Endothelin-1, CCL1/TCA3, CCL11, CCL12/MCP-5, CCL13/MCP-4,CCL14, CCL15, CCL16, CCL17/TARC, CCL18, CCL19, CCL2/MCP-1, CCL20, CCL21,CCL22/MDC, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL3L3, CCL4,CCL4L1/LAG-1, CCL5, CCL6, CCL7, CCL8, CCL9, CX3CL1, CXCL1, CXCL10,CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CXCL2/MIP-2,CXCL3, CXCL4, CXCL5, CXCL6, CXCL7/Ppbp, CXCL9, IL8/CXCL8, XCL1, XCL2,FAM19A1, FAM19A2, FAM19A3, FAM19A4, FAM19A5, CLCF1, CNTF, IL11, IL31,IL6, Leptin, LIF, OSM, IFNA1, IFNA10, IFNA13, IFNA14, IFNA2, IFNA4,IFNA7, IFNB1, IFNE, IFNG, IFNZ, IFNA8, IFNA5/IFNaG, IFNw/IFNW1, BAFF,4-1BBL, TNFSF8, CD40LG, CD70, CD95L/CD178, EDA-A1, TNFSF14, LTA/TNFB,LTB, TNFa, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TNFSF15, TNFSF4, IL18,IL18BP, IL1A, IL1B, IL1F10, IL1F3/IL1RA, IL1F5, IL1F6, IL1F7, IL1F8,IL1RL2, IL1F9, IL33 or a fragment thereof. Further markers comprisemembrane microparticle, platelet count, mean platelet volume (MPV),sCD14-ST, prothrombinase, antithrombin and/antithrombin activity,cationic protein 18 (CAP18), von Willebrand factor (vWF)-cleavingproteases, lipoproteins in combination with CRP, fibrinogen, fibrin,B2GP1, GPIIb-IIIa, non-denatured D-dimer of fibrin, platelet factor 4,histones and a PT-Assay.

Components of the coagulation system may also be considered as markersof biomarkers in the sense of the present invention and comprise,without limitation, platelets, factor I (fibrinogen), factor II(prothrombin), factor III (tissue factor or tissue thromboplastin),factor IV Calcium, factor V (proaccelerin, labile factor), factor VI,factor VII (stable factor, proconvertin), factor VIII (Antihemophilicfactor A), factor IX (Antihemophilic factor B or Christmas factor),factor X (Stuart-Prower factor), factor XI (plasma thromboplastinantecedent), factor XII (Hageman factor), factor XIII(fibrin-stabilizing factor), von Willebrand factor, prekallikrein(Fletcher factor), high-molecular-weight kininogen (HMWK) (Fitzgeraldfactor), fibronectin, antithrombin III, heparin cofactor II, protein C,protein S, protein Z, Protein Z-related protease inhibitor (ZPI),plasminogen, alpha 2-antiplasmin, tissue plasminogen activator (tPA),urokinase, plasminogen activator inhibitor-1 (PAI1), plasminogenactivator inhibitor-2 (PAI2), cancer procoagulant

As used herein, “procalcitonin” or “PCT” relates to a peptide spanningamino acid residues 1-116, 2-116, 3-116, or fragments thereof, of theprocalcitonin peptide. PCT is a peptide precursor of the hormonecalcitonin. Thus the length of procalcitonin fragments is at least 12amino acids, preferably more than 50 amino acids, more preferably morethan 110 amino acids. PCT may comprise post-translational modificationssuch as glycosylation, liposidation or derivatisation.

Procalcitonin is a precursor of calcitonin and katacalcin. Thus, undernormal conditions the PCT levels in the circulation are very low (<about0.05 ng/ml).

The level of PCT in the sample of the subject can be determined byimmunoassays as described herein. As used herein, the level ofribonucleic acid or deoxyribonucleic acids encoding “procalcitonin” or“PCT” can also be determined. Methods for the determination of PCT areknown to a skilled person, for example by using products obtained fromThermo Fisher Scientific/B⋅R⋅A⋅H⋅M⋅S GmbH.

It is understood that “determining the level of at least one histone” orthe like refers to determining the level of at least one histone or afragment of the at least one histone in the sample. In particular, thelevel of the histone H2B, H3, H2A, and/or H4 is determined in thesample. Accordingly, the at least one histone determined in the samplecan be a free histone or the at least one histone determined in thesample can occur and can be assembled in a macromolecular complex, forexample, in the octamer, nucleosome and/or NETs.

The fragment of the at least one histone can have any length, e.g. atleast about 5, 10, 20, 30, 40, 50 or 100 amino acids, so long as thefragment allows the unambiguous determination of the level of theparticular histone. Various exemplary fragments of the histones aredisclosed herein below that are suitable to determine the level of thehistone in the sample of the subject. It is also herein understood thatthe level of the histones can be determined by determining a fragmentspanning the N-terminal or C-terminal tail of the histones. In addition,the histone or the fragment thereof to be determined in the context ofthe present invention may also be modified, e.g. by post-translationalmodification. Exemplary post translational modifications can beacetylation, citrullination, deacetylation, methylation, demethylation,deimination, isomerization, phosphorylation and ubiquitination.Preferably, the histones or fragments thereof a circulating.

In particular aspects of the invention, a level of a histone or afragment thereof can be determined in the sample that is not assembledin a macromolecular complex, such as a nucleosome, octamer or aneutrophil extracellular trap (NET). Such histone(s) are herein referredto as “free histone(s)”. Accordingly, the level of the at least onehistone may particularly be a level of at least one free histone.

The level of such free histones can be determined by the detection ofamino acid sequences or structural epitopes of histones that are notaccessible in an assembled stoichiometric macromolecular complex, like amono-nucleosome or an octamer. In such structures, particular regions ofthe histones are covered and are thus sterically inaccessible as shownfor the neutrophil extracellular traps (“NETs”). In addition, in theoctamer or nucleosome, regions of histones also participate inintramolecular interactions, such as between the individual histones.

Accordingly, the region/peptide/epitope of the histone that isdetermined in the context of the invention may determine whether thehistone is a free histone or a histone that is assembled in amacromolecular complex. For example, in an immunoassay based method, theutilized antibodies may not detect histones, e.g. H4, when they are partof the octameric core of nucleosomes as the epitopes are structurallyinaccessible. Herein below, regions/peptides/epitopes of the histone areexemplified that could be employed to determine a free histone. Forexample, regions/peptides/epitopes of the N-terminal or C-terminal tailof the histones can be employed to determine histones independent ofwhether they are assembled in the macromolecular complex or are freehistones according to the present invention.

“Stoichiometric” in this context relates to intact complexes, e.g. amononucleosome or an octamer. “Free histone proteins” can also comprisenon-chromatin-bound histones. For example, “free histone proteins” mayalso comprise individual histone proteins or non-octameric histonecomplexes. Free histones may (e.g. transiently) be bound to individualhistones, for instance, histones may form homo- or hetero-dimers. Thefree histones may also form homo- or hetero-tetramers. The homo- orheterotetramer may consist of four molecules of histones, e.g. H2A, H2B,H3 and/or H4. A typical heterotetramer is formed by two heterodimers,wherein each heterodimer consists of H3 and H4. It is also understoodherein that a heterotetramer may be formed by H2A and H2B. It is alsoenvisaged herein that a heterotetramer may be formed by one heterodimerconsisting of H3 and H4, and one heterodimer consisting of H2A and H2B.Free histones are thus herein referred to as and can be monomeric,heterodimeric or tetrameric histone proteins, which are not assembled ina (“stoichiometric”) macromolecular complex consisting of the histoneoctamer bound to nucleic acid, e.g. a nucleosome. In addition, freehistones may also be bound to nucleic acids, and wherein said freehistones are not assembled in a (“stoichiometric”) macromolecularcomplex, e.g. an intact nucleosome. Preferably, the free histone(s)is/are essentially free of nucleic acids.

Lactate, or lactic acid, is an organic compound with the formulaCH₃CH(OH)COOH, which occurs in bodily fluids including blood. Bloodtests for lactate are performed to determine the status of the acid basehomeostasis in the body. Lactic acid is a product of cell metabolismthat can accumulate when cells lack sufficient oxygen (hypoxia) and mustturn to a less efficient means of energy production, or when a conditioncauses excess production or impaired clearance of lactate. Lacticacidosis can be caused by an inadequate amount of oxygen in cells andtissues (hypoxia), for example if someone has a condition that may leadto a decreased amount of oxygen delivered to cells and tissues, such asshock, septic shock or congestive heart failure, the lactate test can beused to help detect and evaluate the severity of hypoxia and lacticacidosis.

C-reactive protein (CRP) is a pentameric protein, which can be found inbodily fluids such as blood plasma. CRP levels can rise in response toinflammation. Measuring and charting CRP values can prove useful indetermining disease progress or the effectiveness of treatments.

As used herein, the “sequential organ failure assessment score” or “SOFAscore” is one score used to track a patient's status during the stay inan intensive care unit (ICU). The SOFA score is a scoring system todetermine the extent of a person's organ function or rate of failure.The score is based on six different scores, one each for therespiratory, cardiovascular, hepatic, coagulation, renal andneurological systems. Both the mean and highest SOFA scores beingpredictors of outcome. An increase in SOFA score during the first 24 to48 hours in the ICU predicts a mortality rate of at least 50% up to 95%.Scores less than 9 give predictive mortality at 33% while above 14 canbe close to or above 95%.

As used herein, the quick SOFA score (qSOFA) is a scoring system thatindicates a patient's organ dysfunction or mortality risk. The score isbased on three criteria: 1) an alteration in mental status, 2) adecrease in systolic blood pressure of less than 100 mm Hg, 3) arespiration rate greater than 22 breaths per minute. Patients with twoor more of these conditions are at greater risk of having an organdysfunction or to die.

As used herein, “APACHE II” or “Acute Physiology and Chronic HealthEvaluation II” is a severity-of-disease classification scoring system(Knaus et al., 1985). It can be applied within 24 hours of admission ofa patient to an intensive care unit (ICU) and may be determined based on12 different physiologic parameters: AaDO2 or PaO2 (depending on FiO2),temperature (rectal), mean arterial pressure, pH arterial, heart rate,respiratory rate, sodium (serum), potassium (serum), creatinine,hematocrit, white blood cell count and Glasgow Coma Scale.

As used herein, “SAPS II” or “Simplified Acute Physiology Score II”relates to a system for classifying the severity of a disease ordisorder (see Le Gall J R et al., A new Simplified Acute PhysiologyScore (SAPS II) based on a European/North American multicenter study.JAMA. 1993; 270(24):2957-63.). The SAPS II score is made of 12physiological variables and 3 disease-related variables. The point scoreis calculated from 12 routine physiological measurements, informationabout previous health status and some information obtained at admissionto the ICU.

The SAPS II score can be determined at any time, preferably, at day 2.The “worst” measurement is defined as the measure that correlates to thehighest number of points. The SAPS II score ranges from 0 to 163 points.The classification system includes the followings parameters: Age, HeartRate, Systolic Blood Pressure, Temperature, Glasgow Coma Scale,Mechanical Ventilation or CPAP, PaO2, FiO2, Urine Output, Blood UreaNitrogen, Sodium, Potassium, Bicarbonate, Bilirubin, White Blood Cell,Chronic diseases and Type of admission. There is a sigmoidalrelationship between mortality and the total SAPS II score. Themortality of a subject is 10% at a SAPSII score of 29 points, themortality is 25% at a SAPSII score of 40 points, the mortality is 50% ata SAPSII score of 52 points, the mortality is 75% at a SAPSII score of64 points, the mortality is 90% at a SAPSII score of 77 points (Le Gallloc. cit.).

As used herein, the term “sample” is a biological sample that isobtained or isolated from the patient or subject. “Sample” as usedherein may, e.g., refer to a sample of bodily fluid or tissue obtainedfor the purpose of diagnosis, prognosis, or evaluation of a subject ofinterest, such as a patient. Preferably herein, the sample is a sampleof a bodily fluid, such as blood, serum, plasma, cerebrospinal fluid,urine, saliva, sputum, pleural effusions, cells, a cellular extract, atissue sample, a tissue biopsy, a stool sample and the like.Particularly, the sample is blood, blood plasma, blood serum, or urine.

Embodiments of the present invention refer to the isolation of a firstsample and the isolation of a second sample. In the context of themethod of the present invention, the terms “first sample” and “secondsample” relate to the relative determination of the order of isolationof the samples employed in the method of the present invention. When theterms first sample and second sample are used in specifying the presentmethod, these samples are not to be considered as absolutedeterminations of the number of samples taken. Therefore, additionalsamples may be isolated from the patient before, during or afterisolation of the first and/or the second sample, or between the first orsecond samples, wherein these additional samples may or may not be usedin the method of the present invention. The first sample may thereforebe considered as any previously obtained sample. The second sample maybe considered as any further or subsequent sample.

“Plasma” in the context of the present invention is the virtuallycell-free supernatant of blood containing anticoagulant obtained aftercentrifugation. Exemplary anticoagulants include calcium ion bindingcompounds such as EDTA or citrate and thrombin inhibitors such asheparinates or hirudin. Cell-free plasma can be obtained bycentrifugation of the anticoagulated blood (e.g. citrated, EDTA orheparinized blood), for example for at least 15 minutes at 2000 to 3000g.

“Serum” in the context of the present invention is the liquid fractionof whole blood that is collected after the blood is allowed to clot.When coagulated blood (clotted blood) is centrifuged serum can beobtained as supernatant.

As used herein, “urine” is a liquid product of the body secreted by thekidneys through a process called urination (or micturition) and excretedthrough the urethra.

In preferred embodiments of the present invention the patient has beendiagnosed as suffering from sepsis. More particularly, the patient mayhave been diagnosed as suffering from severe sepsis and/or septic shock.

“Sepsis” in the context of the invention refers to a systemic responseto infection. Alternatively, sepsis may be seen as the combination ofSIRS with a confirmed infectious process or an infection. Sepsis may becharacterized as clinical syndrome defined by the presence of bothinfection and a systemic inflammatory response (Levy M M et al. 2001SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.Crit Care Med. 2003 April; 31(4):1250-6). The term “sepsis” used hereinincludes, but is not limited to, sepsis, severe sepsis, septic shock.

The term “sepsis” used herein includes, but is not limited to, sepsis,severe sepsis, septic shock. Severe sepsis in refers to sepsisassociated with organ dysfunction, hypoperfusion abnormality, orsepsis-induced hypotension. Hypoperfusion abnormalities include lacticacidosis, oliguria and acute alteration of mental status. Sepsis-inducedhypotension is defined by the presence of a systolic blood pressure ofless than about 90 mm Hg or its reduction by about 40 mm Hg or more frombaseline in the absence of other causes for hypotension (e.g.cardiogenic shock). Septic shock is defined as severe sepsis withsepsis-induced hypotension persisting despite adequate fluidresuscitation, along with the presence of hypoperfusion abnormalities ororgan dysfunction (Bone et al., CHEST 101(6): 1644-55, 1992).

The term sepsis may alternatively be defined as life-threatening organdysfunction caused by a dysregulated host response to infection. Forclinical operationalization, organ dysfunction can preferably berepresented by an increase in the Sequential Organ Failure Assessment(SOFA) score of 2 points or more, which is associated with anin-hospital mortality greater than 10%. Septic shock may be defined as asubset of sepsis in which particularly profound circulatory, cellular,and metabolic abnormalities are associated with a greater risk ofmortality than with sepsis alone. Patients with septic shock can beclinically identified by a vasopressor requirement to maintain a meanarterial pressure of 65 mm Hg or greater and serum lactate level greaterthan 2 mmol/L (>18 mg/dL) in the absence of hypovolemia.

The term “sepsis” used herein relates to all possible stages in thedevelopment of sepsis.

The term “sepsis” also includes severe sepsis or septic shock based onthe SEPSIS-2 definition (Bone et al., 2009). The term “sepsis” alsoincludes subjects falling within the SEPSIS-3 definition (Singer et al.,2016). The term “sepsis” used herein relates to all possible stages inthe development of sepsis.

As used herein, “infection” within the scope of the invention means apathological process caused by the invasion of normally sterile tissueor fluid by pathogenic or potentially pathogenic agents/pathogens,organisms and/or microorganisms, and relates preferably to infection(s)by bacteria, viruses, fungi, and/or parasites. Accordingly, theinfection can be a bacterial infection, viral infection, and/or fungalinfection. The infection can be a local or systemic infection. For thepurposes of the invention, a viral infection may be considered asinfection by a microorganism.

Further, the subject suffering from an infection can suffer from morethan one source(s) of infection simultaneously. For example, the subjectsuffering from an infection can suffer from a bacterial infection andviral infection; from a viral infection and fungal infection; from abacterial and fungal infection, and from a bacterial infection, fungalinfection and viral infection, or suffer from a mixed infectioncomprising one or more of the infections listed herein, includingpotentially a superinfection, for example one or more bacterialinfections in addition to one or more viral infections and/or one ormore fungal infections.

As used herein “infectious disease” comprises all diseases or disordersthat are associated with bacterial and/or viral and/or fungalinfections.

According to the present invention, critically ill patients, such asseptic patients may need a very strict control, with respect of vitalfunctions and/or monitoring of organ protection and may be under medicaltreatment.

In the context of the present invention, the term “medical treatment” or“treatment” comprises various treatments and therapeutic strategies,which comprise, without limitation, anti-inflammatory strategies,administration of proADM-antagonists such as therapeutic antibodies,si-RNA or DNA, the extracorporal blood purification or the removal ofharmful substances via apheresis, dialyses, adsorbers to prevent thecytokine storm, removal of inflammatory mediators, plasma apheresis,administration of vitamines such as vitamin C, ventilation likemechanical ventilation and non-mechanical ventilation, to provide thebody with sufficient oxygen, for example, focus cleaning procedures,transfusion of blood products, infusion of colloids, renal or liverreplacement, antibiotic treatment, invasive mechanical ventilation,non-invasive mechanical ventilation, renal replacement therapy,vasopressor use, fluid therapy, apheresis and measures for organprotection, provision of corticosteroids, blood or platelet transfusion,transfusion of blood components, such as serum, plasma or specific cellsor combinations thereof, drugs promoting the formation of thrombocytes,source control, surgeries, causative treatment or performing asplenectomy.

Further treatments of the present invention comprise the administrationof cells or cell products like stem cells, blood or plasma, and thestabilization of the patients circulation and the protection ofendothelial glycocalyx, for example via optimal fluid managementstrategies, for example to reach normovolemia and prevent or treathypervolemia or hypovolemia. Moreover, vasopressors or e.g.catecholamine as well as albumin or heparanase inhibition viaunfractionated heparin or N-desulfated re-N-acetylated heparin areuseful treatments to support the circulation and endothelial layer.

Additionally, medical treatments of the present invention comprise,without limitation, stabilization of the blood clotting, iNOSinhibitors, anti-inflammatory agents like hydrocortisone, sedatives andanalgetics as well as insuline.

“Renal replacement therapy” (RRT) relates to a therapy that is employedto replace the normal blood-filtering function of the kidneys. Renalreplacement therapy may refer to dialysis (e.g. hemodialysis orperitoneal dialysis), hemofiltration, and hemodiafiltration. Suchtechniques are various ways of diverting the blood into a machine,cleaning it, and then returning it to the body.

Renal replacement therapy may also refer to kidney transplantation,which is the ultimate form of replacement in that the old kidney isreplaced by a donor kidney. The hemodialysis, hemofiltration, andhemodiafiltration may be continuous or intermittent and can use anarteriovenous route (in which blood leaves from an artery and returnsvia a vein) or a venovenous route (in which blood leaves from a vein andreturns via a vein). This results in various types of RRT. For example,the renal replacement therapy may be selected from the group of, but notlimited to continuous renal replacement therapy (CRRT), continuoushemodialysis (CHD), continuous arteriovenous hemodialysis (CAVHD),continuous venovenous hemodialysis (CVVHD), continuous hemofiltration(CHF), continuous arteriovenous hemofiltration (CAVH or CAVHF),continuous venovenous hemofiltration (CVVH or CVVHF), continuoushemodiafiltration (CHDF), continuous arteriovenous hemodiafiltration(CAVHDF), continuous venovenous hemodiafiltration (CVVHDF), intermittentrenal replacement therapy (IRRT), intermittent hemodialysis (IHD),intermittent venovenous hemodialysis (IVVHD), intermittenthemofiltration (IHF), intermittent venovenous hemofiltration (IVVH orIVVHF), intermittent hemodiafiltration (IHDF) and intermittentvenovenous hemodiafiltration (IVVHDF).

Artificial and mechanical ventilation are effective approaches toenhance proper gas exchange and ventilation and aim to save life duringsevere hypoxemia. Artificial ventilation relates to assisting orstimulating respiration of the subject. Artificial ventilation may beselected from the group consisting of mechanical ventilation, manualventilation, extracorporeal membrane oxygenation (ECMO) and noninvasiveventilation (NIV). Mechanical ventilation relates to a method tomechanically assist or replace spontaneous breathing. This may involve amachine called a ventilator. Mechanical ventilation may beHigh-Frequency Oscillatory Ventilation or Partial Liquid Ventilation.

“Fluid management” refers to the monitoring and controlling of the fluidstatus of a subject and the administration of fluids to stabilize thecirculation or organ vitality, by e.g. oral, enteral or intravenousfluid administration. It comprises the stabilization of the fluid andelectrolyte balance or the prevention or correction of hyer- orhypovolemia as well as the supply of blood products.

Surgical emergencies/Emergency surgery are needed if a subject has amedical emergency and an immediate surgical intervention may be requiredto preserve survival or health status. The subject in need of emergencysurgery may be selected from the group consisting of subjects sufferingfrom acute trauma, an active uncontrolled infection, organtransplantation, organ-preventive or organ-stabilizing surgery orcancer.

Cleaning Procedures are hygienic methods to prevent subjects frominfections, especially nosocomial infections, comprising desinfection ofall organic and anorganic surfaces that could get in contact with apatient, such as for example, skin, objects in the patient's room,medical devices, diagnostic devices, or room air. Cleaning proceduresinclude the use of protective clothes and units, such as mouthguards,gowns, gloves or hygiene lock, and actions like restricted patientvisits. Furthermore, cleaning procedures comprise the cleaning of thepatient itself and the clothes or the patient.

In the case of critical illness, such as sepsis or severe infections itis very important to have an early diagnosis as well a prognosis andrisk assessment for the outcome of a patient to find the optimal therapyand management. The therapeutic approaches need to be very individualand vary from case to case. A therapeutic monitoring is needed for abest practice therapy and is influenced by the timing of treatment, theuse of combined therapies and the optimization of drug dosing. A wrongor omitted therapy or management will increase the mortality ratehourly.

A medical treatment of the present invention may be an antibiotictreatment, wherein one or more “antibiotics” or “antiinfective agents”may be administered if an infection has been diagnosed or symptoms of aninfectious disease have been determined.

Furthermore, antibiotic agents comprise bacteriophages for treatment ofbacterial infections, synthetic antimicrobial peptides oriron-antagonists/iron chelator. Also, therapeutic antibodies orantagonist against pathogenic structures like anti-VAP-antibodies,anti-resistant clone vaccination, administration of immune cells, suchas in vitro primed or modulated T-effector cells, are antibiotic agentsthat represent treatment options for critically ill patients, such assepsis patients. Further antibiotic agents/treatments or therapeuticstrategies against infection or for the prevention of new infectionsinclude the use of antiseptics, decontamination products, anti-virulenceagents like liposomes, sanitation, wound care, surgery.

It is also possible to combine several of the aforementioned antibioticagents or treatments strategies with fluid therapy, platelet transfusionor transfusion of blood products.

According to the present invention proADM and optionally PCT and/orother markers or clinical scores are employed as markers for therapymonitoring, comprising prognosis, prognosis, risk assessment and riskstratification of a subsequent adverse event in the health of a patientwhich has been diagnosed as being critically ill.

A skilled person is capable of obtaining or developing means for theidentification, measurement, determination and/or quantification of anyone of the above proADM molecules, or fragments or variants thereof, aswell as the other markers of the present invention according to standardmolecular biological practice.

The level of proADM or fragments thereof as well as the levels of othermarkers of the present invention can be determined by any assay thatreliably determines the concentration of the marker. Particularly, massspectrometry (MS) and/or immunoassays can be employed as exemplified inthe appended examples. As used herein, an immunoassay is a biochemicaltest that measures the presence or concentration of amacromolecule/polypeptide in a solution through the use of an antibodyor antibody binding fragment or immunoglobulin.

Methods of determining proADM or other the markers such as PCT used inthe context of the present invention are intended in the presentinvention. By way of example, a method may be employed selected from thegroup consisting of mass spectrometry (MS), luminescence immunoassay(LIA), radioimmunoassay (RIA), chemiluminescence- andfluorescence-immunoassays, enzyme immunoassay (EIA), Enzyme-linkedimmunoassays (ELISA), luminescence-based bead arrays, magnetic beadsbased arrays, protein microarray assays, rapid test formats such as forinstance immunochromatographic strip tests, rare cryptate assay, andautomated systems/analyzers.

Determination of proADM and optionally other markers based on antibodyrecognition is a preferred embodiment of the invention. As used herein,the term, “antibody” refers to immunoglobulin molecules andimmunologically active portions of immunoglobulin (Ig) molecules, i.e.,molecules that contain an antigen binding site that specifically binds(immuno reacts with) an antigen. According to the invention, theantibodies may be monoclonal as well as polyclonal antibodies.Particularly, antibodies that are specifically binding to at test proADMor fragments thereof are used.

An antibody is considered to be specific, if its affinity towards themolecule of interest, e.g. proADM, or the fragment thereof is at least50-fold higher, preferably 100-fold higher, most preferably at least1000-fold higher than towards other molecules comprised in a samplecontaining the molecule of interest. It is well known in the art how todevelop and to select antibodies with a given specificity. In thecontext of the invention, monoclonal antibodies are preferred. Theantibody or the antibody binding fragment binds specifically to theherein defined markers or fragments thereof. In particular, the antibodyor the antibody binding fragment binds to the herein defined peptides ofproADM. Thus, the herein defined peptides can also be epitopes to whichthe antibodies specifically bind. Further, an antibody or an antibodybinding fragment is used in the methods and kits of the invention thatbinds specifically to proADM or proADM, particularly to MR-proADM.

Further, an antibody or an antibody binding fragment is used in themethods and kits of the invention that binds specifically to proADM orfragments thereof and optionally to other markers of the presentinventions such as PCT. Exemplary immunoassays can be luminescenceimmunoassay (LIA), radioimmunoassay (RIA), chemiluminescence- andfluorescence-immunoassays, enzyme immunoassay (EIA), Enzyme-linkedimmunoassays (ELISA), luminescence-based bead arrays, magnetic beadsbased arrays, protein microarray assays, rapid test formats, rarecryptate assay. Further, assays suitable for point-of-care testing andrapid test formats such as for instance immune-chromatographic striptests can be employed. Automated immunoassays are also intended, such asthe KRYPTOR assay.

Alternatively, instead of antibodies, other capture molecules ormolecular scaffolds that specifically and/or selectively recognizeproADM may be encompassed by the scope of the present invention. Herein,the term “capture molecules” or “molecular scaffolds” comprisesmolecules which may be used to bind target molecules or molecules ofinterest, i.e. analytes (e.g. proADM, proADM, MR-proADM, and PCT), froma sample. Capture molecules must thus be shaped adequately, bothspatially and in terms of surface features, such as surface charge,hydrophobicity, hydrophilicity, presence or absence of lewis donorsand/or acceptors, to specifically bind the target molecules or moleculesof interest. Hereby, the binding may, for instance, be mediated byionic, van-der-Waals, pi-pi, sigma-pi, hydrophobic or hydrogen bondinteractions or a combination of two or more of the aforementionedinteractions or covalent interactions between the capture molecules ormolecular scaffold and the target molecules or molecules of interest. Inthe context of the present invention, capture molecules or molecularscaffolds may for instance be selected from the group consisting of anucleic acid molecule, a carbohydrate molecule, a PNA molecule, aprotein, a peptide and a glycoprotein. Capture molecules or molecularscaffolds include, for example, aptamers, DARpins (Designed AnkyrinRepeat Proteins). Affimers and the like are included.

In certain aspects of the invention, the method is an immunoassaycomprising the steps of:

a) contacting the sample with

-   -   i. a first antibody or an antigen-binding fragment or derivative        thereof specific for a first epitope of said proADM, and    -   ii. a second antibody or an antigen-binding fragment or        derivative thereof specific for a second epitope of said proADM;        and

b) detecting the binding of the two antibodies or antigen-bindingfragments or derivates thereof to said proADM.

Preferably, one of the antibodies can be labeled and the other antibodycan be bound to a solid phase or can be bound selectively to a solidphase. In a particularly preferred aspect of the assay, one of theantibodies is labeled while the other is either bound to a solid phaseor can be bound selectively to a solid phase. The first antibody and thesecond antibody can be present dispersed in a liquid reaction mixture,and wherein a first labeling component which is part of a labelingsystem based on fluorescence or chemiluminescence extinction oramplification is bound to the first antibody, and a second labelingcomponent of said labeling system is bound to the second antibody sothat, after binding of both antibodies to said proADM or fragmentsthereof to be detected, a measurable signal which permits detection ofthe resulting sandwich complexes in the measuring solution is generated.The labeling system can comprise a rare earth cryptate or chelate incombination with a fluorescent or chemiluminescent dye, in particular ofthe cyanine type.

In a preferred embodiment, the method is executed as heterogeneoussandwich immunoassay, wherein one of the antibodies is immobilized on anarbitrarily chosen solid phase, for example, the walls of coated testtubes (e.g. polystyrol test tubes; coated tubes; CT) or microtiterplates, for example composed of polystyrol, or to particles, such as forinstance magnetic particles, whereby the other antibody has a groupresembling a detectable label or enabling for selective attachment to alabel, and which serves the detection of the formed sandwich structures.A temporarily delayed or subsequent immobilization using suitable solidphases is also possible.

The method according to the present invention can furthermore beembodied as a homogeneous method, wherein the sandwich complexes formedby the antibody/antibodies and the marker, proADM or a fragment thereof,which is to be detected remains suspended in the liquid phase. In thiscase it is preferred, that when two antibodies are used, both antibodiesare labeled with parts of a detection system, which leads to generationof a signal or triggering of a signal if both antibodies are integratedinto a single sandwich. Such techniques are to be embodied in particularas fluorescence enhancing or fluorescence quenching detection methods. Aparticularly preferred aspect relates to the use of detection reagentswhich are to be used pair-wise, such as for example the ones which aredescribed in U.S. Pat. No. 4,882,733, EP0180492 or EP0539477 and theprior art cited therein. In this way, measurements in which onlyreaction products comprising both labeling components in a singleimmune-complex directly in the reaction mixture are detected, becomepossible. For example, such technologies are offered under the brandnames TRACE® (Time Resolved Amplified Cryptate Emission) or KRYPTOR®,implementing the teachings of the above-cited applications. Therefore,in particular preferred aspects, a diagnostic device is used to carryout the herein provided method. For example, the level of proADM orfragments thereof and/or the level of any further marker of the hereinprovided method, such as PCT, is determined.

In particular preferred aspects, the diagnostic device is KRYPTOR®.

The level of the marker of the present invention, e.g. the proADM orfragments thereof, PCT or fragments thereof, or other markers, can alsobe determined by a mass spectrometric (MS) based methods. Such a methodmay comprise detecting the presence, amount or concentration of one ormore modified or unmodified fragment peptides of e.g. proADM or the PCTin said biological sample or a protein digest (e.g. tryptic digest) fromsaid sample, and optionally separating the sample with chromatographicmethods, and subjecting the prepared and optionally separated sample toMS analysis. For example, selected reaction monitoring (SRM), multiplereaction monitoring (MRM) or parallel reaction monitoring (PRM) massspectrometry may be used in the MS analysis, particularly to determinethe amounts of proADM or fragments thereof.

Herein, the term “mass spectrometry” or “MS” refers to an analyticaltechnique to identify compounds by their mass. In order to enhance themass resolving and mass determining capabilities of mass spectrometry,the samples can be processed prior to MS analysis.

Accordingly, the invention relates to MS detection methods that can becombined with immuno-enrichment technologies, methods related to samplepreparation and/or chromatographic methods, preferably with liquidchromatography (LC), more preferably with high performance liquidchromatography (HPLC) or ultra high performance liquid chromatography(UHPLC).

Sample preparation methods comprise techniques for lysis, fractionation,digestion of the sample into peptides, depletion, enrichment, dialysis,desalting, alkylation and/or peptide reduction.

However, these steps are optional. The selective detection of analyteions may be conducted with tandem mass spectrometry (MS/MS). Tandem massspectrometry is characterized by mass selection step (as used herein,the term “mass selection” denotes isolation of ions having a specifiedm/z or narrow range of m/z's), followed by fragmentation of the selectedions and mass analysis of the resultant product (fragment) ions.

The skilled person is aware how quantify the level of a marker in thesample by mass spectrometric methods. For example, relativequantification “rSRM” or absolute quantification can be employed asdescribed above.

Moreover, the levels (including reference levels) can be determined bymass spectrometric based methods, such as methods determining therelative quantification or determining the absolute quantification ofthe protein or fragment thereof of interest.

Relative quantification “rSRM” may be achieved by:

1. Determining increased or decreased presence of the target protein bycomparing the SRM (Selected reaction monitoring) signature peak areafrom a given target fragment peptide detected in the sample to the sameSRM signature peak area of the target fragment peptide in at least asecond, third, fourth or more biological samples.

2. Determining increased or decreased presence of target protein bycomparing the SRM signature peak area from a given target peptidedetected in the sample to SRM signature peak areas developed fromfragment peptides from other proteins, in other samples derived fromdifferent and separate biological sources, where the SRM signature peakarea comparison between the two samples for a peptide fragment arenormalized for e.g to amount of protein analyzed in each sample.

3. Determining increased or decreased presence of the target protein bycomparing the SRM signature peak area for a given target peptide to theSRM signature peak areas from other fragment peptides derived fromdifferent proteins within the same biological sample in order tonormalize changing levels of histones protein to levels of otherproteins that do not change their levels of expression under variouscellular conditions.

4. These assays can be applied to both unmodified fragment peptides andto modified fragment peptides of the target proteins, where themodifications include, but are not limited to phosphorylation and/orglycosylation, acetylation, methylation (mono, di, tri), citrullination,ubiquitinylation and where the relative levels of modified peptides aredetermined in the same manner as determining relative amounts ofunmodified peptides.

Absolute quantification of a given peptide may be achieved by:

1. Comparing the SRM/MRM signature peak area for a given fragmentpeptide from the target proteins in an individual biological sample tothe SRM/MRM signature peak area of an internal fragment peptide standardspiked into the protein lysate from the biological sample. The internalstandard may be a labeled synthetic version of the fragment peptide fromthe target protein that is being interrogated or the labeled recombinantprotein. This standard is spiked into a sample in known amounts before(mandatory for the recombinant protein) or after digestion, and theSRM/MRM signature peak area can be determined for both the internalfragment peptide standard and the native fragment peptide in thebiological sample separately, followed by comparison of both peak areas.This can be applied to unmodified fragment peptides and modifiedfragment peptides, where the modifications include but are not limitedto phosphorylation and/or glycosylation, acetylation, methylation (e.g.mono-, di-, or tri-methylation), citrullination, ubiquitinylation, andwhere the absolute levels of modified peptides can be determined in thesame manner as determining absolute levels of unmodified peptides.

2. Peptides can also be quantified using external calibration curves.The normal curve approach uses a constant amount of a heavy peptide asan internal standard and a varying amount of light synthetic peptidespiked into the sample. A representative matrix similar to that of thetest samples needs to be used to construct standard curves to accountfor a matrix effect. Besides, reverse curve method circumvents the issueof endogenous analyte in the matrix, where a constant amount of lightpeptide is spiked on top of the endogenous analyte to create an internalstandard and varying amounts of heavy peptide are spiked to create a setof concentration standards. Test samples to be compared with either thenormal or reverse curves are spiked with the same amount of standardpeptide as the internal standard spiked into the matrix used to createthe calibration curve.

The invention further relates to kits, the use of the kits and methodswherein such kits are used. The invention relates to kits for carryingout the herein above and below provided methods. The herein provideddefinitions, e.g. provided in relation to the methods, also apply to thekits of the invention. In particular, the invention relates to kits fortherapy monitoring, comprising the prognosis, risk assessment or riskstratification of a subsequent adverse event in the health of a patient,wherein said kit comprises

-   -   detection reagents for determining the level proADM or        fragment(s) thereof, and optionally additionally for determining        the level of PCT, lactate and/or C-reactive protein or        fragment(s) thereof, in a sample from a subject, and—detection        reagents for determining said level of proADM in said sample of        said subject, and    -   reference data, such as a reference level, corresponding to high        and/or low severity levels of proADM, wherein the low severity        level is below 4 nmol/l, preferably below 3 nmol/l, more        preferably below 2.7 nmol/l, and the high severity level is        above 6.5 nmol/l, preferably above 6.95 nmol/l, more preferably        above 10.9 nmol/l, and optionally PCT, lactate and/or C-reactive        protein levels, wherein said reference data is preferably stored        on a computer readable medium and/or employed in the form of        computer executable code configured for comparing the determined        levels of proADM or fragment(s) thereof, and optionally        additionally the determined levels of PCT, lactate and/or        C-reactive protein or fragment(s) thereof, to said reference        data.

As used herein, “reference data” comprise reference level(s) of proADMand optionally PCT, lactate and/or C-reactive protein. The levels ofproADM and optionally PCT, lactate and/or C-reactive protein in thesample of the subject can be compared to the reference levels comprisedin the reference data of the kit. The reference levels are hereindescribed above and are exemplified also in the appended examples. Thereference data can also include a reference sample to which the level ofproADM and optionally PCT, lactate and/or C-reactive protein iscompared. The reference data can also include an instruction manual howto use the kits of the invention.

The kit may additionally comprise items useful for obtaining a sample,such as a blood sample, for example the kit may comprise a container,wherein said container comprises a device for attachment of saidcontainer to a canula or syringe, is a syringe suitable for bloodisolation, exhibits an internal pressure less than atmospheric pressure,such as is suitable for drawing a pre-determined volume of sample intosaid container, and/or comprises additionally detergents, chaotropicsalts, ribonuclease inhibitors, chelating agents, such as guanidiniumisothiocyanate, guanidinium hydrochloride, sodium dodecylsulfate,polyoxyethylene sorbitan monolaurate, RNAse inhibitor proteins, andmixtures thereof, and/or A filter system containing nitro-cellulose,silica matrix, ferromagnetic spheres, a cup retrieve spill over,trehalose, fructose, lactose, mannose, poly-ethylen-glycol, glycerol,EDTA, TRIS, limonene, xylene, benzoyl, phenol, mineral oil, anilin,pyrol, citrate, and mixtures thereof.

As used herein, the “detection reagent” or the like are reagents thatare suitable to determine the herein described marker(s), e.g. ofproADM, PCT, lactate and/or C-reactive protein. Such exemplary detectionreagents are, for example, ligands, e.g. antibodies or fragmentsthereof, which specifically bind to the peptide or epitopes of theherein described marker(s). Such ligands might be used in immunoassaysas described above. Further reagents that are employed in theimmunoassays to determine the level of the marker(s) may also becomprised in the kit and are herein considered as detection reagents.Detection reagents can also relate to reagents that are employed todetect the markers or fragments thereof by MS based methods. Suchdetection reagent can thus also be reagents, e.g. enzymes, chemicals,buffers, etc, that are used to prepare the sample for the MS analysis. Amass spectrometer can also be considered as a detection reagent.Detection reagents according to the invention can also be calibrationsolution(s), e.g. which can be employed to determine and compare thelevel of the marker(s).

The sensitivity and specificity of a diagnostic and/or prognostic testdepends on more than just the analytical “quality” of the test, theyalso depend on the definition of what constitutes an abnormal result. Inpractice, Receiver Operating Characteristic curves (ROC curves), aretypically calculated by plotting the value of a variable versus itsrelative frequency in “normal” (i.e. apparently healthy individuals nothaving an infection and “disease” populations, e.g. subjects having aninfection. For any particular marker (like proADM), a distribution ofmarker levels for subjects with and without a disease/condition willlikely overlap. Under such conditions, a test does not absolutelydistinguish normal from disease with 100% accuracy, and the area ofoverlap might indicate where the test cannot distinguish normal fromdisease. A threshold is selected, below which the test is considered tobe abnormal and above which the test is considered to be normal or belowor above which the test indicates a specific condition, e.g. infection.The area under the ROC curve is a measure of the probability that theperceived measurement will allow correct identification of a condition.ROC curves can be used even when test results do not necessarily give anaccurate number. As long as one can rank results, one can create a ROCcurve. For example, results of a test on “disease” samples might beranked according to degree (e.g. 1=low, 2=normal, and 3=high). Thisranking can be correlated to results in the “normal” population, and aROC curve created. These methods are well known in the art; see, e.g.,Hanley et al. 1982. Radiology 143: 29-36. Preferably, a threshold isselected to provide a ROC curve area of greater than about 0.5, morepreferably greater than about 0.7, still more preferably greater thanabout 0.8, even more preferably greater than about 0.85, and mostpreferably greater than about 0.9. The term “about” in this contextrefers to +/−5% of a given measurement.

The horizontal axis of the ROC curve represents (1-specificity), whichincreases with the rate of false positives. The vertical axis of thecurve represents sensitivity, which increases with the rate of truepositives. Thus, for a particular cut-off selected, the value of(1-specificity) may be determined, and a corresponding sensitivity maybe obtained. The area under the ROC curve is a measure of theprobability that the measured marker level will allow correctidentification of a disease or condition. Thus, the area under the ROCcurve can be used to determine the effectiveness of the test.

Accordingly, the invention comprises the administration of an antibioticsuitable for treatment on the basis of the information obtained by themethod described herein.

As used herein, the terms “comprising” and “including” or grammaticalvariants thereof are to be taken as specifying the stated features,integers, steps or components but do not preclude the addition of one ormore additional features, integers, steps, components or groups thereof.This term encompasses the terms “consisting of” and “consistingessentially of”.

Thus, the terms “comprising”/“including”/“having” mean that any furthercomponent (or likewise features, integers, steps and the like) can/maybe present. The term “consisting of” means that no further component (orlikewise features, integers, steps and the like) is present.

The term “consisting essentially of” or grammatical variants thereofwhen used herein are to be taken as specifying the stated features,integers, steps or components but do not preclude the addition of one ormore additional features, integers, steps, components or groups thereofbut only if the additional features, integers, steps, components orgroups thereof do not materially alter the basic and novelcharacteristics of the claimed composition, device or method.

Thus, the term “consisting essentially of” means those specific furthercomponents (or likewise features, integers, steps and the like) can bepresent, namely those not materially affecting the essentialcharacteristics of the composition, device or method. In other words,the term “consisting essentially of” (which can be interchangeably usedherein with the term “comprising substantially”), allows the presence ofother components in the composition, device or method in addition to themandatory components (or likewise features, integers, steps and thelike), provided that the essential characteristics of the device ormethod are not materially affected by the presence of other components.

The term “method” refers to manners, means, techniques and proceduresfor accomplishing a given task including, but not limited to, thosemanners, means, techniques and procedures either known to, or readilydeveloped from known manners, means, techniques and procedures bypractitioners of the chemical, biological and biophysical arts.

The present invention is further described by reference to the followingnon-limiting examples.

EXAMPLES

Methods of the Examples:

Study Design and Patients:

This study is a secondary analysis of the Placebo-Controlled Trial ofSodium Selenite and Procalcitonin Guided Antimicrobial Therapy in SevereSepsis (SISPCT), which was performed across 33 multidisciplinaryintensive care units (ICUs) throughout Germany from November 2009 untilFebruary 2013 (26). Eligibility criteria included adult patients yearspresenting with new onset severe sepsis or septic shock (24 hours),according to the SEPSIS-1 definition of the ACCP/SCCM ConsensusConference Committee, and further classified according to the 2016definitions (sepsis-3 and septic shock-3) (4). Details of the studydesign, data collection and management were described previously (26).The ethics committee of Jena University Hospital and all other centresapproved the study and written informed consent was obtained whenevernecessary.

Biomarker Measurements:

Patients were enrolled up to 24 hours after diagnosis of severe sepsisor septic shock and PCT, CRP and lactate measured immediatelythereafter. PCT was measured on devices with a measuring range of0.02-5000 ng/ml, and a functional assay sensitivity and lower detectionlimit of at least 0.06 ng/ml and 0.02 ng/ml, respectively. Additionalblood samples from all patients were collected and stored at the centralstudy laboratory in Jena at −80° C. MR-proADM plasma concentrations weremeasured retrospectively (Kryptor®, Thermo Fisher Scientific, Germany)with a limit of detection of 0.05 nmol/L. Clinical severity scoresincluding the Sequential Organ Failure Assessment (SOFA), AcutePhysiological and Chronic Health Evaluation (APACHE) II and SimplifiedAcute Physiological (SAPS) II score were taken upon study enrollment.

Statistical Analysis:

Differences in demographic and clinical characteristics with regards to28 day mortality were assessed using the χ2 test for categoricalvariables, and Student's t-test or Mann-Whitney U test for continuousvariables, depending on distribution normality. Normally andnon-normally distributed variables were expressed as mean (standarddeviation) and median [first quartile−third quartile], respectively. Theassociation between mortality and each biomarker and clinical score atall time points was assessed using area under the receiver operatingcharacteristic curves (AUROC) and Cox regression analysis, withmultivariate analysis corrected for age and the presence ofcomorbidities and septic shock. Patients were further classified intothree severity subgroups (low, intermediate and high) based on thecalculation of two AUROC cut-offs across the total population for eachbiomarker and clinical score at each time point, with a predefinedsensitivity and specificity of close to 90%. A subgroup clinicallystable patients was subsequently identified with an absence of any ICUassociated procedures or complications (including focus cleaningprocedures, emergency surgery, the emergence of new infections,transfusion of blood products, infusion of colloids, invasive mechanicalventilation, renal/liver replacement or vasopressor therapy and adeterioration in the patient's general clinical signs and symptoms), anda further group identified with corresponding low MR-proADMconcentrations which had not shown any increase since the previousmeasurement. Mortality rates and average lengths of stay were calculatedin both groups and compared against the patient group who weredischarged at each specific time point.

Finally, two models stratifying patients with PCT changes of 20%(baseline to day 1, based on average PCT decreases observed over thistime period) and 50% (baseline to day four, based on a previouslyconstructed model (26)) were constructed. Patient subgroups weresubsequently identified based on MR-proADM severity levels, andrespective mortality rates calculated. The risk of mortality within eachsubgroup was calculated by Cox regression analysis and illustrated byKaplan-Meier curves. The predicted risk of developing new infections andthe requirement for focus cleaning procedures and emergency surgery overdays 4 to 7 were subsequently investigated in the baseline to day 4model. All data were analysed using the statistics software R (version3.1.2).

Example 1: Patient Characteristics

Patient characteristics upon study enrollment are summarized in Table 1.

A total of 1089 patients with either severe sepsis (13.0%) or septicshock (87.0%) were analysed, with 445 (41.3%) and 633 (58.7%) patientsalso satisfying the criteria for sepsis-3 and septic shock-3,respectively. Enrolled patients had an average age of 65.7 (13.7) yearsand a mean SOFA score of 10.0 (3.3) points. The 28 day all-causemortality rate (N=1076) was 26.9% (sepsis-3: 20.0%; septic shock-3:32.1%), with a hospital mortality rate of 33.4% (sepsis-3: 24.4%; septicshock-3: 40.4%). Infections originating from a single focus were foundin 836 patients (77.7%), with pneumological (N=324; 30.1%),intra-abdominal (N=252; 23.4%), urogenital (N=57; 5.3%) and bone/softtissue (N=50; 4.6%) origins most prevalent.

Corresponding mortality rates were 26.5%, 24.6%, 22.8% and 28.0%,respectively. Multiple origins of infection were found in 240 (22.3%)patients. The most common causes of mortality included sepsis inducedmultiple organ failure (N=132; 45.7%), refractory septic shock (N=54;18.7%), death due to pre-existing illness (N=35; 12.1%) and acuterespiratory insufficiency (N=17; 5.9%). Other causes such as cardiogenicand hemorrhagic shock, pulmonary embolism, cerebral oedema, myocardialinfarction and cardiac arrhythmia accounted for a combined mortalityrate of 8.6%. A limitation of therapy was applied to 3.4% of patients.

Example 2: Association of Baseline Biomarkers and Clinical Scores withMortality

Univariate and multivariate Cox regression analysis found that MR-proADMhad the strongest association with 28 day mortality across the totalpatient population, as well as within the sepsis-3 and septic shock-3subgroups (Table 2). Corresponding AUROC analysis found significantdifferences in all biomarker and clinical score comparisons withMR-proADM, apart from APACHE II (sepsis-3 patient subgroup).

Similar results were also found for 7 day, 90 day, ICU and hospitalmortality prediction (Table 3), with the addition of MR-proADM to allpotential biomarkers and clinical score combinations (N=63)significantly increasing prognostic capability (Table 4).

Example 3: Identification of High-Risk Patients

The total patient population was further stratified according toexisting SOFA severity levels, and biomarker and clinical scoreperformance in predicting 28 day mortality assessed in each subgroup.MR-proADM showed the highest accuracy of all parameters in the low (SOFA7) and moderate (8 SOFA 13) severity SOFA subgroups (Table 5; Table 6).

Two corresponding MR-proADM cut-offs were subsequently calculated toidentify low (2.7 nmol/L) and high (>10.9 nmol/L) severity subgroups atbaseline. Compared to SOFA, a more accurate reclassification could bemade at both low (MR-proADM vs. SOFA: N=265 vs. 232; 9.8% vs. 13.8%mortality) and high (MR-proADM vs. SOFA: N=161 vs. 155; 55.9% vs. 41.3%)severity cut-offs (Table 7).

A subgroup of 94 patients (9.3%) with high MR-proADM concentrations andcorresponding low or intermediate SOFA had 28 and 90 day mortality ratesof 57.4% and 68.9%, respectively, compared to 19.8% and 30.8% in theremaining patient population with low and intermediate SOFA values.Similar patterns could be found for SAPS II, APACHE II and lactate,respectively (Tables 8-10).

Example 4: Identification of Low Risk Patients Throughout ICU Stay

The study cohort comprises a subset of clinically stable patients thatdid not face ICU related procedures or complications, such as focuscleaning procedures, emergency surgery, new infections, transfusion ofblood products, infusion of colloids, invasive mechanical ventilation,renal/liver replacement, deterioration in the patient's general clinicalsigns and symptoms.

This group of clinically stable patients was categorized as low riskpatients.

MR-proADM showed the strongest association with 28 day mortality acrossall subsequent time points (Table 11), and could provide a stablecut-off of 2.25 nmol/L in identifying a low risk patient population,resulting in the classification of greater patient numbers with lowermortality rates compared to other biomarkers and clinical scores (Table12). Accordingly, 290 low MR-proADM severity patients could beidentified on day 4, of which 79 (27.2%) were clinically stable and hadno increase in MR-proADM concentrations from the last measurement (Table13). A continuously low MR-proADM concentration could be found in 51(64.6%) patients, whilst a decrease from an intermediate to low levelseverity level could be observed in 28 (35.4%) patients. The average ICUlength of stay was 8 [7-10] days, with a 28 and 90 day mortality rate of0.0% and 1.4%, respectively. In comparison, only 43 patients wereactually discharged from the ICU on day 4, with a 28 and 90 daymortality rate of 2.3% and 10.0%. Analysis of the MR-proADMconcentrations within this group of patients indicated a range ofvalues, with 20 (52.6%), 16 (42.1%) and 2 (5.3%) patients having low,intermediate and high severity concentrations, respectively. Similarresults were found for patients remaining on the ICU on days 7 and 10.

MR-proADM with a stable cut-off of 2.25 nmol/L could identify a greaternumber of low risk patients with lower mortality rates compared to otherbiomarkers and clinical scores. Based on that finding more patientscould be discharged from the ICU compared to classifications withoutusing ADM. By discharging more patients, the hospital can moreefficiently occupy ICU beds and benefits from avoided costs.

Example 5: Additional Impact of MR-proADM on Procalcitonin GuidedTherapy

Time-dependent Cox regression analysis indicated that the earliestsignificant additional increase in prognostic information to MR-proADMbaseline values could be observed on day 1, with subsequent single orcumulative measurements resulting in significantly stronger associationswith 28 day mortality (Table 14). Hence two PCT guided algorithm modelswere constructed investigating PCT changes from baseline to either day 1or day 4, with corresponding subgroup analysis based on MR-proADMseverity classifications.

Patients with decreasing PCT concentrations of ≥20% from baseline to day1 (Table 15 and Table 16) or ≥50% from baseline to day 4 (Table 17 andTable 18) were found to have 28 day mortality rates of 18.3% (N=458) and17.1% (N=557), respectively. This decreased to 5.6% (N=125) and 1.8%(N=111) when patients had continuously low levels of MR-proADM, althoughincreased to 66.7% (N=27) and 53.8% (N=39) in patients with continuouslyhigh MR-proADM values (HR [95% CI]: 19.1 [8.0-45.9] and 43.1[10.1-184.0]).

Furthermore, patients with decreasing PCT values of 50% (baseline to day4), but continuously high or intermediate MR-proADM concentrations, hada significantly greater risk of developing subsequent nosocomialinfections (HR [95% CI]: high concentrations: 3.9 [1.5-10.5];intermediate concentrations: 2.4 [1.1-5.1] vs. patients withcontinuously low concentrations; intermediate concentrations: 2.9[1.2-6.8]) vs. decreasing intermediate to low concentrations), orrequiring emergency surgery (HR [95% CI]: intermediate concentrations:2.0 [1.1-3.7] vs.

decreasing intermediate to low concentrations). Conversely, patientswith increasing intermediate to high concentrations were more likely torequire cleaning of the infectious origin compared to those withcontinuously intermediate (HR [95% CI]: 3.2 [1.3-7.6]), or decreasing(HR [95% CI]: intermediate to low: 8.7 [3.1-24.8]); high tointermediate: 4.6 [1.4-14.5]) values. When PCT levels failed to decreaseby 50%, a significantly increased risk of requiring emergency surgerywas observed if MR-proADM concentrations were either at a continuouslyhigh (HR [95% CI]: 5.7 [1.5-21.9]) or intermediate (HR [95% CI]: 4.2[1.3-13.2]) level, as opposed to being continuously low.

Example 6: Association of Baseline Biomarkers and Clinical Scores withMortality

MR-proADM showed the strongest association in patients withpneumological and intra-abdominal infections, as well as in patientswith Gram positive infections, irrespective of the infectious origin(Tables 19-20). When patients were grouped according to operativeemergency, non-operative emergency and elective surgery historyresulting in admission to the ICU, MR-proADM provided the strongest andmost balanced association with 28 day mortality across all groups (Table21).

Example 7: Correlation of Biomarkers and Clinical Scores with SOFA atBaseline and Day 1

MR-proADM had the greatest correlation of all biomarkers with the SOFAscore at baseline, which was significantly increased when baselinevalues were correlated with day 1 SOFA scores. The greatest correlationcould be found between MR-proADM and SOFA on day 10, with differencesbetween individual SOFA subscores found throughout (Tables 22-24).

Example 8: Identification of High-Risk Patients

Similar results could be found in a subgroup of 124 patients (12.0%)with high MR-proADM concentrations and either low or intermediate SAPSII values (High MR-proADM subgroup: [54.8% and 65.6% mortality];remaining SAPS II population [19.7% and 30.0% mortality]), as well as in109 (10.6%) patients with either low or intermediate APACHE II values(High MR-proADM subgroup: [56.9% and 66.7% mortality]; remaining APACHEII population: [19.5% and 30.3% mortality]).

Example 9: Improved Procalcitonin (PCT) Guided Therapy by Combining PCTand ADM

Two PCT guided algorithm models were constructed investigating PCTchanges from baseline to either day 1 or day 4, with correspondingsubgroup analysis based on MR-proADM severity classifications (Tables25-30).

The previous examples show an add-on value for ADM in patients having aPCT decrease at <20% or <50%, as well as in patients where PCT decreasedby ≥20% or 50%. However, additional analysis demonstrates that ADM canbe an add-on regardless of % of decrease or even increase of PCT.Decreasing PCT values could reflect patients where the antibiotictreatment appears to be working, therefore the clinician thinks they areon a good way to survival (i.e. kill the root cause of the sepsis—thebacteria—should result in the patient getting better).

For example, some patients have decreasing PCT levels from baseline (dayof admission) to day 1 with a 28d mortality rate of 19%. By additionallymeasuring ADM, you can conclude from patients with low ADM a much higherchance of survival or much lower probability to die (Table 25; compare19% mortality rate decreasing PCT only vs. 5% mortality rate PCT+lowADM). By having a reduced risk of dying, patients could be dischargedfrom ICU with more confidence, or fewer diagnostic tests are required(i.e. you know they are on a good path to recovery).

On the other hand, new measures need to be considered for those with ahigh ADM value. They are at a much higher risk with regard to mortality(compare 19% mortality rate decreasing PCT only vs 58.8% mortality ratePCT+high ADM). The physician thinks the patient is getting better due tothe decrease in PCT value, but in fact the ADM concentration remains thesame. It can be therefore concluded that treatment isn't working, andneeds to be adapted as soon as possible).

In a similar way, ADM can help to stratify those patients withincreasing PCT values (Table 25).

Development of New Infections

PCT and MR-proADM changes were analyzed in two models, either frombaseline to day 1, or from baseline to day 4. Patients were groupedaccording to overall PCT changes and MR-proADM severity levels.

The number of new infections over days 1, 2, 3 and 4 (Table 26) and overdays 4, 5, 6 and 7 (Table 27) were subsequently calculated in eachpatient who was present on day 1 or day 4 respectively. In some cases,patients were discharged during the observation period. It is assumedthat no new infections were developed after release. Patients withmultiple infections over the observation days were counted as a singlenew infection.

As a clinical consequence, patients with high MR-proADM concentrationsshould potentially be treated with a broad-spectrum antibiotic on ICUadmission, in conjunction with others, in order to stop the developmenton new infections. Special care should be taken with these patients dueto their high susceptibility to pick up new infections.

Requirement for Focus Cleaning

PCT and MR-proADM changes were analyzed in two models, either frombaseline to day 1, or from baseline to day 4. Patients were groupedaccording to overall PCT changes and MR-proADM severity levels.

The number of focus cleaning events over days 1, 2, 3 and 4 (Table 28)and over days 4, 5, 6 and 7 (Table 29) were subsequently calculated ineach patient who was present on day 1 or day 4 respectively. In somecases, patients were discharged during the observation period.

Requirement of Emergency Surgery

PCT and MR-proADM changes were analyzed in two models, either frombaseline to day 1, or from baseline to day 4. Patients were groupedaccording to overall PCT changes and MR-proADM severity levels.

The number of emergency surgery requirements/events over days 1, 2, 3and 4 (Table 30) were subsequently calculated in each patient who waspresent on day 1. In some cases, patients were discharged during theobservation period.

Example 10: Requirement for Antibiotic Change or Modification

When combined within a PCT guided antibiotic algorithm, MR-proADM canstratify those patients who will require a future change or modificationin antibiotic therapy, from those who will not.

PCT and MR-proADM changes were analyzed in two models, either frombaseline to day 1, or from baseline to day 4. Patients were groupedaccording to overall PCT changes and MR-proADM severity levels.

The percentage of antibiotic changes on day 4 required for each patientgroup was subsequently calculated (Tables 31 and 32).

In Patients with Decreasing PCT Values ≥50%

Patients with increasing MR-proADM concentrations, from a low tointermediate severity level, were more likely to require a modificationin antibiotic therapy on day 4 than those who had continuously lowlevels (Odds Ration [95% CI]: 1.5 [0.6-4.1]).

In Patients with Decreasing PCT Values <50%

Patients with either increasing MR-proADM concentrations, from anintermediate to high severity level, or continuously highconcentrations, were also more likely to require changes in theirantibiotic therapy on day 4 than patients with continuously lowMR-proADM concentrations (Odds Ratio [95% CI]: 5.9 [1.9-18.1] and 2.9[0.8-10.4], respectively).

Conclusion

Despite increasing PCT concentrations, either from baseline to day 1, orbaseline to day 4, patients with continuously low MR-proADMconcentrations had significantly lower modifications made to theirprescribed antibiotic treatment than those with continuouslyintermediate or high concentrations. As a clinical consequence, whenfaced with increasing PCT concentrations, a physician should check thepatient's MR-proADM levels before deciding on changing antibiotics.

Those with low MR-proADM concentrations should be considered for eitheran increased dose or increased strength of the same antibiotic beforechanges are considered. Those with higher MR-proADM concentrationsshould be considered for earlier antibiotic changes (i.e. on days 1 to3, as opposed to day 4).

Example 11: Identification of Patients with Abnormal Platelet Levels andIdentification of High Risk Patients with Thrombocytopenia (Tables 33,34 and 35)

Proadrenomedullin and Procalcitonin levels were measured and analyzedwith regard to thrombocyte count, mortality rate and platelettransfusion at baseline and day 1. Increasing proADM and PCTconcentrations correlate with decreasing platelet numbers and plateletnumbers (<150.000 per μl) that reflect thrombocytopenia. The strongestdecrease of platelet count was observed in patients with the highestproADM levels at baseline. Moreover increased proADM and PCTconcentrations were in line with patients who required a platelettransfusion therapy. It could also confirmed that a higher mortalityrate is associated with patients having thrombocytopenia and increasedproADM (>6 nmol/L) and PCT (>7 ng/ml) levels.

Pro-ADM levels were investigated in patients who had normal thrombocytelevels at baseline to see if increasing proADM could predictthrombocytopenia. 39.4% of patients with continually elevated proADMlevels at baseline and on day 1(proADM>10.9 nmol/l) developedthrombocytopenia. 25.6% of patients with increased proADM levels atbaseline (proADM>2.75 nmol/L) and on day 1 (proADM>9.5 nmol/L) developedthrombocytopenia. 14.7% of patients with continually low proADM level atbaseline and on day 1 (proADM≤2.75 nmol/L) developed thrombocytopenia.The increased level of proADM correlated with the severity of thethrombocytopenic event and the associated increased mortality rate(proADM>10.9 nmol/L mortality rate of 51%; proADM≤2.75 nmol/L mortalityrate 9.1%).

Example 11 Refers to Tables 33-35

Discussion of Examples

An accurate and rapid assessment of disease severity is crucial in orderto initiate the most appropriate treatment at the earliest opportunity.Indeed, delayed or insufficient treatment may lead to a generaldeterioration in the patient's clinical condition, resulting in furthertreatment becoming less effective and a greater probability of a pooreroverall outcome (8, 27). As a result, numerous biomarkers and clinicalseverity scores have been proposed to fulfil this unmet clinical need,with the Sequential Organ Failure Assessment (SOFA) score currentlyhighlighted as the most appropriate tool, resulting in its central rolein the 2016 sepsis-3 definition (4). This secondary analysis of theSISPCT trial (26), for the first time, compared sequential measurementsof conventional biomarkers and clinical scores, such as lactate,procalcitonin (PCT) and SOFA, with those of the microcirculatorydysfunction marker, MR-proADM, in a large patient population with severesepsis and septic shock.

Our results indicate that the initial use of MR-proADM within the first24 hours after sepsis diagnosis resulted in the strongest associationwith short, mid and long-term mortality compared to all other biomarkersor scores. Previous studies largely confirm our findings (17, 28, 29),however conflicting results (30) may be explained in part by the smallersample sizes analysed, as well as other factors highlighted within thisstudy, such as microbial species, origin of infection and previoussurgical history preceding sepsis development, all of which mayinfluence biomarker performance, thus adding to the potentialvariability of results in small study populations.

Furthermore, our study also closely confirms the results of a previousinvestigation (17), highlighting the superior performance of MR-proADMin low and intermediate organ dysfunction severity patients. Indeed,Andaluz-Ojeda et al. (17) place significant importance on the patientgroup with low levels of organ dysfunction, since “this group representseither the earliest presentation in the clinical course of sepsis and/orthe less severe form of the disease”.

Nevertheless, a reasonable performance could be maintained across allseverity groups with respect to mortality prediction, which was also thecase across both patient groups defined according to the sepsis-3 andseptic shock-3 criteria.

Analysis of the sequential measurements taken after onset of sepsisallowed for the identification of specific patients groups based ondisease severity. The identification of both low and high-risk patientswas of significant interest in our analysis. In many ICUs, the demandfor ICU beds can periodically exceed availability, which may lead to aninadequate triage, a rationing of resources, and a subsequent decreasein the likelihood of correct ICU admission (32-35). Consequently, anaccurate assessment of patients with a low risk of hospital mortalitythat may be eligible for an early ICU discharge to a step down unit maybe of significant benefit. At each time point measured within our study,MR-proADM could identify a higher number of low severity patients withthe lowest ICU, hospital and 28 day mortality rates. Further analysis ofthe patient group with a low severity and no further ICU specifictherapies indicated that an additional 4 days of ICU stay were observedat each time point after biomarker measurements were taken. Whencompared to the patient population who were actually discharged at eachtime point, a biomarker driven approach to accurately identify lowseverity patients resulted in decreased 28 and 90 day mortality rates.Indeed, patients who were discharged had a variety of low, intermediateand high severity MR-proADM concentrations, which was subsequentlyreflected in a higher mortality rate.

It is, however, unknown whether a number of patients within this groupstill required further ICU treatment for non-microcirculatory, non-lifethreatening issues, or that beds in a step down unit were available.Nevertheless, such a biomarker driven approach to ICU discharge inaddition to clinician judgement may improve correct stratification ofthe patient, with accompanied clinical benefits and potential costsavings.

Conversely, the identification of high-risk patients who may requireearly and targeted treatment to prevent a subsequent clinicaldeterioration may be of even greater clinical relevance.

Substantial cost savings and reductions in antibiotic use have alreadybeen observed following a PCT guided algorithm in the SISPCT study andother trials (26, 36, 37), however relatively high mortality rates canstill be observed even when PCT values appear to be decreasing steadily.Our study revealed that the addition of MR-proADM to the model of PCTdecreases over subsequent ICU days allowed the identification of low,intermediate and high risk patient groups, with increasing anddecreasing MR-proADM severity levels from baseline to day 1 providing asensitive and early indication as to treatment success. In addition, theprediction of the requirement for future focus cleaning or emergencysurgery, as well as the susceptibility for the development of newinfections, may be of substantial benefit in initiating additionaltherapeutic and interventional strategies, thus attempting to preventany future clinical complications at an early stage.

The strength of our study includes the thorough examination of severaldifferent subgroups with low and high disease severities from arandomized trial database, adjusting for potential confounders andincluding the largest sample size of patients with sepsis, characterizedby both SEPSIS 1 and 3 definitions, and information on MR-proADMkinetics. In conclusion, MR-proADM outperforms other biomarkers andclinical severity scores in the ability to identify mortality risk inpatients with sepsis, both on initial diagnosis and over the course ofICU treatment. Accordingly, MR-proADM may be used as a tool to identifyhigh severity patients who may require alternative diagnostic andtherapeutic interventions, and low severity patients who may potentiallybe eligible for an early ICU discharge in conjunction with an absence ofICU specific therapies.

TABLES

TABLE 1 Patient characteristics at baseline for survival up to 28 daysNon- Total Survivors Survivors (N = 1076) (N = 787) (N = 289) P valueAge (years) (mean, S.D.)  65.7 (13.7)  64.3 (14.0)  69.5 (12.0) <0.0001Male gender (n, %)   681 (63.3%)   510 (64.8%)   171 (59.2%) 0.0907Definitions of sepsis and length of stay Severe sepsis (n, %)   139(12.9%)   109 (13.9%)    30 (10.4%) 0.1251 Septic shock (n, %)   937(87.1%)   678 (86.2%)   259 (89.6%) 0.1251 Sepsis-3 (n, %)   444 (41.3%)  356 (45.4%)    88 (30.4%) <0.0001 Septic shock-3 (n, %)   630 (58.7%)  429 (54.6%)   201 (69.6%) <0.0001 ICU length of stay (days) (median,IQR)    12 [6-23]    13 [7-26]     8 [4-15] <0.0001 Hospital length ofstay (days) (median,    28 [17-45]    34 [22-51]    14 [7-23] <0.0001IQR) Pre-existing comorbidities History of diabetes (n, %)   280 (26.0%)  188 (23.9%)    92 (31.8%) 0.0094 Heart failure (n, %)   230 (21.4%)  150 (19.1%)    80 (27.7%) 0.0027 Renal dysfunction (n, %)   217(20.2%)   135 (17.2%)    82 (28.4%) <0.0001 COPD (n, %)   131 (12.2%)   90 (11.4%)    41 (14.2%) 0.2277 Liver cirrhosis (n, %)    50 (4.7%)   27 (3.4%)    23 (8.0%) 0.0030 History of cancer (n, %)   319 (29.7%)  224 (28.5%)    95 (32.9%) 0.1630 Immunosuppression (n, %)    46 (4.3%)   30 (3.8%)    16 (5.5%) 0.2271 Microbiology Gram positive (n, %)   146(13.6%)   113 (14.4%)    33 (11.4%) 0.2050 Gram negative (n, %)   132(12.3%)    95 (12.1%)    37 (12.8%) 0.7467 Fungal (n, %)    51 (4.7%)   37 (4.7%)    14 (4.8%) 0.9223 Gram positive and negative (n, %)   183(17.0%)   133 (16.9%)    50 (17.3%) 0.8767 Gram positive and fungal (n,%)    92 (8.6%)    68 (8.6%)    24 (8.3%) 0.8610 Gram negative andfungal (n, %)    51 (4.7%)    35 (4.5%)    16 (5.5%) 0.4631 Grampositive and negative and fungal   115 (10.7%)    81 (10.3%)    34(11.8%) 0.4922 (n, %) Origin of infection Pneumonia (n, %)   453 (43.7%)  327 (42.9%)   126 (46.0%) 0.3798 Upper or lower respiratory (n, %)   44 (4.3%)    29 (3.8%)    15 (5.5%) 0.2523 Thoracic (n, %)    44(4.3%)    35 (4.6%)     9 (3.3%) 0.3444 Bones/soft tissue (n, %)    78(7.5%)    56 (7.4%)    22 (8.0%) 0.7161 Gastrointestinal (n, %)    80(7.7%)    68 (8.9%)    12 (4.4%) 0.0107 Catheter associated (n, %)    30(2.9%)    18 (2.4%)    12 (4.4%) 0.1015 Surgical wound (n, %)    41(4.0%)    31 (4.1%)    10 (3.7%) 0.7586 Intraabdominal (n, %)   375(36.2%)   276 (36.2%)    99 (36.1%) 0.9790 Cardiovascular (n, %)     6(0.6%)     4 (0.5%)     2 (0.7%) 0.7082 Urogenital (n, %)    99 (9.6%)   70 (9.2%)    29 (10.6%) 0.5039 Central nervous system (n, %)     3(0.3%)     2 (0.3%)     1 (0.4%) 0.7916 Bacteremia (n, %)    31 (3.0%)   20 (2.6%)    11 (4.0%) 0.2611 Organ dysfunction Neurological (n, %)  348 (32.3%)   240 (30.5%)   108 (37.4%) 0.0340 Respiratory (n, %)  486 (45.2%)   350 (44.5%)   136 (47.1%) 0.4502 Cardiovascular (n, %)  829 (77.0%)   584 (74.2%)   245 (84.8%) 0.0002 Renal dysfunction (n,%)   382 (35.5%)   249 (31.6%)   133 (46.0%) <0.0001 Haematological (n,%)   156 (14.5%)    89 (11.3%)    67 (23.2%) <0.0001 Gastrointestinal(n, %)   387 (36.0%)   271 (34.4%)   116 (40.1%) 0.0855 Metabolicdysfunction (n, %)   718 (66.7%)   504 (64.0%)   214 (74.1%) 0.0017Other organ dysfunction (n, %)   499 (46.4%)   380 (48.3%)   119 (41.2%)0.0378 Treatment upon ICU admission Invasive mechanical ventilation (n,%)   789 (73.3%)   567 (72.1%)   222 (76.8%) 0.1133 Non-invasivemechanical ventilation (n,    64 (5.9%)    46 (5.8%)    18 (6.2%) 0.8145%)          Renal replacement therapy (n, %)   326 (30.8%)   158 (20.5%)  168 (58.1%) <0.0001 Vasopressor use (n, %)   980 (91.1%)   712 (90.5%)  268 (92.7%) 0.2391 Biomarker and severity scores MR-proADM (nmol/L)(median, IQR)   5.0 [2.6-8.8]   4.0 [2.3-7.2]   8.2 [5.2-12.6] <0.0001PCT (ng/mL) (median, IQR)   7.4 [1.6-26.9]   6.6 [1.4-25.1]   9.3[2.6-31.8] 0.0325 Lactate (mmol/L) (median, IQR)   2.7 [1.6-4.7]   2.4[1.5-4.0]   3.7 [2.1-7.2] <0.0001 CRP (mg/L) (median, IQR)   188[120.9-282]   189 [120.5-277.4]   188 [122-287] 0.7727 SOFA (points)(mean, S.D.) 10.02 (3.33)  9.58 (3.18) 11.22 (3.43) <0.0001 SAPS II(points) (mean, S.D.) 63.27 (14.18) 61.08 (13.71) 69.24 (13.74) <0.0001APACHE II (points) (mean, S.D.) 24.24 (7.60) 23.05 (7.37) 27.49 (7.28)<0.0001 ICU: Intensive Care Unit; COPD: chronic obstructive pulmonarydisease; MR-proADM, mid-regional proadrenomedullin; PCT: procalcitonin;CRP: C-reactive protein; SOFA: Sequential Organ Failure Assessment; SAPSII: Simplified Acute Physiological score; APACHE II: Acute Physiologicaland Chronic Health Evaluation. Data are presented as absolute number andpercentages in brackets, indicating the proportion of surviving andnon-surviving patients at 28 days.

TABLE 2 Prediction of 28 day mortality following sepsis diagnosisUnivariate Multivariate AUR C- HR IQR C- HR IQR N Events OC LR X² index[95%] p LR X² index [95%] All patients MR- 1030 275 0.73 142.7 0.71 3.2[2.6- <0.0001 161.69 0.72 2.9 [2.4- proADM 3.9] 3.6] PCT 1031 275 0.5612.2 0.56 1.4 [1.2- 0.0005 70.28 0.64 1.4 [1.1- 1.7] 1.7] CRP 936 2510.49 0.12 0.51 1.0 [0.9- 0.7304 50.54 0.62 1.1 [0.9- 1.2] 1.2] Lactate1066 289 0.65 78.3 0.64 2.2 [1.8- <0.0001 122.72 0.69 2.1 [1.7- 2.5]2.5] SOFA 1051 282 0.64 47.3 0.62 1.6 [1.4- <0.0001 96.05 0.67 1.6 [1.4-1.8] 1.8] SAPS II 1076 289 0.67 70.5 0.65 1.8 [1.6- <0.0001 100.3 0.671.6 [1.4- 2.0] 1.9] APACHE 1076 289 0.67 69.9 0.65 1.9 [1.6- <0.000199.21 0.67 1.7 [1.4- II 2.2] 2.0] Sepsis-3 MR- 425 83 0.73 40.9 0.71 2.8[2.0- <0.0001 61.4 0.74 2.6 [1.8- proADM 3.8] 3.7] PCT 425 83 0.56 4.60.56 1.4 [1.0- 0.0312 40.6 0.70 1.5 [1.1- 1.9] 2.1] CRP 382 81 0.55 2.10.54 0.9 [0.7- 0.1505 36.7 0.69 0.9 [0.7- 1.1] 1.1] Lactate 439 88 0.577.7 0.56 1.3 [1.1- 0.0057 45.0 0.69 1.3 [1.1- 1.6] 1.7] SOFA 428 86 0.583.2 0.56 1.2 [1.0- 0.0745 40.8 0.69 1.2 [1.0- 1.5] 1.5] SAPS II 439 880.62 14.5 0.61 1.7 [1.3- 0.0001 45.0 0.69 1.5 [1.1- 2.3] 2.0] APACHE 43988 0.70 30.8 0.68 2.1 [1.6- <0.0001 52.6 0.71 1.7 [1.3- II 2.6] 2.3]Septic MR- 597 192 0.72 77.4 0.69 2.4 [2.0- <0.0001 93.5 0.71 2.3 [1.8-shock-3 proADM 3.0] 2.9] PCT 597 192 0.50 0.4 0.51 1.1 [0.9- 0.5264 35.70.62 1.1 [0.9- 1.3] 1.4] CRP 545 170 0.53 2.1 0.53 1.1 [1.0- 0.1498 31.70.63 1.1 [1.0- 1.3] 1.4] Lactate 627 201 0.64 52.2 0.64 2.0 [1.7-<0.0001 79.4 0.68 2.0 [1.7- 2.4] 2.4] SOFA 616 196 0.65 31.1 0.62 1.6[1.4- <0.0001 56.5 0.66 1.6 [1.3- 1.9] 1.9] SAPS II 627 201 0.67 42.20.65 1.7 [1.4- <0.0001 59.8 0.66 1.6 [1.3- 1.9] 1.8] APACHE 627 201 0.6328.3 0.61 1.6 [1.3- <0.0001 50.7 0.65 1.5 [1.3- II 1.9] 1.8] N: Number;AUROC: Area under the Receiver Operating Curve; LR X²: HR: Hazard Ratio;IQR: Interquartile range. All multivariate analyses were associated by p< 0.0001 to 28 day mortality.

TABLE 3 Survival analysis for 7 day, 90 day, ICU and hospital mortalityUnivariate Multivariate Patients Mortality AURO LR C- HR IQR p- LR C- HRIQR (N) (N) C X² index [95% CI] value X² index [95% CI] 7 day MR- 1037131 0.72 71.6 0.71 3.3 [2.4- <0.0001 82.1 0.73 3.4 [2.5- proADM 4.3]4.6] PCT 1038 131 0.58 9.7 0.58 1.5 [1.2- 0.0019 28.4 0.64 1.6 [1.2-2.0] 2.1] CRP 943 111 0.55 1.2 0.55 1.1 [0.9- 0.2843 16.6 0.62 1.2 [0.9-1.4] 1.4] Lactate 1074 135 0.72 86.0 0.71 3.1 [2.4- <0.0001 99.1 0.733.1 [2.4- 3.9] 4.0] SOFA 1059 130 0.63 25.5 0.63 1.7 [1.4- <0.0001 41.00.67 1.7 [1.4- 2.0] 2.1] SAPS II 1085 135 0.66 38.5 0.66 1.8 [1.5-<0.0001 50.1 0.67 1.8 [1.5- 2.2] 2.2] APACH 1085 135 0.63 24.4 0.63 1.7[1.4- <0.0001 37.8 0.65 1.7 [1.4- E II 2.1] 2.1] 90 day MR- 1000 3790.71 146.2 0.68 2.7 [2.3- <0.0001 194.1 0.71 2.4 [2.0- proADM 3.2] 2.8]PCT 1000 379 0.55 11.8 0.55 1.3[1.1- 0.0006 113.5 0.65 1.3[1.1- 1.5]1.5] CRP 909 348 0.51 0.2 0.51 1.0 [0.9- 0.6641 92.3 0.64 1.1 [0.9- 1.2]1.2] Lactate 1037 399 0.64 83.2 0.63 2.0 [1.7- <0.0001 168.8 0.68 1.9[1.6- 2.3] 2.2] SOFA 1021 388 0.62 48.1 0.61 1.5 [1.4- <0.0001 143.70.67 1.5 [1.3- 1.7] 1.7] SAPS II 1045 399 0.66 81.1 0.64 1.7 [1.5-<0.0001 144.4 0.67 1.5 [1.3- 1.9] 1.7] APACH 1045 399 0.67 86.4 0.64 1.8[1.6- <0.0001 146.8 0.67 1.6 [1.4- E II 2.1] 1.8] ICU MR- 1023 264 0.73136.4 0.73 4.0 [3.1- <0.0001 158.3 0.75 3.7 [2.8- proADM 5.2] 4.9] PCT1024 264 0.58 18.0 0.58 1.6 [1.3- <0.0001 73.0 0.67 1.6 [1.3- 2.0] 2.1]CRP 928 237 0.54 2.5 0.54 1.1 [1.0- 0.1108 51.4 0.65 1.2 [1.0- 1.3] 1.4]Lactate 1059 277 0.66 75.2 0.66 2.4 [2.0- <0.0001 115.5 0.71 2.4 [1.9-3.0] 2.9] SOFA 1044 270 0.64 48.6 0.64 1.8 [1.5- <0.0001 95.2 0.69 1.8[1.5- 2.2] 2.2] SAPS II 1070 277 0.65 58.7 0.65 1.9 [1.6- <0.0001 91.20.68 1.8 [1.5- 2.3] 2.2] APACH 1070 277 0.66 62.5 0.66 2.1 [1.7- <0.000191.6 0.69 1.9 [1.5- E II 2.6] 2.3] Hospital MR- 980 323 0.73 152.0 0.744.0 [3.1- <0.0001 186.8 0.76 3.6 [2.7- proADM 5.2] 4.6] PCT 981 323 0.5715.0 0.57 1.5 [1.2- 0.0001 96.2 0.68 1.5 [1.2- 1.9] 1.9] CRP 891 2990.52 0.9 0.52 1.1 [0.9- 0.3480 76.0 0.67 1.1 [1.0- 1.3] 1.3] Lactate1016 342 0.66 77.8 0.66 2.4 [2.0- <0.0001 146.2 0.72 2.3 [1.9- 2.9] 2.9]SOFA 1001 333 0.63 41.3 0.63 1.7 [1.4- <0.0001 118.9 0.70 1.7 [1.4- 2.0]2.0] SAPS II 1027 342 0.65 59.1 0.65 1.9 [1.6- <0.0001 115.9 0.69 1.7[1.4- 2.2] 2.0] APACH 1027 342 0.67 76.7 0.67 2.2 [1.9- <0.0001 127.10.71 1.9 [1.6- E II 2.7] 2.4] All multivariate p values <0.0001 apartfrom PCT and CRP for 7 day mortality (0.0015 and 0.0843, respectively).

TABLE 4 Survival analysis for MR-proADM when added to individualbiomarkers or clinical scores Bivariate Added value Multivariate Addedvalue Patients Mortality LR C- HR IQR LR p- LR C- HR IQR LR p- (N) (N)X² index [95% CI] X² value X² index [95% CI] X² value 7 day PCT 1037 13176.5 0.72 4.0 [2.9- 66.8 <0.0001 86.2 0.73 4.2 [2.9- 57.8 <0.0001 5.6]6.1] CRP 904 108 56.9 0.71 3.2 [2.3- 55.0 <0.0001 67.7 0.73 3.3 [2.3-49.4 <0.0001 4.3] 4.7] Lactate 1029 131 112.5 0.75 2.3 [1.7- 28.1<0.0001 125.1 0.76 2.4 [1.7- 26.4 <0.0001 3.1] 3.3] SOFA 1014 126 77.80.72 3.3 [2.3- 53.5 <0.0001 86.9 0.74 3.3 [2.3- 46.6 <0.0001 4.6] 4.7]SAPS 1037 131 83.1 0.73 2.8 [2.0- 48.1 <0.0001 93.5 0.74 2.9 [2.1- 46.7<0.0001 II 3.7] 4.0] APACH 1037 131 73.3 0.71 3.0 [2.2- 50.9 <0.000184.5 0.73 3.1 [2.2- 48.6 <0.0001 E II 4.1] 4.2] 28 day PCT 1030 275163.0 0.73 4.3 [3.4- 150.7 <0.0001 174.9 0.73 3.9 [3.0- 105.0 <0.00015.5] 5.1] CRP 898 239 114.4 0.70 3.0 [2.5- 114.2 <0.0001 132.4 0.72 2.8[2.2- 80.5 <0.0001 3.8] 3.6] Lactate 1022 275 163.8 0.72 2.7 [2.2- 85.9<0.0001 184.5 0.73 2.5 [2.0- 61.4 <0.0001 3.3] 3.1] SOFA 1007 268 150.60.72 3.1 [2.5- 104.1 <0.0001 169.9 0.73 2.8 [2.2- 74.4 <0.0001 3.9] 3.6]SAPS 1030 275 163.4 0.72 2.7 [2.2- 97.1 <0.0001 176.5 0.73 2.6 [2.1-79.1 <0.0001 II 3.3] 3.3] APACH 1030 275 153.6 0.72 2.7 [2.2- 88.8<0.0001 169.1 0.73 2.6 [2.1- 74.1 <0.0001 E II 3.4] 3.3] 90 day PCT 1000379 170.8 0.70 3.6 [3.0- 159.0 <0.0001 208.2 0.71 3.1 [2.5- 94.8 <0.00014.4] 3.9] CRP 872 331 116.0 0.68 2.6 [2.2- 116.0 <0.0001 160.3 0.70 2.3[1.9- 68.8 <0.0001 3.1] 2.8] Lactate 993 379 169.4 0.69 2.3 [1.9- 86.6<0.0001 217.5 0.71 2.0 [1.7- 50.2 <0.0001 2.7] 2.4] SOFA 977 368 151.00.69 2.6 [2.1- 103.1 <0.0001 200.6 0.71 2.2 [1.8- 59.9 <0.0001 3.1] 2.7]SAPS 1000 379 173.7 0.70 2.3 [1.9- 94.7 <0.0001 208.4 0.71 2.2 [1.8-67.6 <0.0001 II 2.7] 2.6] APACH 1000 379 165.0 0.70 2.3 [1.9- 83.3<0.0001 202.9 0.71 2.1 [1.8- 62.5 <0.0001 E II 2.7] 2.6] ICU PCT 1023264 149.5 0.75 5.7 [4.1- 131.4 <0.0001 165.3 0.76 4.9 [3.5- 92.6 <0.00017.9] 7.0] CRP 889 226 104.6 0.72 3.7 [2.8- 102.5 <0.0001 127.4 0.74 3.4[2.5- 75.6 <0.0001 4.8] 4.6] Lactate 1015 264 153.5 0.74 3.2 [2.4- 78.9<0.0001 175.6 0.76 2.9 [2.2- 57.5 <0.0001 4.2] 3.9] SOFA 1000 257 140.70.74 3.6 [2.7- 91.8 <0.0001 163.8 0.76 3.2 [2.4- 65.8 <0.0001 4.8] 4.4]SAPS 1023 264 152.5 0.75 3.4 [2.6- 94.4 <0.0001 169.2 0.76 3.3 [2.5-77.7 <0.0001 II 4.4] 4.3] APACH 1023 264 148.2 0.74 3.3 [2.5- 87.9<0.0001 165.7 0.76 3.3 [2.5- 75.6 <0.0001 E II 4.4] 4.3] Hospital PCT980 323 174.7 0.76 6.4 [4.6- 159.5 <0.0001 198.9 0.77 5.2 [3.6- 103.2<0.0001 8.8] 7.3] CRP 852 283 117.9 0.72 3.7 [2.9- 117.3 <0.0001 150.10.75 3.3 [2.5- 77.7 <0.0001 4.8] 4.3] Lactate 972 323 167.4 0.75 3.3[2.5- 89.2 <0.0001 202.5 0.76 2.8 [2.1- 57.6 <0.0001 4.3] 3.8] SOFA 957314 155.5 0.74 3.9 [3.0- 113.7 <0.0001 191.3 0.76 3.4 [2.5- 74.6 <0.00015.2] 4.5] SAPS 980 323 165.8 0.75 3.5 [2.7- 107.7 <0.0001 194.2 0.76 3.2[2.4- 81.3 <0.0001 II 4.5] 4.2] APACH 980 323 169.7 0.75 3.3 [2.6- 95.4<0.0001 197.2 0.76 3.1 [2.4- 75.1 <0.0001 E II 4.3] 4.1] HR IQR [95% CI]indicates the hazard ratio for MR-proADM in each bivariate ormultivariate model. 2 degrees of freedom in each bivariate model,compared to 11 in each multivariate model.

TABLE 5 AUROC analysis for 28 day mortality prediction based on SOFAseverity levels Univariate Multivariate AUR LR C- HR IQR LR C- HR IQR NEvents OC X² index [95%] p X² index [95%] p SOFA ≤7 MR- 232 32 0.74 25.10.72 3.6 [2.2- <0.0001 37.6 0.77 3.1 [1.7- <0.0001 proADM 6.0] 5.6] PCT232 32 0.55 0.9 0.55 1.3 [0.8- 0.3519 22.4 0.72 1.2 [0.7- 0.0134 2.2]2.1] CRP 210 32 0.45 1.1 0.55 1.3 [0.8- 0.2881 17.5 0.69 1.3 [0.8-0.0647 2.0] 2.1] Lactate 236 35 0.62 5.5 0.61 1.8 [1.1- 0.0186 24.3 0.711.7 [1.0- 0.0069 3.0] 2.8] SAPS II 240 35 0.65 9.3 0.50 2.0 [1.3- 0.002322.5 0.71 1.4 [0.8- 0.013 3.0] 2.5] APACHE 240 35 0.69 14.3 0.64 2.4[1.5- 0.0002 24.6 0.71 1.7 [1.0- 0.0061 II 3.9] 3.0] SOFA 8-13 MR- 620172 0.72 74.3 0.70 2.7 [2.1- <0.0001 89.3 0.72 2.3 [1.8- <0.0001 proADM3.3] 3.0] PCT 620 172 0.54 3.9 0.54 1.3 [1.0- 0.0482 46.3 0.65 1.3 [1.0-<0.0001 1.6] 1.6] CRP 572 161 0.51 0.1 0.52 1.0 [0.9- 0.7932 39.3 0.641.0[0.9- <0.0001 1.2] 1.2] Lactate 650 181 0.61 26.9 0.61 1.7 [1.4-<0.0001 61.6 0.67 1.6 [1.3- <0.0001 2.0] 2.0] SAPS II 653 181 0.64 27.70.57 1.6 [1.3- 0.0014 53.9 0.64 1.4 [1.2- <0.0001 1.9] 1.7] APACHE 653181 0.63 22.1 0.62 1.5 [1.3- <0.0001 49.3 0.65 1.3 [1.1- <0.0001 II 1.8]1.6] SOFA ≥14 MR- 155 64 0.67 14.9 0.65 2.0 [1.4- 0.0001 25.6 0.69 2.2[1.4- 0.0043 proADM 3.0] 3.3] PCT 155 64 0.49 0.2 0.52 1.1 [0.8- 0.694411.5 0.62 1.2 [0.8- 0.3169 1.5] 1.7] CRP 136 53 0.57 2.0 0.55 0.9 [0.7-0.1569 14.9 0.64 2.6 [1.7- 0.0004 1.1] 3.8] Lactate 158 66 0.69 22.60.68 2.5 [1.7- <0.0001 32.3 0.71 0.9 [0.7- 0.1370 3.6] 1.1] SAPS II 15866 0.54 2.8 0.56 1.3 [0.9 0.0930 15.3 0.63 1.2 [0.8- 0.2958 1.8] 1.7]APACHE 158 66 0.54 1.8 0.54 1.3 [0.9- 0.1754 11.8 0.62 1.2 [0.9- 0.2487II 1.7] 1.7] N: Number; AUROC: Area under the Receiver Operating Curve;LR X²: HR: Hazard Ratio; IQR: Interquartile range.

TABLE 6 Survival analysis for MR-proADM within different organdysfunction severity groups when combined with individual biomarkers orclinical scores Univariate Multivariate Patients Mortality LR C- HR IQRp- LR C- HR IQR p- (N) (N) X² index [95% CI] value X² index [95% CI]value SOFA ≤7 PCT 232 32 30.0 0.75 5.3 [2.8- <0.0001 41.8 0.78 5.0 [2.3-<0.0001 10.1] 5.3] CRP 204 29 20.1 0.71 3.1 [1.8- <0.0001 30.5 0.75 2.7[1.4- 0.0013 5.3] 5.0] Lactate 229 32 25.1 0.72 3.5 [2.0- <0.0001 37.20.77 3.1 [1.7- 0.0001 5.9] 5.7] SOFA 232 32 27.3 0.73 3.9 [2.3- <0.000140.4 0.78 3.5 [1.9- <0.0001 6.7] 6.5] SAPS 232 32 28.9 0.74 3.2 [1.9-<0.0001 38.4 0.78 3.1 [1.7- 0.0001 II 5.4] 5.5] APAC 232 32 34.2 0.772.9 [1.7- <0.0001 41.4 0.79 3.0 [1.7- <0.0001 HE II 4.9] 5.5] SOFA 8-13PCT 620 172 90.4 0.72 3.8 [2.8- <0.0001 98.0 0.72 3.2 [2.3- <0.0001 5.0]4.4] CRP 544 153 63.1 0.69 2.6 [2.0- <0.0001 78.6 0.71 2.4 [1.7- <0.00013.3] 2.9] Lactate 617 172 81.4 0.70 2.4 [1.9- <0.0001 97.0 0.72 2.1[1.6- <0.0001 3.1] 2.7] SOFA 620 172 76.2 0.70 2.6 [2.0- <0.0001 90.70.72 2.3 [1.8- <0.0001 3.2] 2.9] SAPS 620 172 87.2 0.71 2.4 [1.9-<0.0001 97.2 0.72 2.3 [1.8- <0.0001 II 3.1] 2.9] APAC 620 172 79.0 0.702.5 [1.9- <0.0001 90.9 0.72 2.3 [1.8- <0.0001 HE II 3.1] 2.9] SOFA ≥14PCT 155 64 16.3 0.66 2.2 [1.5- 0.0001 27.1 0.69 2.4 [1.5- 0.0001 3.2]3.9] CRP 134 52 13.4 0.65 1.9 [1.3- 0.0007 26.9 0.70 2.1 [1.3- 0.00072.9] 3.3] Lactate 155 64 28.9 0.69 1.7 [1.1- 0.0063 38.1 0.71 1.8 [1.1-0.0068 2.5] 2.8] SOFA 155 64 15.3 0.65 2.0 [1.3- 0.0004 26.7 0.69 2.1[1.3- 0.0004 2.9] 3.2] SAPS 155 64 17.0 0.65 2.1 [1.4- 0.0001 26.2 0.692.2 [1.4- 0.0001 II 3.1] 3.3] APAC 155 64 15.1 0.64 2.0 [1.3- 0.000225.7 0.69 2.1 [1.4- 0.0002 HE II 2.9] 3.3]

TABLE 7 Corresponding 28 day SOFA and MR-proADM disease severity groupsSOFA severity groups Low severity Intermediate severity High severity(≤7 points) (≤8 points ≤13) (≥14 points) MR-proADM N = 232, 13.8% N =620, 27.7% N = 155, 41.3% severity groups mortality mortality mortalityLow severity N = 111 (41.9%) N = 139 (52.8%) N = 15 (5.7%) (≤2.7 nmol/L)7.2% mortality 10.8% mortality 20.0% mortality N = 265, 9.8% mortalityIntermediate severity N = 114 (19.6%) N = 394 (68.0%) N = 73 (12.6%)(<2.7 nmol/L ≤10.9) 15.8% mortality 27.7% mortality 34.2% mortality N =581, 26.2% mortality High severity N = 7 (4.3%) N = 87 (53.4%) N = 67(41.6%) (>10.9 nmol/L) 85.7% mortality 55.2% mortality 53.7% mortality N= 161 55.9% mortality MR-proADM: mid-regional proadrenomedullin; SOFA:Sequential Organ Failure Assessment

TABLE 8 Corresponding 28 day SAPS II and MR-proADM disease severitygroups SAPS II severity groups Low severity Intermediate severity Highseverity (≤53 points) (≤54 points ≤79) (≥80 points) MR-proADM N = 235,11.5% N = 656, 29.3% N = 139, 40.3% severity groups mortality mortalitymortality Low severity N = 108 (39.9%) N = 143 (52.8%) N = 20 (7.4%)(≤2.7 nmol/L) 7.4% mortality 11.2% mortality 20.0% mortality N = 271,10.3% mortality Intermediate severity N = 118 (19.9%) N = 398 (67.0%) N= 78 (13.1%) (<2.7 nmol/L ≤10.9) 13.6% morality 27.9% mortality 38.5%mortality N = 594, 26.4% mortality High severity N = 9 (5.5%) N = 115(69.7%) N = 41 (24.8%) (>10.9 nmol/L) 33.3% mortality 56.5% mortality53.7% mortality N = 165, 54.5% mortality MR-proADM: mid-regionalproadrenomedullin; SAPS II: Simplified Acute Physiological II

TABLE 9 Corresponding 28 day APACHE II and MR-proADM disease severitygroups APACHE II severity groups Low severity Intermediate severity Highseverity (≤19 points) (≤20 points ≤32) (≥33 points) MR-proADM N = 287,11.5% N = 591, 30.3% N = 152, 41.4% severity groups mortality mortalitymortality Low severity N = 122 (45.0%) N = 137 (50.6%) N = 12 (4.4%)(≤2.7 nmol/L) 7.4% mortality 10.9% mortality 33.3% mortality N = 271,10.3% mortality Intermediate severity N = 154 (25.9%) N = 356 (59.9%) N= 84 (14.1%) (<2.7 nmol/L ≤10.9) 12.3% mortality 30.1% mortality 36.9%mortality N = 594, 26.4% mortality High severity N = 11 (6.7%) N = 98(59.4%) N = 56 (33.9%) (>10.9 nmol/L) 45.5% mortality 58.2% mortality50.0% mortality N = 165, 54.5% mortality MR-proADM: mid-regionalproadrenomedullin; APACHE II: Acute Physiological and Chronic HealthEvaluation II

TABLE 10 Corresponding 28 day lactate and MR-proADM disease severitygroups Lactate severity groups Low severity Intermediate severity Highseverity (≤1.4 mmol/L) (<1.4 mmol/L ≤6.4) (>6.4 mmol/L) MR-proADM N =196, 15.8% N = 668, 24.1% N = 158, 52.5% severity groups mortalitymortality mortality Low severity N = 99 (37.1%) N = 154 (57.7%) N = 14(5.2%) (≤2.7 nmol/L) 8.1% mortality 9.1% mortality 42.9% mortality N =267, 10.5% mortality Intermediate severity N = 90 (15.2%) N = 421(71.2%) N = 80 (13.5%) (<2.7 nmol/L ≤10.9) 21.1% mortality 25.2%mortality 40.0% mortality N = 591, 26.6% mortality High severity N = 7(4.3%) N = 93 (56.7%) N = 64 (39.0%) (>10.9 nmol/L) 57.1% mortality44.1% mortality 70.3% mortality N = 164, 54.9% mortality MR-proADM:mid-regional proadrenomedullin

TABLE 11 Biomarker and SOFA association with 28 day mortality at days 1,4, 7 and 10 Patients Mortality AUR LR C- HR IQR p- LR C- HR IQR p- (N)(N) OC X² index [95% CI] value X² index [95% CI] value Day 1 MR- 993 2420.76 152.5 0.73 3.3 [2.8- <0.0001 173.2 0.74 3.2 [2.6- <0.0001 proADM4.0] 4.0] PCT 993 242 0.59 23.1 0.59 1.6 [1.3- <0.0001 74.6 0.65 1.6[1.3- <0.0001 2.0] 2.0] CRP 919 226 0.54 6.2 0.54 0.9 [0.8- 0.0128 61.20.65 0.9 [0.8- <0.0001 1.0] 1.0] Lactate 1041 265 0.73 206.4 0.72 2.4[2.2- <0.0001 253.9 0.75 2.5 [2.2- <0.0001 2.7] 2.8] SOFA 1011 260 0.74143.8 0.72 2.5 [2.2- <0.0001 192.8 0.75 2.6 [2.2- <0.0001 2.9] 3.0] Day4 MR- 777 158 0.76 100.5 0.73 3.2 [2.5- <0.0001 123.7 0.75 3.0 [2.3-<0.0001 proADM 4.0] 3.8] PCT 777 158 0.62 22.6 0.61 1.7 [1.4- <0.000169.3 0.68 1.8 [1.4- <0.0001 2.1] 2.2] CRP 708 146 0.48 0.7 0.52 1.1[0.9- 0.3925 45.8 0.65 1.1 [0.9- <0.0001 1.3] 1.4] Lactate 803 166 0.6960.6 0.68 1.8 [1.6- <0.0001 100.9 0.71 1.7 [1.5- <0.0001 2.0] 2.0] SOFA767 162 0.75 111.5 0.72 3.0 [2.4- <0.0001 155.9 0.76 3.1 [2.5- <0.00013.6] 3.8] Day 7 MR- 630 127 0.78 93.7 0.76 3.4 [2.6- <0.0001 117.8 0.763.3 [2.5- <0.0001 proADM 4.3] 4.3] PCT 631 128 0.72 62.3 0.70 2.6 [2.1-<0.0001 101.6 0.74 2.7 [2.1- <0.0001 3.3] 3.4] CRP 583 121 0.56 3.5 0.551.3 [1.0- 0.0606 47.1 0.67 1.3 [1.0- <0.0001 1.6] 1.7] Lactate 658 1380.68 69.4 0.68 2.0 [1.7- <0.0001 112.2 0.73 2.0 [1.7- <0.0001 2.3] 2.4]SOFA 617 128 0.75 107.7 0.73 2.7 [2.3- <0.0001 140.2 0.77 2.8 [2.3-<0.0001 3.3] 3.4] Day 10 MR- 503 82 0.78 72.6 0.76 4.3 [3.0- <0.000190.9 0.78 3.8 [2.6- <0.0001 proADM 6.1] 5.5] PCT 503 82 0.75 52.0 0.742.8 [2.2- <0.0001 90.4 0.78 3.1 [2.3- <0.0001 3.7] 4.2] CRP 457 80 0.6110.0 0.60 1.6 [1.2- <0.0001 51.2 0.71 1.8 [1.3- <0.0001 2.2] 2.6]Lactate 516 88 0.61 19.8 0.61 1.6 [1.3- <0.0001 54.7 0.70 1.6 [1.3-<0.0001 2.0] 2.0] SOFA 490 84 0.76 85.8 0.75 3.3 [2.6- <0.0001 107.80.78 3.1 [2.4- <0.0001 4.3] 4.1]

TABLE 12 Low and high risk severity groups and corresponding mortalityrates throughout ICU treatment Low severity patient population OptimalHigh severity patient population Patients Mortality cut- PatientsMortality Optimal (N) (N, %) off Sensitivity Specificity (N) (N, %)cut-off Sensitivity Specificity Day 1 MR- 304 24 (7.9%) 2.80 0.90 0.37162 87 (53.7%) 9.5 0.36 0.90 proADM PCT 203 25 (12.3%) 1.02 0.90 0.24115 40 (34.8%) 47.6 0.17 0.90 CRP 101 32 (31.7%) 99 0.90 0.14 88 18(4.8%) 373 0.08 0.90 Lactate 310 33 (10.6%) 1.22 0.88 0.36 185 109(58.9%) 3.5 0.43 0.89 SOFA 435 49 (11.3%) 8.0 0.88 0.40 165 87 (52.7%)14 0.33 0.90 Day 4 MR- 290 16 (5.5%) 2.25 0.90 0.44 120 58 (48.3%) 7.70.37 0.90 proADM PCT 147 16 (10.9%) 0.33 0.90 0.21 87 25 (28.7%) 14.080.16 0.90 CRP 65 9 (13.8%) 32.7 0.90 0.06 51 15 (29.4%) 276.5 0.06 0.90Lactate 124 15 (12.1%) 0.89 0.91 0.17 136 65 (47.8%) 2.15 0.39 0.89 SOFA213 15 (7.0%) 5.5 0.91 0.33 137 67 (48.9%) 12.75 0.41 0.88 Day 7 MR- 25214 (5.6%) 2.25 0.89 0.47 104 54 (51.9%) 6.95 0.43 0.90 proADM PCT 184 14(7.6%) 0.31 0.89 0.34 85 35 (41.2%) 4.67 0.27 0.90 CRP 62 12 (19.4%)27.4 0.90 0.11 69 23 (37.7%) 207 0.19 0.90 Lactate 104 15 (14.4%) 0.840.89 0.17 102 51 (50.0%) 2.10 0.37 0.90 SOFA 207 16 (7.7%) 5.5 0.88 0.3991 48 (52.7%) 12.5 0.38 0.91 Day 10 MR- 213 8 (3.8%) 2.25 0.90 0.49 7835 (44.9%) 7.45 0.43 0.90 proADM PCT 177 9 (5.1%) 0.30 0.89 0.40 74 32(43.2%) 2.845 0.39 0.90 CRP 69 8 (11.6%) 32.1 0.90 0.16 52 14 (26.9%)204 0.18 0.90 Lactate 47 7 (14.9%) 0.68 0.92 0.09 65 24 (36.9%) 2.150.27 0.90 SOFA 116 9 (7.8%) 4.5 0.89 0.26 85 42 (49.4%) 11.5 0.50 0.89

TABLE 13 Mortality and duration of ICU therapy based on MR-proADMconcentrations and ICU specific therapies Length 28 day 90 day Patientof stay mortality mortality severity group N SOFA (days) (N, %) (N, %)Day 4 Total patient 777 8.4 (4.3)   16 [10-27] 158 (20.3%) 256 (33.9%)population Clinically stable 145 4.5 (2.4)   8 [6-11] 10 (6.9%)  22(15.8%) Clinically stable and low MR-proADM 79 3.6 (1.5)   8 [7-10]  0(0.0%)  1 (1.4%) Actual day 4 43 3.6 (2.1) —  1 (2.3%)   4 (10.0%)discharges* Day 7 Total patient 630 8.0 (4.2)   19 [13-31] 127 (20.2%)214 (34.9%) population Clinically stable 124 3.9 (1.7) 11.5 [9-16]  9(7.3%)  17 (13.9%) Clinically stable and 78 3.4 (1.6)   11 [9-14]  1(1.3%)  4 (5.3%) low MR-proADM   Actual day 7 36 3.6 (2.6) —  2 (5.6%)  5 (13.9%) discharges* Day 10 Total patient 503 7.6 (4.0) 23.5[17-34.25]  82 (16.3%) 159 (32.6%) population Clinically stable 85 3.5(1.8)   15 [13-22]   9 (10.6%)  14 (17.3%) Clinically stable and 57 3.2(1.3)   14 [12.25-19]  1 (1.8%)  2 (3.8%) low MR-proADM Actual day 10 294.0 (2.6) —   5 (17.2%)   7 (24.1%) discharges* *excludes same or nextday mortalities

TABLE 14 Time dependent Cox regressions for single and cumulativeadditions of MR-proADM Univariate model Multivariate model LR AddedAdded p- LR Added Added p- X² DF LR X² DF value X² DF LR X² DF valueAddition of single days to baseline values MR-proADM baseline 144.2 1Reference 163.0 10 Reference +Day 1 169.8 2 25.6 1 <0.001 190.6 11 27.61 <0.001 +Day 4 161.9 2 17.7 1 <0.001 180.4 11 17.4 1 <0.001 +Day 7175.7 2 31.5 1 <0.001 195.1 11 32.1 1 <0.001 +Day 10 179.8 2 35.6 1<0.001 197.9 11 34.9 1 <0.001 Addition of consecutive days to baselinevalues MR-proADM baseline 144.2 1 Reference 163.0 10 Reference +Day 1169.8 2 25.6 1 <0.001 190.6 11 27.6 1 <0.001 +Day 1 + Day 4 174.9 3 5.11 0.0243 195.4 12 4.8 1 0.0280 +Day 1 + Day 4 + Day 7 188.7 4 13.9 1<0.001 210.4 13 15.0 1 <0.001 +Day 1 + Day 4 + 195.2 5 6.5 1 0.0111216.6 14 6.2 1 0.0134 Day 7 + Day 10 MR-proADM: mid-regionalproadrenomedullin; DF: Degrees of Freedom

TABLE 15 28 and 90 day mortality rates following PCT and MR-proADMkinetics Biomarker Kinetics 28 day mortality 90 day mortality BaselineDay 1 N % HR IQR [95% Cl] N % HR IQR [95% Cl] PCT decrease ≥ 20% 45818.3% 447 28.2% MR-proADM Low Low 125 5.6% 3.6 [1.6-8.1]* 121 13.2% 2.7[1.6-4.8]* severity level Intermediate Intermediate 204 19.1% 5.3[3.0-9.3]** 201 32.3% 3.8 [2.3-6.3]** High High 27 66.7% 19.1[8.0-45.9]*** 27 70.4% 10.4 [5.3-20.2]*** Increasing Low Intermediate 250.0% — 2 50.0% — Intermediate High 10 40.0% 2.5 [0.9-7.0]†† 10 50.0%1.9 [0.8-4.8]†† Decreasing High Intermediate 30 36.7% 0.4 [0.2-0.9]‡ 2944.8% 0.5 [0.2-0.9]‡ High Low — — — — — — Intermediate Low 60 8.3% 0.4[0.2-1.0]‡‡ 57 12.3% 0.3 [0.2-0.7]‡‡ PCT decrease < 20% 522 29.7% 50842.5% MR-proADM Low Low 106 10.4% 3.1 [1.7-5.9]* 105 16.2% 3.2[1.9-5.3]* severity level Intermediate Intermediate 229 29.7% 2.0[1.3-2.9]** 221 43.4% 1.9 [1.3-2.6]** High High 77 49.4% 6.2[3.2-12.2]*** 75 64.0% 5.9 [3.4-10.3]*** Increasing Low Intermediate 2917.2% 1.8 [0.6-5.2]† 27 44.4% 3.2 [1.5-6.7]† Intermediate High 45 53.3%2.3 [1.4-3.6]†† 45 68.9% 2.1 [1.4-3.6]†† Decreasing High Intermediate 1154.5% — 11 72.7% — High Low 1 0.0% — 1 100.0% — Intermediate Low 2412.5% 0.4 [0.1-1.2]‡‡ 23 13.0% 0.2 [0.1-0.8]‡‡ Hazard ratios forpatients with: *continuously intermediate vs. low values; **continuouslyhigh vs. intermediate values ***continuously high vs. low values;†Increasing low to intermediate vs. continuously low values;††Increasing intermediate to high vs. continuously intermediate values;‡decreasing high to intermediate vs. continuously high values;‡‡Decreasing intermediate to low vs. increasing intermediate to highvalues. Kaplan Meier plots illustrate either individual patientsubgroups, or grouped increasing or decreasing subgroups.

TABLE 16 Mortality rates following changes in PCT concentrations andMR-proADM severity levels 7 day mortality ICU mortality Hospitalmortality HR IQR HR IQR HR IQR Baseline Day 1 N % [95% Cl] N % [95% Cl]N % [95% Cl] PCT decrease ≥ 20% 461 6.1% 456 16.7% 439 24.1% MR- Low Low126 2.4% 1.9 [0.5-6.9]* 126 4.8% 3.9 [1.6-9.6]* 123 7.3% 4.9 [2.3-10.3]*proADM Inter- Inter- 205 4.4% 8.2 [3.4-21.2]** 202 16.3% 8.7[3.7-20.7]** 194 27.8% 6.2 [2.5-14.9]** severity mediate mediate levelHigh High 27 29.6% 15.2 [4.0-57.3]*** 27 63.0% 34.0 [11.0-105.5]*** 2770.4% 30.1 [10.3-87.6]*** Increasing Low Inter- 3 0.0% — 2 0.0% — 2 0.0%— mediate Inter- High 10 20.0% 4.7 [1.0-21.6]†† 10 30.0% 2.2 [0.5-8.9]††10 50.0% 2.6 [0.7-9.3]†† mediate Decreasing High Inter- 30 16.7% 0.5[0.2-1.6]‡ 29 37.9% 0.4 [0.1-1.1]‡ 28 46.4% 0.4 [0.1-1.1]‡ mediateInter- Low 60 1.7% 0.4 [0.0-3.0]‡‡ 59 10.2% 0.6 [0.1-1.5]‡‡ 55 10.9% 0.3[0.1-0.8]‡‡ mediate PCT decrease < 20% 526 13.7% 517 30.2% 493 36.9% MR-Low Low 107 5.6% 2.0 [0.8-4.9]* 107 10.3% 3.4 [1.7-6.8]* 102 13.7% 3.6[1.9-6.8]* proADM Inter- Inter- 230 10.9% 2.6 [1.5-4.7]** 225 28.0% 3.0[1.8-5.2]** 216 36.6% 2.4 [1.4-4.2]** severity mediate mediate levelHigh High 77 26.0% 5.3 [2.1-13.2]*** 74 54.1% 10.3 [4.7-22.3]*** 7258.3% 8.8 [4.2-18.3]*** Increasing Low Inter- 30 13.3% 2.5 [0.7-8.9]† 2931.0% 3.9 [1.4-10.7]† 27 37.0% 3.7 [1.4-9.7]† mediate Inter- High 4628.3% 3.0 [1.5-5.8]†† 45 57.8% 3.3 [1.7-6.4]†† 43 65.1% 3.2 [1.6-6.4]††mediate Decreasing High Inter- 11 36.6% 0.5 [0.2-1.6]†† 11 54.5% 1.0[0.3-3.7]†† 10 80.0% — mediate High Low 1 0.0% — 1 0.0% — 1 0.0% —Inter- Low 24 0.0% ? 24 4.2% 0.1 [0.0-0.8]‡‡ 22 4.5% 0.1 [0.0-0.6]‡‡mediate Hazard ratios for patients with: *continuously intermediate vs.low values; **continuously high vs. intermediate values ***continuouslyhigh vs. low values; †increasing low to intermediate vs. continuouslylow values; ††increasing intermediate to high vs. continuouslyintermediate values; ‡decreasing high to intermediate vs. continuouslyhigh values; ‡‡decreasing intermediate to low vs. continuouslyintermediate values

TABLE 17 28 and 90 day mortality rates following changes in PCTconcentrations and MR-proADM severity levels Biomarker Kinetics 28 daymortality 90 day mortality Baseline Day 4 N % HR IQR [95% Cl] N % HR IQR[95% Cl] PCT decrease ≥ 50% 557 17.1% 542 29.3% MR-proADM Low Low 1111.8% 11.2 [2.7-46.4]* 107 7.5% 5.3 [2.5-10.9]* severity levelIntermediate Intermediate 209 18.7% 3.8 [2.3-6.5]** 206 33.5% 3.3[2.1-5.1]** High High 39 53.8% 43.1 [10.1-184.0]*** 39 71.8% 17.4[7.9-38.2]*** Increasing Low Intermediate 24 25.0% 15.6 [3.1-77.2]† 2441.7% 7.1 [2.8-17.9]† Intermediate High 23 43.5% 2.6 [1.3-5.3]†† 2365.2% 2.6 [1.5-4.5]†† Decreasing High Intermediate 42 21.4% 0.3[0.1-0.7]‡ 41 36.6% 0.3 [0.2-0.6]‡ High Low 3 0.0% — 2 50.0% —Intermediate Low 105 7.6% 0.4 [0.2-0.8]‡‡ 100 13.0% 0.3 [0.2-0.6]‡‡ PCTdecrease < 50% 210 29.5% 203 45.5% MR-proADM Low Low 56 7.1% 6.3[2.2-18.1]* 55 12.7% 6.2 [2.8-13.9]* severity level IntermediateIntermediate 70 38.6% 1.5 [0.8-3.0]** 68 57.4% 1.3 [0.7-2.3]** High High23 52.2% 9.5 [3.1-29.5]*** 22 63.6% 7.9 [3.2-19.5]*** Increasing LowIntermediate 17 17.6% 2.8 [0.6-12.5]† 15 53.3% 5.5 [2.0-15.2]† Low High4 0.0% — 4 25.0% — Intermediate High 30 46.7% 1.4 [0.7-2.6]†† 30 66.7%1.3 [0.8-2.2]†† Decreasing High Intermediate — — — — — — High Low — — —— — — Intermediate Low 10 20.0% — 9 33.4% — Hazard ratios for patientswith: *continuously intermediate vs. low values; **continuously high vs.intermediate values ***continuously high vs. low values; †Increasing lowto intermediate vs. continuously low values; ††Increasing intermediateto high vs. continuously intermediate values; ‡decreasing high tointermediate vs. continuously high values; ‡‡Decreasing intermediate tolow vs. continuously intermediate values

TABLE 18 ICU and hospital mortality rates following changes in PCTconcentrations and MR-proADM severity levels ICU mortality Hospitalmortality Baseline Day 4 N % HR IQR [95% Cl] N % HR IQR [95% Cl] PCTdecrease ≥ 50% 555 16.8% 532 24.1% MR-proADM Low Low 114 2.6% 6.9[2.1-23.1]* 109 2.8% 13.3 [4.1-43.8]* severity level IntermediateIntermediate 208 15.9% 8.1 [3.8-17.2]** 197 27.4% 5.1 [2.4-10.7]** HighHigh 38 60.5% 56.2 [15.0-210.2]*** 38 65.8% 67.9 [18.0-256.6]*** LowIntermediate 24 29.2% 15.1 [3.6-64.1]† 24 33.3% 17.7 [4.2-73.6]†Intermediate High 23 43.5% 4.1 [1.7-10.0]†† 23 56.5% 3.4 [1.4-8.3]††High Intermediate 41 22.0% 0.2 [0.1-0.5]‡ 39 33.3% 1.3 [0.6-2.7]‡ HighLow 3 0.0% — 2 50.0% — Intermediate Low 103 8.7% 0.5 [0.2-1.0]‡‡ 9911.1% 0.3 [0.2-0.7] PCT decrease < 50% 204 28.9% 194 30.4% MR-proADM LowLow 56 1.8% 28.1 [3.7-216.3]* 54 7.4% 10.1 [3.3-31.2]* severity levelIntermediate Intermediate 68 33.8% 1.8 [0.7-4.8]** 65 44.6% 1.9[0.7-5.2]** High High 21 47.6% 50.0 [5.8-431.5]*** 20 60.0% 18.8[4.8-72.7]*** Low Intermediate 16 43.7% 42.8 [4.7-390.2]† 14 57.1% 16.7[3.8-72.4]† Low High 4 0.0% — 4 25.0% — Intermediate High 29 58.6% 2.8[1.1-6.8]†† 28 64.3% 2.2 [0.9-5.6]†† High Intermediate — — — — — HighLow — — — — — Intermediate Low 10 10.0% — 9 33.3% — Hazard ratios forpatients with: *continuously intermediate vs. low values; **continuouslyhigh vs. intermediate values ***continuously high vs. low values;†Increasing low to intermediate vs. continuously low values;††Increasing intermediate to high vs. continuously intermediate values;‡decreasing high to intermediate vs. continuously high values;‡‡Decreasing intermediate to low vs. continuously intermediate values

TABLE 19 Influence of infectious origin on 28 day mortality predictionUnivariate Multivariate HR HR Patients Mortality LR C- IQR p- LR C- IQRp- (N) (N) AUROC X² index [95% Cl] value X² index [95% Cl] valuePneumological MR- 313 83 0.72 37.9 0.69 2.7 [2.0-3.7] <0.0001 45.1 0.712.5 [1.7-3.6] <0.0001 proADM PCT 313 83 0.59 6.4 0.58 1.6 [1.1-2.2]0.0112 26.0 0.66 1.5 [1.1-2.2] 0.0038 CRP 267 65 0.46 0.8 0.53 0.9[0.7-1.1] 0.3754 14.7 0.63 0.9 [0.7-1.1] 0.1422 Lactate 322 86 0.61 12.60.61 1.6 [1.2-2.1] 0.0004 30.1 0.67 1.5 [1.1-2.0] 0.0008 SOFA 315 830.63 12.4 0.62 1.7 [1.3-2.3] 0.0004 29.6 0.68 1.6 [1.1-2.2] 0.0010 SAPSII 324 86 0.63 13.2 0.62 1.6 [1.3-2.1] 0.0003 28.8 0.67 1.5 [1.1-1.9]0.0014 APACHE 324 86 0.63 19.5 0.64 1.9 [1.4-2.5] <0.0001 33.4 0.68 1.7[1.3-2.3] 0.0002 II Intraabdominal MR- 238 58 0.78 47.4 0.75 4.5[2.9-7.1] <0.0001 55.7 0.76 4.8 [2.9-8.0] <0.0001 proADM PCT 238 58 0.520.4 0.52 1.1 [0.8-1.7] 0.5249 15.0 0.64 1.2 [0.8-1.9] 0.1312 CRP 233 590.48 0.1 0.53 1.0 [0.8-1.3] 0.7807 12.0 0.62 1.1 [0.8-1.4] 0.2864Lactate 249 62 0.67 18.0 0.66 2.2 [1.5-3.0] <0.0001 28.2 0.70 2.1[1.5-3.0] 0.0017 SOFA 248 62 0.66 8.9 0.63 1.5 [1.2-2.0] 0.0029 18.30.64 1.5 [1.1-2.0] 0.0494 SAPS II 252 62 0.68 17.9 0.66 1.9 [1.4-2.6]<0.0001 24.3 0.67 1.9 [1.3-2.6] 0.0069 APACHE 252 62 0.68 14.6 0.65 1.8[1.3-2.3] 0.0001 20.6 0.66 1.6 [1.2-2.2] 0.0241 II MR-proADM AUROCvalues are significantly greater than all other parameters apart fromAPACHE II in pneumological origins of infection.

TABLE 20 Influence of microbial species on 28 day mortality predictionUnivariate Multivariate Patients Mortality LR C- IQR p- LR C- IQR p- (N)(N) AUROC X² index [95% Cl] value X² index [95% Cl] value Gram MR- 14133 0.82 37.2 0.81 5.0 <0.0001 50.0 0.84 5.0 <0.0001 positive proADM[2.9-8.6] [2.7-9.2] PCT 142 33 0.64 7.9 0.64 2.4 0.0050 30.3 0.76 3.00.0008 [1.3-4.4] [1.5-5.7] CRP 131 31 0.54 0.2 0.51 0.9 0.6561 19.8 0.711.0 0.0309 [0.7-1.3] [0.7-1.4] Lactate 143 33 0.75 28.9 0.74 4.6 <0.000144.9 0.83 5.0 <0.0001 [2.6-8.1] [2.6-9.7] SOFA 143 32 0.66 8.8 0.65 1.90.0031 31.8 0.76 2.7 0.0004 [1.3-2.8] [1.6-4.6] SAPS II 146 33 0.72 16.81.71 2.9 <0.0001 28.4 0.76 2.7 0.0016 [1.7-4.7] [1.5-4.9] APACHE 146 330.73 17.3 0.71 2.4 <0.0001 33.1 0.77 2.8 0.0003 II [1.6-3.5] [1.7-4.7]Gram MR- 124 35 0.69 12.1 0.68 2.3 0.0005 26.0 0.75 2.2 0.0037 negativeproADM [1.4-3.8] [1.2-3.8] PCT 124 35 0.54 0.6 0.54 1.2 0.4580 17.8 0.671.2 0.0580 [0.7-2.1] [0.7-2.3] CRP 110 30 0.57 0.4 0.56 1.2 0.5255 17.10.68 1.4 0.0727 [0.7-1.8] [0.9-2.2] Lactate 131 37 0.65 10.0 0.64 1.90.0016 23.4 0.71 1.7 0.0093 [1.3-2.8] [1.1-2.7] SOFA 129 37 0.65 9.00.64 1.8 0.0027 25.5 0.72 1.9 0.0045 [1.2-2.7] [1.2-2.9] SAPS II 132 370.67 9.9 0.65 1.9 0.0017 25.1 0.71 1.9 0.0051 [1.3-2.8] [1.2-3.0] APACHE132 37 0.69 7.9 0.66 1.7 0.0049 22.3 0.70 1.7 0.0139 II [1.2-2.4][1.1-2.6] Fungal MR- 50 14 0.74 7.9 0.69 2.5 0.0051 14.4 0.78 3.4 0.1548proADM [1.3-4.9]  [1.1-10.7] PCT 50 14 0.46 0.3 0.52 1.3 0.6104 8.5 0.721.1 0.5792 [0.5-3.0] [0.4-3.0] CRP 43 12 0.65 0.6 0.65 0.8 0.4404 14.70.81 0.5 0.1427 [0.5-1.3] [0.2-1.2] Lactate 51 14 0.60 2.7 0.59 2.00.1032 13.2 0.74 3.3 0.2128 [0.9-4.7]  [1.0-11.0] SOFA 49 12 0.54 0.80.54 1.4 0.3668 7.1 0.73 1.1 0.7164 [0.7-2.8] [0.5-2.8] SAPS II 51 140.60 2.2 0.60 1.5 0.1412 10.0 0.75 1.4 0.4427 [0.9-2.6] [0.7-2.8] APACHE51 14 0.62 1.6 0.62 1.6 0.2053 10.1 0.76 1.7 0.4321 II [0.8-3.3][0.7-4.4]

TABLE 21 Influence of mode of ICU entry on 28 day mortality predictionUnivariate Multivariate Patients Mortality LR C- IQR p- LR C- IQR p- (N)(N) AUROC X² index [95% Cl] value X² index [95% Cl] value Operative MR-466 113 0.77 87.4 0.75 4.1 <0.0001 106.4 0.77 3.8 <0.0001 proADM[3.0-5.6] [2.8-5.3] PCT 466 113 0.60 11.8 0.59 1.6 0.0006 53.1 0.70 1.7<0.0001 [1.2-2.2] [1.3-2.4] CRP 421 106 0.48 1.2 0.52 1.1 0.2696 39.70.68 1.2 <0.0001 [0.9-1.4] [0.9-1.4] Lactate 483 120 0.68 46.4 0.67 2.4<0.0001 73.7 0.71 2.3 <0.0001 [1.9-3.1] [1.8-3.0] SOFA 482 118 0.68 34.90.65 2.0 <0.0001 65.7 0.71 2.0 <0.0001 [1.6-2.4] [1.6-2.5] SAPS II 489120 0.71 50.5 0.68 2.2 <0.0001 65.9 0.70 2.0 <0.0001 [1.8-2.7] [1.6-2.5]APACHE 489 120 0.71 47.8 0.68 2.3 <0.0001 64.8 0.71 2.0 <0.0001 II[1.8-2.8] [1.6-2.5] Non- MR- 448 132 0.70 48.6 0.68 2.6 <0.0001 56.50.69 2.4 <0.0001 operative proADM [2.0-3.4] [1.8-3.3] PCT 449 132 0.520.8 0.52 1.1 0.3644 24.4 0.62 1.1 0.0066 [0.9-1.5] [0.8-1.4] CRP 424 1210.50 0.2 0.49 1.0 0.6280 23.6 0.62 1.0 0.0088 [0.8-1.2] [0.8-1.2]Lactate 462 137 0.62 24.5 0.62 1.9 <0.0001 43.7 0.67 1.8 <0.0001[1.5-2.4] [1.4-2.3] SOFA 450 132 0.62 15.9 0.61 1.7 0.0001 39.5 0.66 1.7<0.0001 [1.3-2.1] [1.3-2.2] SAPS II 466 137 0.65 25.4 0.64 1.6 <0.000143.4 0.66 1.5 <0.0001 [1.3-1.9] [1.3-1.8] APACHE 466 137 0.64 23.9 0.631.7 <0.0001 40.2 0.66 1.6 <0.0001 II [1.4-2.1] [1.3-2.0] Elective MR-116 30 0.71 12.1 0.69 2.8 0.0005 17.3 0.72 2.3 0.0440 proADM [1.6-5.2][1.2-4.5] PCT 116 30 0.59 3.3 0.59 1.6 0.0675 15.1 0.70 1.7 0.0873[1.0-2.6] [1.0-2.8] CRP 91 24 0.51 0.0 0.50 1.0 0.8650 11.5 0.70 0.80.3219 [0.7-1.4] [0.5-1.3] Lactate 121 32 0.63 9.5 0.63 2.2 0.0020 21.00.72 2.2 0.0211 [1.4-3.6] [1.3-3.6] SOFA 119 32 0.58 0.9 0.56 1.2 0.347613.7 0.69 1.0 0.1860 [0.9-1.6] [0.7-1.3] SAPS II 121 32 0.60 1.4 0.591.3 0.2333 13.1 0.68 0.9 0.2177 [0.9-1.9] [0.6-1.5] APACHE 121 32 0.571.1 0.57 1.3 0.2945 13.1 0.69 0.9 0.2164 II [0.8-1.9] [0.6-1.5]

TABLE 22 Baseline biomarker and clinical score correlation with SOFA atbaseline and day 1 Baseline SOFA Day 1 SOFA Correlation CorrelationPatients (N) [95% Cl] p-value Patients (N) [95% Cl] p-value MR-proADM1007 0.46 [0.41-0.51] <0.0001 MR-proADM* 969 0.47 [0.41-0.51] <0.0001969 0.57 [0.52-0.61] <0.0001 PCT 1007 0.23 [0.17-0.29] <0.0001 969 0.22[0.16-0.28] <0.0001 CRP 918 0.06 [0.00-0.13] 0.0059 885 0.04 [0.00-0.12]0.2709 Lactate 1044 0.33 [0.27-0.38] <0.0001 1005 0.40 [0.35-0.45]<0.0001 SAPS II 1051 0.60 [0.56-0.64] <0.0001 1011 0.50 [0.45-0.54]<0.0001 APACHE II 1051 0.62 [0.58-0.65] <0.0001 1011 0.53 [0.48-0.57]<0.0001 *using the same patients on baseline as on day 1

TABLE 23 Baseline MR-proADM correlations with SOFA subscores on baselineand day 1 Baseline SOFA Day 1 SOFA SOFA Correlation Correlation subscorePatients (N) [95% Cl] p-value Patients (N) [95% Cl] p-value Circulation1022 0.18 [0.12-0.23] <0.0001 995 0.23 [0.17-0.29] <0.0001 Pulmonary1025 0.12 [0.06-0.18] <0.0001 994 0.15 [0.09-0.21] <0.0001 Coagulation1028 0.30 [0.25-0.36] <0.0001 1002 0.40 [0.35-0.45] <0.0001 Renal 10300.50 [0.45-0.54] <0.0001 1001 0.62 [0.58-0.66] <0.0001 Liver 1014 0.20[0.14-0.26] <0.0001 993 0.36 [0.30-0.40] <0.0001 CNS 1030  0.03[−0.03-0.09] 0.3856 1003 0.08 [0.02-0.14] 0.0089

TABLE 24 Biomarker correlations with SOFA scores throughout ICUtreatment MR-proADM PCT CRP Lactate Day 1 Patients (N) 960 960 894 1008Correlation [95% CI] 0.51 [0.46-0.55] 0.24 [0.18-0.30] −0.04[−0.10-0.03] 0.48 [0.43-0.53] p-value <0.0001 <0.0001 <0.0001 <0.0001Day 4 Patients (N) 729 729 667 754 Correlation [95% CI] 0.58 [0.53-0.63]0.13 [0.06-0.20] 0.14 [0.06-0.21] 0.36 [0.29-0.42] p-value <0.00010.0003 0.0004 <0.0001 Day 7 Patients (N) 580 581 547 612 Correlation[95% CI] 0.58 [0.53-0.64]   0.05 [−0.03-0.13] 0.15 [0.07-0.23] 0.43[0.37-0.50] p-value <0.0001 0.2368 0.0004 <0.0001 Day 10 Patients (N)473 473 429 483 Correlation [95% CI] 0.65 [0.59-0.70] 0.28 [0.20-0.37]0.13 [0.03-0.22] 0.34 [0.26-0.42] p-value <0.0001 <0.0001 0.0076 <0.0001

TABLE 25 Mortalities based on MR-proADM severities and increasing ordecreasing PCT concentrations - Baseline to day 1 28 day 90 day 7 dayICU Hospital mortality mortality mortality mortality mortality BaselineDay 1 N % N % N % N % N % Decreasing PCT 657 19.0% 636 28.9% 657  6.4%650 11.6% 623 25.2 MR- Low Low 161  5.0% 157 14.0% 163  2.5% 162  5.6%157 8.3% proADM Intermediate Intermediate 314 19.1% 308 31.8% 316  4.7%310 17.1% 299 27.8% severity High High 51 58.8% 50 64.0% 51 23.5% 5154.9% 49 63.3% level Increasing Low Intermediate 10 20.0% 10 30.0% 11 0.0% 11 18.2% 10 20.0% Intermediate High 17 35.3% 17 41.2% 17 17.6% 1729.4% 17 41.2% Decreasing High Intermediate 35 40.0% 34 47.1% 35 20.0%34 41.2% 32 50.0% High Low — — — — — — — — — — Intermediate Low 63  7.9%60 10.0% 63  1.6% 63  7.9% 58 8.6% Increasing PCT 329 35.0% 319 46.6%331 17.5% 324 35.8% 31 42.3% MR- Low Low 66 13.6% 65 15.4% 66  7.6% 6610.6% 64 14.1% proADM Intermediate Intermediate 131 36.6% 126 51.6% 13114.5% 128 35.2% 122 42.6% severity High High 53 49.1% 52 67.3% 53 20.2%50 58.0% 50 60.0% level Increasing Low Intermediate 25 20.0% 23 47.8% 2615.4% 25 32.0% 23 39.1% Low High — — — — — — — — — — Intermediate High38 57.9% 38 76.3% 39 30.8% 39 61.5% 36 72.2% Decreasing HighIntermediate 6 50.0% 6 66.7% 6 33.3% 6 50.0% 6 83.3% High Low 1  0.0% 1100.0%  1  0.0% 1  0.0% 1 0.0% Intermediate Low 9 22.2% 8 25.0% 9  0.0%9  0.0% 8 0.0%

TABLE 26 PCT kinetics from baseline to day 1-development of newinfections over days 1, 2, 3, 4. New infections over Days 1, 2, 3, 4Baseline Day 1 N % Decreasing PCT 652  9.7% MR-proADM Low Low 161  6.8%severity level Intermediate Intermediate 315 11.7% High High 51 11.8%Increasing Low Intermediate 10  0.0% Intermediate High 17  5.9%Decreasing High Intermediate 34  8.8% High Low — — Intermediate Low 63 7.9% Increasing PCT 329 18.5% MR-proADM Low Low 66  9.1% severity levelIntermediate Intermediate 131 18.3% High High 53 22.6% Increasing LowIntermediate 25 24.0% Low High — — Intermediate High 38 18.4% DecreasingHigh Intermediate 6 50.0% High Low 1  0.0% Intermediate Low 9 33.3%

TABLE 27 PCT kinetics from baseline to day 4-development of newinfections over days 4, 5, 6, 7. New infections over Days 4, 5, 6, 7Baseline Day 4 N % Decreasing PCT 681 14.5% MR-proADM Low Low 144  8.3%severity level Intermediate Intermediate 256 17.6% High High 57 28.1%Increasing Low Intermediate 31 22.6% Intermediate High 36 13.9%Decreasing High Intermediate 42 11.9% High Low 3  0.0% Intermediate Low111  8.1%

TABLE 28 PCT kinetics from baseline to day 1-requirement for focuscleaning over days 1, 2, 3, 4. Focus cleaning events over days 1, 2, 3,4 Baseline Day 1 N % Increasing PCT 329  21.0% MR-proADM Low Low 57 10.5% severity level Intermediate Intermediate 113  20.4% High High 58 19.0% Increasing   Low Intermediate 31  32.3% Low High 3  33.3%Intermediate High 59  28.8% Decreasing High Intermediate 1  0.0% HighLow 1 100.0% Intermediate Low 6  0.0%

TABLE 29 PCT kinetics from baseline to day 4-requirement for focuscleaning over days 4, 5, 6, 7. Focus cleaning events over days 4, 5, 6,7 Baseline Day 4 N % Decreasing PCT 681 22.0% MR-proADM Low Low 14416.7% severity Intermediate Intermediate 256 24.2% level High High 5731.6% Increasing Low Intermediate 31 32.3% Intermediate High 36 50.0%Decreasing High Intermediate 42 16.7% High Low 3  0.0% Intermediate Low111  9.9%

TABLE 30 PCT kinetics from baseline to day 1-requirement of emergencysurgery over days 1, 2, 3, 4. Emergency surgery requirement over days 1,2, 3, 4 Baseline Day 1 N % Increasing PCT 329  23.7% MR-proADM Low Low66  18.2% severity Intermediate Intermediate 131  26.0% level High High53  28.3% Increasing   Low Intermediate 25  16.0% Low High — —Intermediate High 38  31.6% Decreasing High Intermediate 6  0.0% HighLow 1 100.0% Intermediate Low 9  0.0%

TABLE 31 Increasing PCT from baseline to day 1-antibiotic changes on day4 Increasing PCT 259  21.6% MR-proADM Low Low 55  5.5% severity levelIntermediate Intermediate 106  27.4% High High 39  25.6% Increasing  Low Intermediate 20  25.0% Intermediate High 26  26.9% Decreasing   HighIntermediate 5  20.0% High Low 1 100.0% Intermediate Low 7  0.0%

TABLE 32 Increasing PCT from baseline to day 4-antibiotic changes on day4 Increasing PCT 85 23.5% MR-proADM Low Low 23  8.7% severity levelIntermediate Intermediate 22 36.4% High High 5 20.0% Increasing LowIntermediate 10 20.0% Intermediate High 17 41.2% Low High 4  0.0%Decreasing High Intermediate — — High Low — — Intermediate Low 4  0.0%

TABLE 33 Biomarker levels based on platelet count Median Median PlateletMedian Median Platelet Median Median Platelet count proADM PCT countproADM PCT level Patients Mortality (baseline; level level Platelet day1; level level (10³/μl) (N) (N, %) 10³/μl)) (baseline) (baseline)transfusion 10³/μl)) (day 1) (day 1) <20 3  1 (33.3%) 12 15.6 171.7  1(33.3%) 15 9.8 58.1 20 to < 150 233 90 (38.6%) 109 6.6 9.0 24 (10.3%) 785.5 7.4 150 to 399 658 165 (25.1%)  249 4.5 7.0 11 (1.7%) 191 4.35.8 >399 177 32 (18.1%) 494 4.9 5.7  1 (0.6%) 342 3.7 4.3

TABLE 34 Platelet count based on proADM levels Median Median % PlateletPlatelet Platelet Median count count decrease proADM Day 1 MR-proADMPatients Mortality (baseline; Platelet (day 1; from levelThrombocytopenia (nmol/L) (N) (N, %) 10³/μl)) transfusion 10³/μl))baseline (day 1) development ≤2.75 271 28 (10.3%) 251.5 3 (1.1%) 206 18%1.7  73 (26.9%) >2.75 and ≤ 10.9 594 157 (26.4%)  246 14 (2.4%)  177 28%5.0 249 (41.9%) >10.9 165 90 (54.5%) 178.5 19 (11.5%) 103.5 42% 11.8 102(61.8%)

TABLE 35 Development of Thrombocytopenia and proADM kinetics at baselineand day 1. Median Median % Platelet Platelet Platelet Median count countdecrease proADM Day 1 MR-proADM Patients Mortality (baseline; Platelet(day 1; from level Thrombocytopenia (nmol/L) (N) (N, %) 10³/μl))transfusion 10³/μl)) baseline (day 1) development ≤2.75 232 21 (9.1%)274 1 (0.4%) 227 17.2% 1.75  34 (14.7%) >2.75 and ≤ 10.9 464 112(24.1%)  281 5 (1.1%) 215 23.5% 4.9 119 (25.6%) >10.9 104 53 (51.0%) 2595 (4.8%) 162 37.5% 11.6  41 (39.4%)

REFERENCES

-   1. Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of    sepsis in the United States from 1979 through 2000. N Engl J Med.    Apr. 17, 2003; 348(16):1546-1554.-   2. Kaukonen K M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality    related to severe sepsis and septic shock among critically ill    patients in Australia and New Zealand, 2000-2012. JAMA. Apr. 2,    2014; 311(13):1308-1316.-   3. Vincent J L, Sakr Y, Sprung C L, et al. Sepsis in European    intensive care units: results of the SOAP study. Crit Care Med.    February 2006; 34(2):344-353.-   4. Singer M, Deutschman C S, Seymour C W, et al. The Third    International Consensus Definitions for Sepsis and Septic Shock    (Sepsis-3). JAMA. Feb. 23, 2016; 315(8):801-810.-   5. Kopterides P, Siempos, I I, Tsangaris I, Tsantes A,    Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy    in the intensive care unit: a systematic review and meta-analysis of    randomized controlled trials. Crit Care Med. November 2010;    38(11):2229-2241.-   6. de Jong E, van Oers J A, Beishuizen A, et al. Efficacy and safety    of procalcitonin guidance in reducing the duration of antibiotic    treatment in critically ill patients: a randomised, controlled,    open-label trial. Lancet Infect Dis. July 2016; 16(7):819-827.-   7. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of    procalcitonin, interleukin-6, and interleukin-8 in critically ill    patients admitted with suspected sepsis. Am J Respir Crit Care Med.    Aug. 1, 2001; 164(3):396-402.-   8. Andriolo B N, Andriolo R B, Salomao R, Atallah A N. Effectiveness    and safety of procalcitonin evaluation for reducing mortality in    adults with sepsis, severe sepsis or septic shock. Cochrane Database    Syst Rev. Jan. 18, 2017; 1:CD010959.-   9. Temmesfeld-Wollbruck B, Brell B, David I, et al. Adrenomedullin    reduces vascular hyperpermeability and improves survival in rat    septic shock. Intensive Care Med. April 2007; 33(4):703-710.-   10. Muller-Redetzky H C, Will D, Hellwig K, et al. Mechanical    ventilation drives pneumococcal pneumonia into lung injury and    sepsis in mice: protection by adrenomedullin. Crit Care. 2014;    18(2):R73.-   11. Vallet B. Endothelial cell dysfunction and abnormal tissue    perfusion. Crit Care Med. May 2002; 30(5 Suppl):S229-234.-   12. Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M.    Urocortin and adrenomedullin prevent lethal endotoxemia by    down-regulating the inflammatory response. Am J Pathol. June 2006;    168(6):1921-1930.-   13. Carrizo G J, Wu R, Cui X, Dwivedi A J, Simms H H, Wang P.    Adrenomedullin and adrenomedullin-binding protein-1 downregulate    inflammatory cytokines and attenuate tissue injury after gut    ischemia-reperfusion. Surgery. February 2007; 141(2):245-253.-   14. Brell B, Hippenstiel S, David I, et al. Adrenomedullin treatment    abolishes ileal mucosal hypoperfusion induced by Staphylococcus    aureus alpha-toxin—an intravital microscopic study on an isolated    rat ileum. Crit Care Med. December 2005; 33(12):2810-2016.-   15. Brell B, Temmesfeld-Wollbruck B, Altzschner I, et al.    Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat    ileum microcirculatory damage. Crit Care Med. April 2005;    33(4):819-826.-   16. Vigue B, Leblanc P E, Moati F, et al. Mid-regional    pro-adrenomedullin (MR-proADM), a marker of positive fluid balance    in critically ill patients: results of the ENVOL study. Crit Care.    Nov. 9, 2016; 20(1):363.-   17. Andaluz-Ojeda D, Cicuendez R, Calvo D, et al. Sustained value of    proadrenomedullin as mortality predictor in severe sepsis. J Infect.    July 2015; 71(1):136-139.-   18. Hartmann O, Schuetz P, Albrich W C, Anker S D, Mueller B,    Schmidt T. Time-dependent Cox regression: serial measurement of the    cardiovascular biomarker proadrenomedullin improves survival    prediction in patients with lower respiratory tract infection. Int J    Cardiol. Nov. 29, 2012; 161(3):166-173.-   19. Albrich W C, Dusemund F, Ruegger K, et al. Enhancement of CURB65    score with proadrenomedullin (CURB65-A) for outcome prediction in    lower respiratory tract infections: derivation of a clinical    algorithm. BMC Infect Dis. 2011; 11:112.-   20. Albrich W C, Ruegger K, Dusemund F, et al. Optimised patient    transfer using an innovative multidisciplinary assessment in Kanton    Aargau (OPTIMA I): an observational survey in lower respiratory    tract infections. Swiss Med Wkly. 2011; 141:w13237.-   21. Albrich W C, Ruegger K, Dusemund F, et al. Biomarker-enhanced    triage in respiratory infections: a proof-of-concept feasibility    trial. Eur Respir J. October 2013; 42(4):1064-1075.-   22. Riera J, Senna A, Cubero M, Roman A, Rello J, Study Group    Investigators T V. Primary Graft Dysfunction and Mortality Following    Lung Transplantation: A Role for Proadrenomedullin Plasma Levels. Am    J Transplant. Oct. 13, 2015.-   23. Schoe A, Schippers E F, Struck J, et al. Postoperative    pro-adrenomedullin levels predict mortality in thoracic surgery    patients: comparison with Acute Physiology and Chronic Health    Evaluation IV Score*. Crit Care Med. February 2015; 43(2):373-381.-   24. Tyagi A, Sethi A K, Girotra G, Mohta M. The microcirculation in    sepsis. Indian J Anaesth. June 2009; 53(3):281-293.-   25. Hernandez G, Bruhn A, Ince C. Microcirculation in sepsis: new    perspectives. Curr Vasc Pharmacol. Mar. 1, 2013; 11(2):161-169.-   26. Bloos F, Trips E, Nierhaus A, et al. Effect of Sodium Selenite    Administration and Procalcitonin-Guided Therapy on Mortality in    Patients With Severe Sepsis or Septic Shock: A Randomized Clinical    Trial. JAMA Intern Med. Sep. 1, 2016; 176(9):1266-1276.-   27. Bloos F, Ruddel H, Thomas-Ruddel D, et al. Effect of a    multifaceted educational intervention for anti-infectious measures    on sepsis mortality: a cluster randomized trial. Intensive Care Med.    May 2, 2017.-   28. Enguix-Armada A, Escobar-Conesa R, La Torre A G, De La    Torre-Prados M V. Usefulness of several biomarkers in the management    of septic patients: C-reactive protein, procalcitonin, presepsin and    mid-regional pro-adrenomedullin. Clin Chem Lab Med. Jun. 17, 2015.-   29. Christ-Crain M, Morgenthaler N G, Struck J, Harbarth S, Bergmann    A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker    in sepsis: an observational study. Crit Care. 2005; 9(6):R816-824.-   30. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M,    Santibanez M. Hospital mortality prognostication in sepsis using the    new biomarkers suPAR and proADM in a single determination on ICU    admission. Intensive Care Med. November 2013; 39(11):1945-1952.-   31. Gillmann H J, Meinders A, Larmann J, et al. Adrenomedullin Is    Associated With Surgical Trauma and Impaired Renal Function in    Vascular Surgery Patients. J Intensive Care Med. Jan. 1,    2017:885066616689554.-   32. Garrouste-Orgeas M, Montuclard L, Timsit J F, Misset B,    Christias M, Carlet J. Triaging patients to the ICU: a pilot study    of factors influencing admission decisions and patient outcomes.    Intensive Care Med. May 2003; 29(5):774-781.-   33. Garrouste-Orgeas M, Montuclard L, Timsit J F, et al. Predictors    of intensive care unit refusal in French intensive care units: a    multiple-center study. Crit Care Med. April 2005; 33(4):750-755.-   34. Mery E, Kahn J M. Does space make waste? The influence of ICU    bed capacity on admission decisions. Crit Care. May 8, 2013;    17(3):315.-   35. Orsini J, Blaak C, Yeh A, et al. Triage of Patients Consulted    for ICU Admission During Times of ICU-Bed Shortage. J Clin Med Res.    December 2014; 6(6):463-468.-   36. Kip M M, Kusters R, M J I J, Steuten L M. A PCT algorithm for    discontinuation of antibiotic therapy is a cost-effective way to    reduce antibiotic exposure in adult intensive care patients with    sepsis. J Med Econ. 2015; 18(11):944-953.-   37. Wilke M H, Grube R F, Bodmann K F. The use of a standardized    PCT-algorithm reduces costs in intensive care in septic patients—a    DRG-based simulation model. Eur J Med Res. Dec. 2, 2011;    16(12):543-548.-   38. Baughman R P, Lower E E, Flessa H C, Tollerud D J.    Thrombocytopenia in the intensive care unit. Chest. 1993;    104(4):1243-7.7.-   39. Drews R E, Weinberger S E. Thrombocytopenic disorders in    critically ill patients. Am J Respir Crit Care Med. 2000; 162(2 Pt    1):347-51.-   40. Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D,    Frans E, Wilmer A, et al. Thrombocytopenia and prognosis in    intensive care. Crit Care Med. 2000; 28(6):1871-6. 9.-   41. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn E G.    Thrombocytopenia in patients in the medical intensive care unit:    bleeding prevalence, transfusion requirements, and outcome. Crit    Care Med. 2002; 30(8):1765-71. 10.-   42. Smith-Erichsen N. Serial determinations of platelets, leucocytes    and coagulation parameters in surgical septicemia. Scand J Clin Lab    Invest Suppl. 1985; 178:7-14. 11.-   43. Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent    J L. Time course of platelet counts in critically ill patients. Crit    Care Med. 2002; 30(4):753-6. 12.-   44. Crowther M A, Cook D J, Meade M O, Grifth L E, Guyatt G H,    Arnold D M, et al. Thrombocytopenia in medical-surgical critically    ill patients: prevalence, incidence, and risk factors. J Crit Care.    2005; 20(4):348-53. 13.-   45. Moreau D, Timsit J F, Vesin A, Garrouste-Orgeas M, de Lassence    A, Zahar J R, et al. Platelet count decline: an early prognostic    marker in critically ill patients with prolonged ICU stays. Chest.    2007; 131(6):1735-41. 14.-   46. Hui P, Cook D J, Lim W, Fraser G A, Arnold D M. The frequency    and clinical signifcance of thrombocytopenia complicating critical    illness: a systematic review. Chest. 2011; 139(2):271-8.15.-   47. Venkata C, Kashyap R, Farmer J C, Afessa B. Thrombocytopenia in    adult patients with sepsis: incidence, risk factors, and its    association with clinical outcome. J Intensive Care. 2013; 1(1):9.-   48. Semple J W, Freedman J. Platelets and innate immunity. Cell Mol    Life Sci. 2010; 67(4):499-511. 17.-   49. Semple J W, Italiano J E Jr, Freedman J. Platelets and the    immune continuum. Nat Rev Immunol. 2011; 11(4):264-74.18.-   50. Vieira-de-Abreu A, Campbell R A, Weyrich A S, Zimmerman G A.    Platelets: versatile efector cells in hemostasis, infammation, and    the immune continuum. Semin Immunopathol. 2012; 34(1):5-30. 19.-   51. Herter J M, Rossaint J, Zarbock A. Platelets in infammation and    immunity. J Thromb Haemost. 2014; 12(11):1764-75.20.-   52. Morrell C N, Aggrey A A, Chapman L M, Modjeski K L. Emerging    roles for platelets as immune and inflammatory cells. Blood. 2014;    123(18):2759-67. 21.-   53. Xu X R, Zhang D, Oswald B E, Carrim N, Wang X, Hou Y, et al.    Platelets are versatile cells: new discoveries in hemostasis,    thrombosis, immune responses, tumor metastasis and beyond. Crit Rev    Clin Lab Sci. 2016; 53(6):409-30.-   54. Yu-Min Shen et al. Evaluating Thrombocytopenia during heparin    therapy. Jama. February 2018; Egede Johansen et al. The potential of    antimicrobials to induce thrombocytopenia in critically ill    patients: data from a arandomized controlled trial. PLOS one.    November 2013; Vol. 8.-   55. Van der Poll et al. Pathogenisis of DIC in sepsis. Sepsis. 1999;    103-109; Koyama et al. Time course of immature platelet count and    its relation to thrombocytopenia and mortality in patients with    sepsis. PLOS one. January 2018.-   56. Guru et al. Association of Thrombocytopenia and Mortality in    Critically III Patients on Continuous Renal Replacement Therapy.    Nephron. 2016; 133:175-182.-   57. Larkin et al. Sepsis-associated thrombocytopenia. Thrombosis    Research. 2016;-   58. Ali N., Auerbach H. (2017), New-onset acute thrombocytopenia in    hospitalized patients: pathophysiology and diagnostic approach,    Journal of Community Hospital Internal Medicine Perspectives, 7:3,    157-167.-   59. Dewitte et al. Blood platelets and sepsis pathophysiology: A new    therapeutic prospect in critical ill patients?. Ann. Intensive Care.    2017; 7:115.

1-29. (canceled)
 30. A method comprising: a. receiving a first bodilyfluid sample of a patient in an intensive care unit (ICU-patient) whohas been treated for low platelet levels and/or thrombocytopenia and/ordisseminated intravascular coagulation (DIC), b. measuring a level ofproADM or fragment(s) thereof in said sample, c. wherein when the levelof proADM or fragment(s) thereof is below 2.25 nmol/l±20%, d.discharging the patient from the ICU.
 31. The method according to claim30, wherein the bodily fluid sample is selected from the groupconsisting of a blood, a blood plasma, a blood serum and a urine sample.32. The method according to claim 30, wherein measuring a level ofproADM or fragment(s) thereof comprises measuring a level ofmid-regional (MR)-proADM in the sample.
 33. The method according toclaim 30, wherein the method comprises the measuring of at least oneadditional parameter, such as markers, biomarkers and clinical scores,selected from the group consisting of procalcitonin (PCT), lactate,C-reactive protein, at least one of the clinical scores SOFA, APACHE II,SAPS II, markers for a dysregulation of the coagulation system, plateletcount, mean platelet volume (MPV), sCD14-ST, prothrombinase,antithrombin, antithrombin activity, cationic protein 18 (CAP18), vonWillebrand factor (vWF)-cleaving proteases, lipoproteins in combinationwith CRP, fibrinogen, fibrin, B2GP1, GPIIb-IIIa, non-denatured D-dimerof fibrin, platelet factor 4, histones and a PT-Assay.
 34. The methodaccording to claim 30, wherein the patient has received a treatment inthe ICU selected from group consisting of Factor V, Factor XIII-AP,shingosine-1-phosphate (S1P), thombomodulin, antibodies against tissuefactor or tissue factor pre-mRNA splicing, reactive nitrogen inhibitingpeptide (RNIP) fragment, TAFIa(i), procoagulant phospholipid and athrombin inhibitor.
 35. The method according to claim 30, wherein thepatient has received treatment in the ICU selected from group consistingof antibiotic treatment, invasive mechanical ventilation, non-invasivemechanical ventilation, renal replacement therapy, vasopressor use,fluid therapy, corticosteroids, blood or platelet transfusion,splenectomy, direct thrombin inhibitors, blood thinners, lithiumcarbonate, folate, extracorporal blood purification and organprotection.
 36. The method according to claim 30, wherein the patienthas received treatment in the ICU selected from group consisting ofcorticosteroids, blood or platelet transfusion, transfusion of bloodcomponents, drugs promoting the formation of thrombocytes and asplenectomy.
 37. A method comprising: a. receiving a first bodily fluidsample of a patient in an intensive care unit (ICU-patient) who has beentreated for low platelet levels and/or thrombocytopenia and/ordisseminated intravascular coagulation (DIC), b. measuring a level ofproADM or fragment(s) thereof in said sample, c. wherein when the levelof proADM or fragment(s) thereof is above 2.75 nmol/l±20%, d.maintaining the patient in the ICU and initiating an additionaltreatment or modifying a treatment for low platelet levels and/orthrombocytopenia and/or disseminated intravascular coagulation (DIC).38. The method according to claim 37, wherein the bodily fluid sample isselected from the group consisting of a blood, a blood plasma, a bloodserum and a urine sample.
 39. The method according to claim 37, whereinmeasuring a level of proADM or fragment(s) thereof comprises measuring alevel of mid-regional (MR)-proADM in the sample.
 40. The methodaccording to claim 37, wherein the method comprises the measuring of atleast one additional parameter, such as markers, biomarkers and clinicalscores, selected from the group consisting of procalcitonin (PCT),lactate, C-reactive protein, at least one of the clinical scores SOFA,APACHE II, SAPS II, markers for a dysregulation of the coagulationsystem, platelet count, mean platelet volume (MPV), sCD14-ST,prothrombinase, antithrombin, antithrombin activity, cationic protein 18(CAP18), von Willebrand factor (vWF)-cleaving proteases, lipoproteins incombination with CRP, fibrinogen, fibrin, B2GP1, GPIIb-IIIa,non-denatured D-dimer of fibrin, platelet factor 4, histones and aPT-Assay.
 41. The method according to claim 37, wherein the patient hasreceived a treatment in the ICU selected from group consisting of FactorV, Factor XIII-AP, shingosine-1-phosphate (S1P), thombomodulin,antibodies against tissue factor or tissue factor pre-mRNA splicing,reactive nitrogen inhibiting peptide (RNIP) fragment, TAFIa(i),procoagulant phospholipid and a thrombin inhibitor.
 42. The methodaccording to claim 37, wherein the patient has received treatment in theICU selected from group consisting of antibiotic treatment, invasivemechanical ventilation, non-invasive mechanical ventilation, renalreplacement therapy, vasopressor use, fluid therapy, corticosteroids,blood or platelet transfusion, splenectomy, direct thrombin inhibitors,blood thinners, lithium carbonate, folate, extracorporal bloodpurification and organ protection.
 43. The method according to claim 37,wherein the patient has received treatment in the ICU selected fromgroup consisting of corticosteroids, blood or platelet transfusion,transfusion of blood components, drugs promoting the formation ofthrombocytes and a splenectomy.
 44. The method according to claim 37,wherein when the level of proADM or fragment(s) thereof is above 2.75nmol/l±20%, the patient receives treatment in the ICU selected fromgroup consisting of Factor V, Factor XIII-AP, shingosine-1-phosphate(S1P), thombomodulin, antibodies against tissue factor or tissue factorpre-mRNA splicing, reactive nitrogen inhibiting peptide (RNIP) fragment,TAFIa(i), procoagulant phospholipid and a thrombin inhibitor.
 45. Themethod according to claim 8, wherein when the level of proADM orfragment(s) thereof is above 2.75 nmol/l±20%, the patient receivestreatment in the ICU selected from group consisting of antibiotictreatment, invasive mechanical ventilation, non-invasive mechanicalventilation, renal replacement therapy, vasopressor use, fluid therapy,corticosteroids, blood or platelet transfusion, splenectomy, directthrombin inhibitors, blood thinners, lithium carbonate, folate,extracorporal blood purification and organ protection.
 46. The methodaccording to claim 37, wherein when the level of proADM or fragment(s)thereof is above 2.75 nmol/l±20%, the patient receives treatment in theICU selected from group consisting of corticosteroids, blood or platelettransfusion, transfusion of blood components, drugs promoting theformation of thrombocytes and a splenectomy.